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ABSTRACT 
 
MSc. Tommaso Stefani            Graduation date: March 2020 
Universidad Autónoma de Nuevo León  Faculty of Chemical Sciences 
 
Title of the Study: METABOLOMIC AND BIODIRECTED PHYTOCHEMICAL 
STUDY OF Hechtia glomerata, EVALUATION OF ITS ANTIBACTERIAL AND 
CYTOTOXIC ACTIVITY, AND DETERMINATION OF THE MECHANISM OF 
ACTION OF ONE ACTIVE COMPOUND. 
 
Number of pages: 326                           Candidate for the grade of Doctor 
in Science with Orientation in Pharmacy 
 
Purpose of the study: The pharmaceutical industry has left the active 
research and development of new antibiotics, and the lack of new molecules 
caused the antibacterial resistance to become an even more threatening 
issue. At the same time cancer resistance is also thriving, making old 
chemotherapeutic drugs useless. Therefore, there is the absolute need of new 
bioactive molecules to contrast these pathologies. Plants’ natural products 
have always been a source for bioactive and structurally complex compounds 
and could represent a solution to these emerging health problems. The 
majority of the world still relies on the use of ethnomedicine for the treatment 
and prevention of diseases. This is why in this work a Mexican medicinal plant: 
Hechtia glomerata Zucc. known as Guapilla was investigated for its curative 
properties. The goal of this study was to find out the actual antibacterial and 
cytotoxic activity of this plant’s extracts and its adequacy as source for 
biologically active compounds. Also, to isolate its major compounds and 
deeply investigate its secondary metabolites production. Finally, the 
mechanism of action of one of its bioactive constituents was investigated by 
microarray assay.  
 
 X 
Results and conclusions: The major constituents of H. glomerata’s 
leaf organic extracts (Hex and C/M) were isolated and characterized. Also, a 
metabolomic study on all H. glomerata’s leaf extracts was performed by 
UPLC-QTOF-MS analysis. This allowed the identification of the chemical 
profile of the plant accounting for a total of 226 compounds comprising a 38% 
of flavonoids and stilbenes, 31% of terpenes and steroids, a 15% of phenolic 
acids and derivatives, 10% of fatty acids and hydrocarbons, 6% of nitrogen 
containing compounds. The statistical analysis of the date permitted the 
visualization of the main differences among the extracts. It was also performed 
a pathway analysis showing which ones are the most predominant 
biosynthetic routes of H. glomerata. The antibacterial and cytotoxic activity of 
both leaf and root extracts was investigated. The MIC values for the extracts 
against resistant bacteria were ³ 500 µg/mL and were considered weak. 
Meanwhile of the isolated compounds only β-sitosteryl acetate had a MIC 
value of 100 µg/mL against carbapenem resistant Acinetobacter baumannii. 
The CHCl3/MeOH leaf extract had instead activity against two sensitive 
bacterial strains: Staphylococcus aureus and Enterobacter faecium with MIC 
values of 125 and 62.5 µg/mL respectively. Therefore, a bioassay-guided 
directed study was performed, testing against these two bacteria the fractions 
of CHCl3/MeOH extract. Fractions 1, 3 and 8 resulted to be the active ones, 
the most active being the fraction 8 with a MIC of 100 and 50 µg/mL against 
S. aureus and E. faecium respectively. The three active fractions were 
analyzed in order to identify their active components with GC-MS and/or 
HPLC-QTOF-MS. The extracts were also tested against cancer cells and only 
the organic leaf extracts resulted active (IC50: 24-32 µg/mL). The most active 
 XI 
was the Hex extract which accounted for the higher number in cell lines 
inhibited. These results highlighted the lack in specificity of this extract and 
also its major constituent (β-sitosterol) was already widely studied in the 
literature. For these reasons it was decided to focus on the CHCl3/MeOH 
extract, which presented activity against PC3 and was slightly active against 
MCF7 cell lines. A bioassay-guided directed study was also conducted on this 
extract showing fractions 3 and 4 as the most active ones. Hence their 
constituents were investigated giving a high similarity in their composition, 
especially they shared many hydroxycinnamic acid derivatives like p-coumaric 
and caffeic acid. Since these two compounds were found so abundant and 
were already isolated and characterized in the same extract, it was decided to 
test them against the two cancer cell lines. For the stability in culture medium 
of p-coumaric acid was selected for the microarray assay on PC3 cells. The 
results gave the up- and down-regulation of many genes involved in cancer, 
some of them specific for prostate cancer (PI3K/AKT, AMPK, MAPK, p53, 
RAS, and TNF among others). Some proteins of the pathways affected by p-
coumaric acid treatment were modeled in silico and their probable binding 
sites identified by molecular docking. Finally, the complex ligand-proteins were 
submitted to molecular dynamic simulation and their binding energy 
calculated. The interactions leading to a negative binding energy confirm the 
spontaneous binding of the p-coumaric acid to its targets: MAPK8, MDM2, 
CCNB2, NTRK3, SLC2A4, MDM4 and the protein complex STK11-STRAD-
CAB39.  
The results obtained in this research confirmed H. glomerata as a 
source of antibacterial and cytotoxic compounds and its use in the Mexican 
 XII 
traditional medicine. 
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CHAPTER 1 
1. INTRODUCTION 
 
 
1.1 Bacterial resistance 
 
Since the discovering of penicillin by Alexander Fleming, the use of 
antibiotics has allowed humanity to overcome many bacterial infections. The 
mechanism of action of these drugs it’s usually focused on the disruption of 
the cell wall, fundamental for the bacteria’s life. For example, b-lactams based 
agents, inhibit the synthesis of the peptidoglycan throughout the inactivation 
of DD-transpeptidase, and other penicillin binding proteins (PBPs) responsible 
of the cell wall production (1). These and other antibacterial molecules can 
exert their bactericidal activity also by hydroxyl radical formation, like 
norfloxacin and ampicillin. Some antibiotics are instead ribosome inhibitors, 
such as chloramphenicol, and tetracycline, and inhibitor of RNA polymerase 
like rifampicin (2). Other drugs of these kind are the macrolides, a group of 
molecules such as erythromycin, which bind ribosomal subunit 70S blocking 
the protein synthesis (3). 
In the course of the decades a new phenomenon has become seriously 
problematic: the antibacterial resistance; which can lead to longer 
hospitalization periods and in some case in untreatable or difficult-to-treat 
infections (4). 
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There are different mechanisms of resistance that the bacteria can rely 
on to defend themselves from antibiotics (Figure 1.1). Four are the principals: 
1. Degradation of the drug by the use of hydrolytic enzymes such as b-
lactamase, which are specific for β-lactams 
2. Modification of the active site of the target or the entire target 
macromolecule 
3. Alteration of the metabolic pathway where the activity of the drug is 
exerted, so that it is removed 
4. Use of efflux pumps to eliminate de drug from the cytoplasm of the 
bacteria. 
 
 
Figure 1.1 Some antibiotics site of actions and resistance mechanisms (5) 
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Other possible mechanisms of antibiotic resistance reported in the 
literature are the production of physical barriers, like biofilms with the objective 
of blocking the passage of the drug, which cannot reach the target. Also the 
bacteria can start a overproduction of the target so that a higher concentration 
of the drug is needed to exert its effect (6).  
The resistant bacteria are classified internationally in base of their level 
of resistance (number of core antibiotic drugs) as drug-resistant (DR), 
multidrug-resistant (MDR), extensively or extremely drug-resistant (XDR) and 
pandrug-resistant (PDR) (7). To support the research and development of new 
antibiotics the world health organization (WHO) published a list of bacterial 
strains divided in to priority subgroups in base of their critical resistance level, 
from the now-days available antibiotics (8). The strains with a higher need of 
new antibiotics are listed in the Table 1.1. 
 
Table 1.1 WHO priority list of pathogens for the research and development of new antibiotics 
Priority Bacteria Resistance 
CRITICAL 
Acinetobacter baumannii Carbapenems 
Pseudomonas aeruginosa Carbapenems 
Enterobacteraceae Carbapenems, 3rd gen. cephalosporins 
HIGH 
Enterococcus faecium Vancomycin 
Staphylococcus aureus Methicillin, Vancomycin 
Helicobacter pilori Clarithromycin 
Campylobacter Fluoroquinolones 
Salmonella spp. Fluoroquinolones 
Neisseria gonorrhoeae 
3rd gen. cephalosporins, 
Fluoroquinolones 
MEDIUM 
Streptococcus pneumoniae Penicillin 
Haemopilus influenzae Ampicillin 
Shigella spp. Fluoroquinolones 
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The resistance to antibiotics can be generated by mutations which 
occurs every 107-108 cellular replications and, if favorable, they can be 
transmitted vertically through the successive generations of bacteria. Even if 
the hypothesis of a favorable mutation is statistically improbable, the 
resistance can also be transmitted from horizontal gene transfer (HGT), 
through mobile genetic elements such as plasmids, between different bacteria 
strains. These events are the result of the selective pressure that can derive 
from the use of antibiotics itself. This might take place in hospitals or can derive 
from the abuse of these drugs. In general, there are more than one cause, but 
it’s appropriate to say that an improper use of antibiotics has given its 
contribution to the resistance development (9). In fact, despite the warnings in 
the matter, these drugs are overprescribed worldwide.  
In some countries there is not a useful regulation and antibiotics are 
even sold over the counter, resulting into a cheap and easily accessible source 
of drugs and thus promoting overuse. Even if proper regulations about the use 
of antibiotics are present, in many cases they are wrongly prescribed. For 
example, studies in the U.S. have shown that the choice of agent, treatment 
indication and duration are incorrect from 30% to 50% of cases. These errors 
have questionable health benefits and increase genetic alteration, through 
antibiotic-induced gene expression. That enhances the virulence and 
mutagenesis spread thanks to HGT, and thus supporting the appearance of 
resistance. 
Another cause of bacterial resistance is the extensive use of antibiotics 
in agriculture, to promote livestock growth and to prevent infections. The 
transfer of resistant bacteria strains from the animals to the farmers is known 
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since more than 35 years and more recently it was also demonstrated that 
resistant bacteria can be passed to consumers through meat products (10). 
Also, antibiotic agents sold for hygienic and cleaning purposes can play a 
contribution role in increasing the problem, blocking proper formation of the 
immune system in children.  
Since the appearance of the first mechanisms of bacterial response to 
penicillin: the production of a modified version of its target DD-transpeptidase 
(as mention before), the so called b-lactamase which deactivates the penicillin 
molecule, new anti-bacterial molecules have been researched and 
synthesized in order to overcome the problem, but it seems to be a never 
ending loop (11). Therefore, the research of new drugs is of extreme 
importance, due to the menace that multidrug resistant bacterial strains 
represent. This fact implies a continuous need of new molecules in order to 
maintain the ability to fight bacterial infections, even the most common ones. 
There are just few available new antibiotics, and this is due to the lack research 
in this field by the majority of the big pharmaceutical companies. The massive 
neglect toward the production of new antibacterial agents, is the result of the 
low income that they produce in comparison with other drugs used in chronic-
conditions (12). For all these reasons, the growth of bacterial resistance it’s a 
health problem of outmost concern, but it’s not the only one, in fact another 
significant problem is represented by cancer. 
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1.2 Cancer: drugs toxicity and resistance 
 
One of the leading causes of death globally is cancer. Although since 
1991 cancer mortality has dropped by 26% and the incidence in women and 
men at the beginning of 2018 was stable and declining respectively, the 
disease is still a big threat to human health. Especially in low- and middle-
income countries, in which cancer mortality represents more than the 70% (13, 
14). 
Cancer is the product of a deregulated cellular behavior, which allows 
a cell to escape the normal function and architecture that is characteristic of a 
given tissue. Tumor cells are therefore capable of unlimited proliferation 
(immortality), and thanks to the lack of recognition proteins they can spread to 
distant sites and thus invade different tissues through the metastasis process. 
A healthy cell can become cancerous from accumulation of deoxyribonucleic 
acid (DNA) defects and/or mutations, which can be enhanced or provoked by 
pollution and poor lifestyle choices or they can be inherited genetic tracts. 
The global cancer observatory (GLOBCAN) 2018, estimated that 185 
countries of the world had 18.1 million new cancer cases, 9.6 million cancer 
deaths in 2018, and 32.6 million people living with cancer (within 5 years of 
diagnosis) in 2012 worldwide (14, 15). It is also expected to have 29.5 million 
new cancer cases and 9 to 15 million cancer deaths every year by 2040 (16). 
Also in 2015, the WHO estimated that in 91 of 172 countries cancer is the first 
or second cause of death before age 70 years, and it was third of fourth in 
other 22 countries (14). 
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The cancer treatments used today are surgery, radiations and drugs 
(chemotherapy). Of these, the last one represents a useful but rarely effective 
weapon arsenal and, it also comes with a lot of backfire. In fact, they can give 
temporary relief from symptoms and prolong the patient’s life but the side 
effects of the majority of the drugs employed, such as platinum derivatives that 
today represent the 75% of anticancer drugs in use, are many and most of the 
times severe. Those effects can be so severe that the success of the cure 
itself depends on the ability of the patient’s body to handle the drug’s toxicity. 
In general, the patients suffer general cellular damaging which causes nausea, 
vomiting, myelo-suppression and immune-suppression, as well as more 
specific damage which results in ototoxicity, nephrotoxicity and hair loss, 
therefore side effects, are the main cause of failure of cancer treatments. The 
toxicity of these drugs is due to lack of specificity action, they are too reactive 
and affect all sorts of tissues. In fact, this may produces allergic reactions 
making it even more difficult for the patient to outstand the treatment (17). 
The mechanism of action of these drugs is generally not completely 
understood, even though for some of them there is some evidence of more 
specifically targeted structures. For example, drugs like taxanes are said to be 
microtubule-stabilizing agents (MSAs), which means that they are able to 
block the cellular mitosis through the inhibition of the formation of the mitotic 
spindle. In a more chemical level, taxanes can block the polymerization of 
microtubules that are fundamental for cell reproduction (18). Platinum based 
drugs instead are known to cause apoptosis in cells throughout the distortion 
of the secondary structure of the DNA, displaying specific enzymes to activate 
in order to repair the damage, which is usually unrepairable. This causes the 
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subsequent activation of many proteins (like caspase) and hence the apoptotic 
signaling which leads to the programmed cell death. But not everything is 
known of their activity, and cellular targets, it is believed that they may take 
part into alternative apoptotic signaling (19). Another common cause of failure 
of the anticancer treatments is resistance, acquired or intrinsic. Acquired 
resistance can appear when chemotherapy goes on for long periods of time, 
instead intrinsic resistance is a resistance already proper of the type of 
neoplasia. The acquired resistance of a tumor can negatively affect a 
treatment that seemed to be having good results; that usually happens in 
patients with recurring tumors. The appearance of resistance is usually 
associated to three molecular mechanisms: increased DNA repair, altered 
cellular accumulation and increased drugs inactivation, which are currently 
under study (Figure 1.2) (20). Since drug resistance has developed rapidly 
new medicines are always required in order to find more efficient and less toxic 
new treatments. Hence is necessary to explore the available sources of new 
molecules and natural products, due to their structural variability and biological 
activities are likely to be useful. 
 
Figure 1.2 Resistance mechanisms in tumor cells (21) 
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1.3 Plants natural products as a potential drugs source 
 
Nature is a vast pool of biologically active molecules. From all the 
natural sources available, one of the most significant and most used since 
ancient times is represented by the vegetal kingdom (22). Metabolites and 
biomolecules are of outmost interest in pharmaceutical chemistry, due to their 
variable forms and activities. Medicinal plants and other natural products have 
been the first source of drugs, and many of the pharmaceutical products we 
use today come from isolated natural products from plants (23). There are 
many reports that state the biological activities of the natural products of plants 
such as antifungal, antibacterial, anticancer, antiviral, anti-inflammatory, anti-
infective, antimutagenic, antidiabetic, anti-nociceptive, hypolipidemic, 
antioxidant, and antimalarial activities (24, 25). 
Treatment of diseases like bacterial infection and cancer, need a 
continuous provision of new drugs, and plants can be a useful source of lead 
molecules. Many are already in use, for example in cancer therapy there are 
various useful phytochemicals such as vinka alkaloids, epipodophyllotoxins, 
taxanes, camptothecins, cephalotaxines and flavones (Figure 1.3). There are 
also many herbs that if consumed contribute to fight cancer like garlic, ginger, 
turmeric, green tea, cilantro, and basil.  
The WHO has estimated that approximately 80% of people worldwide 
relay on ethnic medicine for their primary health care. Some of the medicinal 
plants used around the world have resulted to contain active principles such 
as taxol and camptothecin. Among other anticancer plants are marijuana 
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(Cannabis sativa), yew (Taxus baccata), sunflower (Helianthus annus), 
licorice (Glycyrrhiza glabra), etc (16). 
Phytochemicals with antibiotic activity are divided into several 
categories. The first category comprehends phenolics and polyphenols, some 
of which are simple bioactive phytochemicals composed by a single 
substituted phenolic ring; for example, caffeic and cinnamic acid. Others 
instead are more complex such as quinones, flavonoids, tannins and 
coumarins. The molecules in this group are also known for their antioxidant 
activity, which makes them also protective toward the infected tissue (26). In 
the second category there are terpenoids and essential oils, which represent 
mostly fragrant unsaponificable lipids. Some essential oils that showed 
antibacterial activity can be extracted from various plants, such as oregano 
(Origanum syriacum L.), thyme (Thymus syriacus L.), and cinnamon 
(Cinnamomum zeylanicum L.). The essential oils of these plants contain 
terpenoids like thymol which have a good activity against gram-negative 
bacteria (27). 
Another category is represented by the alkaloids, which are the most 
abundant phytochemicals produced by plants and sometimes the reason why 
they are present is not entirely clear. They have many and different structures 
and origins, and thus they cannot be classified with a single taxonomic 
principle. The alkaloids are classified by chemical structure, biochemical origin 
and/or natural origin. From the chemical structure they are divided in two main 
groups: the heterocyclic or typical alkaloids and the non-heterocyclic or 
atypical alkaloids. Some examples of typical alkaloids with antibacterial activity 
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are quinolines, indoles and phenanthridines (28). Other molecules that 
showed antibiotic capabilities are lectins and polypeptides (29). 
Plant products and metabolites are numerous and have displayed 
plenty of useful activities, so this work will focus into the isolation and structural 
characterization of compounds with antibacterial and cytotoxic activities from 
Hechtia glomerata as well as the determination of mode of action of the most 
active compound.  
 
   
Vincristine    Paclitaxel 
 
    
 
Epipodophyllotoxin  Camptothecin         Cephalotaxine 
 
 
Figure 1.3 Some antitumor natural products derived from plants already in use 
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CHAPTER 2 
2. BACKGROUND 
 
 
2.1 Bromeliaceae family 
 
The Bromeliaceae family is a large group of angiosperms, monocots, 
commelinids plants. It comprehends 58 genera and about 3140 species and 
its divided in eight subfamilies (Figure 2.1): Brocchinioideae, Lindmanioideae, 
Tillandsioideae, Hechtioideae, Navioideae, Pitcairnioideae, Puyoideae and 
Bromelioideae (30). Almost all the family plants are mainly found in the 
American continent, except for one species Pitcairnia felicina which is from 
Africa. Some of these plants have been studied and their phytochemicals 
isolated and characterized (Table 2.1) however their biological activities are 
yet to be investigated. In Mexico there are 426 species of Bromeliads (31) 
some are widely known, such as pineapple (Ananas comosus) and some other 
have already been studied for pharmacological purposes (32–37) and part of 
their composition has already been elucidated (38, 39). Bromeliaceae are 
mostly known from their edible fruits, such as A. comosus which is the most 
known and studied among them (40).  
A molecular common mark of this family are betaines which are always 
found, even in small concentration (41). These kinds of molecules are able to 
protect proteins and membranes from the osmotic stress effects of high salt 
and low water concentrations. For example, trimethylglycine and trigonelline 
(Figure 2.2), which are always found in the family of Bromeliaceae, are two of 
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a group of compounds known as osmoprotectants. Cells undergoing osmotic 
stress produce and accumulate additional levels of osmoprotectants such as 
betaine.  
 
 
 
Figure 2.1 Representative species of bromeliads subfamilies (30); Brocchinioideae: (a) 
Brocchinia prismatica, Venezuela; (b) B. reducta, Venezuela and Guyana; (c) tree-like B. 
micrantha, Venezuela and Guyana. Lindmanioideae: (d) Lindmania guianensis, Venezuela 
and Guyana; (e) Connellia augustae, Venezuela and Guyana. Tillandsioideae: (f) Catopsis 
berteroniana, Florida to Brazil; (g) Guzmania lingulata, Central and South America; (h) 
Tillandsia dyeriana, Ecuador; (i) T. setacea (above branch) and T. usneoides (spanish moss, 
below branch), widespread; (j) Vriesea heliconioides, Mexico to Bolivia; (k) T. ionantha, 
flowers, Central America. Hechtiodeae: (l) Hechtia mooreana, Mexico; (m) partial 
inflorescence, H. rosea, Mexico. Navioideae: (n) Navia aff. lactea, Venezuela; (o) Sequencia 
serrata, Colombia. Pitcairnioideae: (p) Pitcairnia holstii, Venezuela; (q) bird-pollinated flowers, 
P. undulata, Mexico; (r) Deuterocohnia lotteae, Bolivia; (s) Encholirium spectabile, Brazil; (t) 
Dyckia lindevaldae, Brazil. Puyoideae: (u) Puya chilensis, Chile. Bromelioideae: (v) Bromelia 
macedoi, Brazil; (w) Fernseea bocainensis, Brazil; (x) Cryptanthus fosterianus, Brazil; (y) 
Neoregelia eleutheropetala var. Bicolor, tropical America; and (z) Canistrum alagoanum, 
Brazil. 
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The likely physical basis of the protective effect is the ability of betaine 
solutions to associate with protein surfaces to help maintain the native protein 
structure. By maintaining proteins in their hydrated form, they are more likely 
to function normally, even when in the presence of inhibitory concentrations of 
salt (42). There are also various reports of metabolomic studies of the 
constituents of A. comosus, where many components are reported from the 
fruit peel, pulp, juice and crown leaves (39, 43). The reported metabolites were 
identified by ultra-high-performance liquid chromatography coupled with mass 
spectrometry detector equipped with quadrupole and time of flight tandem 
mass analyzers (UPLC-QTOF-MS). Also, in the plant metabolic network 
(PMN) are reported 2,162 molecules supposedly identified from A. comosus 
and reported throughout the years (44). Other composition of bromeliads 
reported are Encholirium spectabile, Neoglaziovia variegata and Macambira 
(Bromelia laciniosa) (38). Their volatile compounds were identified by gas 
chromatography coupled with mass spectrometry (GC-MS). 
A. comosus contains, like the most of species of Bromeliaceae, a 
mixture of enzymes (mostly cysteine proteases) named bromelain (Table 2.1) 
with promising anticancer activities (45, 46). Also water extracts from the 
crown leaves of pineapple showed high antibacterial activity and wound 
healing properties (47). Even from the solid state fermentation of the pineapple 
residues, using Kluyveromyces marxianus were produced secondary products 
that could lead to interesting anticancer and antioxidant agents (48). With the 
same activity as the pineapple extracts are the ones from the Flaming Torch 
(Billbergia pyramidalis), which contain an enzyme mixture (cysteine protease) 
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similar to the bromelain, and that showed antiproliferative effects on malignant 
cell lines (49).  
 
    
 
 
Figure 2.2 Structures of two betaines found in some studied plants of the Bromeliaceae 
family 
 
Between other plants that have demonstrated some biological activity 
there is E. spectabile, which contains various active phytochemicals such as 
alkaloids, coumarins, flavonoids and terpenes. The leaves extracts of this 
plant have shown a good antibacterial and antioxidant activity, especially the 
ethanol and hexane extracts which contained primarily flavonoids and tannins, 
lignans, terpenes and steroids (32). The chloroform extract of the Jamaican 
Ball Moss (Tillandsia recurvata L.) had interesting anticancer activity against 
melanoma, breast and prostate cancer; the phytochemicals responsible for 
antitumor activity were two dicinnamates (50). The extracts of N. variegata and 
B. laciniosa showed antibacterial activity (51) and some metabolites of 
Bromelia balansae has shown antimycobacterial activity (52). 
Concerning antibacterial and antitumor activity of the phytochemicals 
from the Bromeliaceae family, some extracts are known to have activity (Table 
2.2), evidencing the lack of knowledge about their constituents and biological 
properties. Since the known plants have already shown antibacterial and 
anticancer activities, it is more than worth to study and explore the vast 
possibilities that this family of plants has to offer.  
N
COO
N COO
Trigonelline Trimethylglycine 
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Table 2.1 Some species of Bromeliaceae family and their isolated compounds (41). 
 
Subfamily Plant Constituents 
Bromelioideae 
Ananas comosus  
Bromelain 
 
Catechin (S)/Epicatechin (R) 
Ananas comosus var. 
Cayenne 
 
Ananasic acid 
Ananas erectofolius 
 
Campesteryl 3 -O-b-D-glucopyranoside 
Greigia sphacelata 
 
1,3-O-di-trans-p-coumaroylglycerol 
Pitcairnioideae 
Hechtia rosea  
b-Sitosterol 
Hechtia scariosa 
Tillandsioideae 
Tillandsia brachycaulos 
Chlorogenic acid 
Tillandsia fasciculata 
 
3-O-glicopyranosil-6,3’,5’-trimethoxy- 3,5,7,4’-
tetrahydroxyflavone 
Tillandsia streptocarpa 
 
1,3-O-dicaffeoylglycerides 
Tillandsia recurvata 
5-hydroxy-2-(3-hydroxy-
4-methoxyphenyl)-6,7,8-trimethoxychroman-4-one 
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Table 2.2 Extracts of Bromeliaceae species and their biological activities 
 
Plant/part Extract Constituents 
Biological 
activity 
Reference 
A. comosus / 
fruits, stems, 
leaves 
H2O, fermented 
wastes, juice 
bromelain 
Anticancer, 
antibacterial 
(46–48, 53) 
B. arenaria / fruits juice - Anticancer (54) 
B. antiacantha / 
leaves, fruits 
EtOH - 
Antibacterial, 
cytotoxic 
(55) 
B. balansae / 
fruits 
MeOH - 
Antioxidant, 
antimycobacterial 
(52) 
B. laciniosa 
/whole plant 
EtOH - Antibacterial (51) 
B. pinguin / twigs, 
leaves 
Petroleum 
ether, EtOAc, 
EtOH, MeOH, 
H2O 
- Anticancer (41, 56) 
B. pyramidalis / 
leaves 
Homogenization 
medium* / Cys 
enzyme 
Cys-enzyme Anticancer (49) 
E. spectabile / 
leaves 
EtOH - 
Antioxidant, 
antibacterial 
(32, 33) 
N. variegata / 
flowers 
EtOH - 
Antibacterial, 
photoprotective 
(35, 51) 
T. recurvata / 
whole plant 
CHCl3 / 
Dicinnamates 
dicinnamates 
Anticancer, 
antibacterial 
(50) 
T. imperialis / 
leaves, flowers 
Hexane, 
CH2Cl2, MeOH 
- Antibacterial (57) 
T. aeranthos / 
leaves 
H2O - Antibacterial (58) 
T. usneoides / 
leaves 
H2O - Antibacterial (58) 
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2.2 Chemistry of the Genus Hechtia 
 
 
 
Figure 2.3 Hechtia glomerata Zucc. 
 
The plant under study is known in Mexico as Guapilla or Lechugilla 
(Hechtia glomerata Zucc.), shown in Figure 2.3. The plant can be easily found 
in Texas, Mexico (especially the northern states) and Guatemala. It also 
belongs to the previously cited family of Bromeliaceae and like the other plants 
of its family, is native of Latino America, and because of its vast distribution is 
considered today the Bromeliad with the larger habitat (59). The people from 
Coahuila, (Mexico) use this plant for the treatment of tumors (personal 
communication of Biologist M.C. Mauricio González Ferrara). The 19th century 
medical gazette of Mexico and other two articles reported the use of this plant 
as food, prepared as flavored waters or as a source of starch. Also it is 
reported its use, in various preparations, as medicine for treatment of 
respiratory and urogenital tracts diseases (colds, bronchitis, laryngitis, 
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whooping cough, nephritis, urethritis and cystitis) (40, 60, 61). Also, H. 
glomerata is taxonomically related to another phylum of the Bromeliads, the 
genus Tillandsia (30) which has already shown anticancer activity (50, 62–64). 
H. glomerata is also classified as a crassulacean acid metabolism 
(CAM) plant, which is common for plants that live in arid environments (65). 
Very little or nothing is known about the chemistry of this plant and the genus 
Hechtia, in which the plant is included. Even if the activity of their 
phytochemicals is acknowledged indirectly through ethnical medicine there 
are just few proofs that these plants actually contain bioactive molecules, like 
and for example compounds with hypoglycemic effects (66). In more recent 
works it has been reported the activities of the infusion of the leaves of the 
Tlasolmic (H. podantha) against dysentery, and the false agave (H. scariosa 
or H. texensis; Figure 2.4) as lice shampoo (67, 68).  
 
 
 
Figure 2.4 Hechtia scariosa (right) and Hechtia rosea (left) 
 
From H. scariosa and H. rosea were isolated two interesting steroids: 
β-sitosterol and hecogenin (Figure 2.5), both molecules were derivatized.  
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Figure 2.5 Chemical structures of hecogenin (right) and β-sitosterol (left) 
 
Thus, the natural products and semi-synthetic derivatives, showed 
effects on various carcinomic tissues, with good results in the reduction of cell 
proliferation (41, 69, 70). On our knowledge, the cited activities represent the 
only pharmacological and phytochemical-related information available in the 
literature about the genus Hechtia (Table 2.3). Therefore, it was conducted a 
review of Bromeliaceae family, with emphasis on the antibacterial and 
anticancer activities in which this work was centered. 
 
Table 2.3 Ethnical use of Hechtia species and isolated compounds 
Plant/part Extraction Constituents Ethnical use Reference 
H. glomerata / 
leaves 
Infusion - 
Colds, bronchitis, 
laryngitis, whooping 
cough, nephritis, 
urethritis and cystitis 
(40, 60, 61) 
H. melanocarpa / 
whole plant 
Steam raw - 
Diabetes, 
hyperglycemia 
(66) 
H. rosea / leaves Infusion 
β-sitosterol 
hecogenin 
Cancer 
(41, 67, 68) 
H. podantha / 
leaves 
Infusion - Dysentery 
H. scariosa / 
leaves 
Infusion 
β-sitosterol 
hecogenin 
Pests, cancer 
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CHAPTER 3 
3. SCIENTIFIC CONTRIBUTION, HYPOTHESIS AND AIMS 
 
 
3.1 Scientific Contribution 
 
The main contributions of this work are in the field of phytochemistry, 
with the first isolation procedures and characterization of the natural products 
obtained from Hechtia glomerata Zucc. The composition of the organic and 
aqueous extracts of the plant was also explored by UPLC-QTOF-MS and GC-
MS, allowing the performance of the first metabolomic study over this species. 
It was also investigated if the extracts and the isolated molecules have 
antibacterial and cytotoxic activities and how they are able to exert these 
activities. 
 
3.2 Hypothesis 
 
Hechtia glomerata Zucc. has phytochemicals with antibacterial and/or 
cytotoxic activities, of which one active compound will have a different 
mechanism of action from those previously reported in the literature. 
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3.3 Aims 
 
 
3.3.1 General aim 
 
To perform the phytochemical, bioassay guided isolation and 
metabolomic study of Hechtia glomerata, determine its antibacterial, cytotoxic 
activity and mechanism of action of one active compound. 
 
3.3.2 Specific aims 
 
1. To investigate the bibliographic information concerning the vegetal specie under 
study. 
2. To dry and ground plant material 
3. To prepare organic and aqueous extracts and fractionate them 
4. To isolate, purify and structurally characterize the major components of the organic 
extracts 
5. To evaluate the antibacterial and cytotoxic activity of raw extracts and isolated 
compounds  
6. To perform the cytotoxic activity screening of the chloroform/methanol extract 
fractions 
7. To determine the chemical composition of the most active fractions 
8. To carry out a metabolomic study of Hechtia glomerata Zucc.  
9. To identify the mechanism or possible mechanism of action of one active compound 
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CHAPTER 4 
4. MATERIALS AND METHODS 
 
 
4.1 Material and equipment 
 
Performance of column chromatographies (CCs) was carried out using 
silica gel (SiO2) branded EMD chemicals Inc. with a particle size of 0.040-
0.063 mm as stationary phase. The mobile phases were solvents as: 
petroleum ether, hexane (Hex), chloroform (CHCl3), dichloromethane (DCM), 
Ethyl acetate (EtOAc), acetone, methanol (MeOH) and distilled water (H2O). 
All solvents were reactive grade and branded Baker, USA. 
Thin layer chromatographies (TLCs) were carried out using silica gel 
films over aluminum 60 F254 of 20x20 cm and 0.2 mm of thickness, and silica 
gel plates over glass 60 F254 of 20x20 cm and 2.0 mm of thickness, branded 
Merck KGA. 
The compounds were revealed using a UV lamp (l: 254 nm and 365 
nm) branded Spectroline, a solution of ceric sulfate stain, a vanillin reagent or 
Dragendorff’s reagent. The determination of melting point was performed 
using a Fisher-Johns apparatus. The structural elucidation was realized by 1 
and 2D NMR nuclear magnetic resonance of hydrogen and carbon (1H and 
13C NMR) in a Brüker NMR400 equipment of 400 MHz and using 
tetramethylsilane as internal standard (TMS).  
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Other techniques used for characterization were high resolution MS, 
infrared spectroscopy in a Brüker ALPHA ATR-FTIR spectrometer, X-ray 
diffraction (XRD) in a Bruker SMART APEX and a Brüker-D2 Phaser and 
elemental analysis. 
Metabolomic study was carried out using an ultra-high-performance 
liquid chromatography (UPLC) Agilent 1290 with a detector Q/TOF 6545, 2.2 
µm hydrophilic polytetrafluorethylene (PTFE) syringe filters (Millipore Sigma & 
trade MillexTM), the UPLC was equipped with a column ZOBRAX Eclipse Pluse 
C18 HD 2.1 x 50mm and 1.8 µ pores; all the solvents used in the process were 
high-performance liquid chromatography (HPLC) grade; the employed 
databases for the compound identification were METLIN Mass Spectral 
Database, PubChem, The Human Metabolomic Database (HMDB), Lipid 
Maps, PhytoHub, ReSpect for Phytochemicals, Knapsack and Plant 
Metabolomic Network (PMN); the statistical analysis was performed using the 
online platform MetaboAnalyst 4.0. 
For the antibacterial activity assays were used bidistilled water, 
dimethylsulfoxyde (DMSO) (J.T.Baker, USA), Mueller-Hinton broth (Difco), 
blood agar base (HIMEDIA), defibrinated sheep blood (E&O Laboratories), 
normal laboratory glassware and plastic materials (testing tubes, petri dishes, 
96-wells microplates, etc.), Incubator INC-80 (Prendo), Freezer -80°C 
(Panasonic). Microplates were read with a Bio Rad LightOne Illuminator.  
Anticancer assays were performance used milli q water, DMSO 
(J.T.Baker, USA), RPMI 1640 or Dulbecco’s modified essential medium 
(DMEM) (Corning), Freezer -80°C (Panasonic), Freezer -20°C (Panasonic), 
Refrigerator 4°C (Panasonic), Laminar flow hood (BIOBASE), vacuum pump 
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(Fisherbrand), Invertoscope (Carl Zeiss). Microplates were read with a BioTek 
ELx800 Absorbance Microplate Reader. 
For the microarray assay, RNA was extracted using TRIzolTM Reagent 
(Invitrogen). The RNA quality was done on agarose gel (1%), and total RNA 
was quantified with an Eppendorf 6131 biophotometer (Eppendorf, 
Hauppauge, NY, USA). The cDNA was synthetized for both treated and 
untreated control. Then hybridization was carried out on a H35K chip (UNAM) 
in a hybridization chamber G2534A (Agilent, Santa Clara, CA, USA). The 
hybridized chip was read with a laser confocal read system ScanArray 4000 
(Packard BioChips Technologies (Massachusetts 01821, USA). The obtained 
data was processed with Array-Pro analyzer 6.3. 
In silico analysis were done in three UNIX based machines, with 8 and 
32 cored processors. Programs used for the molecular docking were 
AutoDock 4.0 and Chimera v1.13.1 (Reagents of the University of California). 
Molecular dynamics simulations were carried out using the programs 
Schrödinger release 2019-3: Desmond Molecular Dynamics System, (D. E. 
Shaw Research, New York, NY, 2019) and Maestro-Desmond Interoperability 
Tools, (Schrödinger, New York, NY, 2019). 
 
4.2 Phytochemistry of Hechtia glomerata 
 
Phytochemical study was carried out in the Natural and Synthetic 
Products (PNS) Laboratory, Division of Postgraduate Studies, Faculty of 
Chemical Sciences (FCQ), Universidad Autónoma de Nuevo León (UANL). 
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4.2.1 Plant material preparation and maceration 
Plant selected for this study was collected in Rayones, Nuevo León, 
Mexico, (25°01′00″N 100°05′00″O, 906 m a.s.l.), on February 15th, 2017 and 
identified by the biologist Mauricio González Ferrara. The vegetal material was 
composed of aerial parts with their roots one of them was selected (in base of 
its integrity and size) and was sent to the herbarium of the faculty of biology of 
the UANL. The plant was there characterized and coded with the voucher 
number 028029.  
The rest of plant material was cleaned and then the roots and pinecone 
were separated from the leaves. Leaves (10.5 Kg) and roots (1.5 Kg) were 
dried in darkness. Afterwards they were first ground in a coffee grinder and 
then in a blender. This process reduces the particles size and gains the largest 
contact surface, leading to the optimization of the extractions. Subsequently, 
the ground leaves were weighted (1.985 kg) and transferred into a 15 L carboy, 
which was labelled with the plant’s name. Then approximatively 10 L of hexane 
were added, and it was left at room temperature (r.t.) for 48 hours. At the end 
of the extraction time, the vegetable material was separated from the organic 
extract by filtration, first by gravity and then under vacuum. The hexane extract 
was distilled under reduced pressure into a rotary-evaporator. The dried 
extract was weighted (9.5 g) and kept in a flask away from the light at 4oC until 
its use. Then, recovered vegetable material was extracted by maceration with 
a 10 L chloroform/methanol (1:1) mixture six consecutive times (until the 
extract resulted clear), the extracts were filtrated, distilled under vacuum, 
combined, weighted (85 g) and kept in a flask at -20oC. At last 20g of the 
vegetable material was also macerated for 24 hours in distilled water (250 mL) 
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at 4°C to prevent fermentation. Then the extract was filtrated, lyophilized, 
weighted (2.1010 g) and kept in a flask at -20°C in the dark. On the other hand, 
300 g of fresh vegetable material was blended with distilled water, filtered and 
the aqueous extract was lyophilized, weighted (8.3799 g) and kept at -20oC 
until its use. For the roots the same procedure of extraction was used, the only 
difference was in the quantity of processed vegetal material (100 g) and the 
absence of fresh aqueous extract. The hexane extract resulted in 164.2 mg 
(0.16 % yield), the CHCl3/MeOH extract gave 3.4230 g (3.42 % yield) and the 
aqueous extract 153.9 mg (0.15 % yield). The whole procedure of the 
preparation and maceration of the vegetal material, as explained in this 
paragraph, are schematized in the following flux diagrams (Scheme 4.1 and 
Scheme 4.2). 
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Ground fresh leaves
10.5Kg
Dried vegetal 
material 2.29Kg
Hexane 
maceration
Recovered vegetal
material
CHCl3/MeOH 1:1 
maceration (x6)
Recovered vegetal
material
Aquous extract
Dryed Aquous 
extract 2.1010g 
Lyophilization
H2O    maceration
CHCl3/MeOH 
extract
Dryed 
CHCl3/MeOH 
extract 85g
Distillation
Hexane extract
Dryed hexane 
extract 9.5g
Distillation
Extraction of fresh 
leaves 
Fresh leaves aquous
extract 8.3799g 
Lyophilization
Scheme 4.1 Flux diagram of the leaves’ extraction process 
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Dried ground roots 
100 g
Hexane maceration
Recovered vegetal
material
CHCl3/MeOH 1:1 
maceration (x5)
Recovered vegetal
material
Aquous extract
Dryed Aquous 
extract 153.9mg 
Lyophilization
H2O maceration
CHCl3/MeOH extract
Dryed CHCl3/MeOH 
extract 3.423g
Distillation
Hexane extract
Dryed hexane
extract 164.2mg
Distillation
Scheme 4.2 Flux diagram of the roots’ extraction process 
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4.2.2 Fractionation of the leaf hexane extract 
Hexane extract (9.5 g) was first analyzed by thin layer chromatography 
(TLC) observing the TLC plates under UV light and sprayed with ceric sulfate. 
It was then decided to fractionate it by column chromatography using silica gel 
(190 g) as stationary phase and a gradient of hexane/ethyl acetate as mobile 
phase. A total of two-hundred and twenty-six fractions were obtained and 
observed under UV lights and with the developing reagents. They were pooled 
into sixteen fractions according to their chromatographic similitude and were 
treated with different chromatographic techniques (Table 4.1). 
 
Table 4.1 Fractions of hexane extract 
 
Fractions Polarity Isolated compound 
1-5 A 100% Hexane 1 
6-28 B 100% Hexane - 
29-44 C 98:2 Hex/EtOAc 2 
45-65 D 96:4 - 94:6 Hex/EtOAc - 
66-84 E 94:6 - 92:8 Hex/EtOAc - 
85-88 F 92:8 Hex/EtOAc - 
89-124 G 90:10 Hex/EtOAc 3-4 
125-137 H 90:10 - 85:15 Hex/EtOAc 5 
138-151 I 85:15 - 80:20 Hex/EtOAc - 
152-161 J 70:30 Hex/EtOAc - 
162-170 K 60:40 Hex/EtOAc - 
171-179 L 50:50 Hex/EtOAc - 
180-192 M 50:50 Hex/EtOAc - 
193-212 N 40:60 Hex/EtOAc - 
213-219 O 100% EtOAc - 
220-226 P 100% MeOH - 
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4.2.3 Isolation and purification of phytochemicals 
4.2.3.1 Isolation and purification of nonacosane (1) 
Compound 1 precipitated from the fraction A as a white amorphous 
wax-like solid (178.2 mg, 0.00008977%). Then it was analyzed by TLC with 
three different systems (Hex/EtOAc, Hex/CHCl3, Petroleum ether/EtOAc) to 
determine the purity. The compound does not reveal under UV light and it was 
found pure with ceric sulfate, revealing as a brown spot. 
 
4.2.3.2 Isolation and purification of hexatriacontanyl stearate (2) 
The compound was cleaned and separated from the other components 
of the fractions C, D, E and F by washing it consecutively with cold hexane, 
until it was white. It appeared as a white wax-like solid (266.8 mg, 
0.00011426%), it was also observed by TLC with three different systems 
(Hex/EtOAc, Hex/acetone, Hex/CHCl3) to determine purity. It did not reveal 
under the UV light, but it was found pure with ceric sulfate as well, developed 
as a dark brown spot. 
 
4.2.3.3 Isolation and purification of hexacosanol (3) 
This compound crystalized as a white translucent solid from the fraction 
G, and it was cleaned deeply by sucesivelly crystallizations in CHCl3 as well 
as isocratic column chromatography (CC) with 2.34 g of silica gel and eluted 
with a gradient of Hex/DCM. From this column was obtained 29.3 mg 
(0.00001476%) of hexacosanol. The purity compound was determined by bi-
dimensional (2D) TLC: 7x7 cm eluted first with a 7:3 DCM/Hex mixture and 
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then perpendicularly with an 85:15 Hex/EtOAc mixture. The alcohol barely 
developed with the UV light as a light-blue stain and with ceric sulfate as a 
black stain. 
 
4.2.3.4 Isolation and purification of oleic acid (4) 
It was separated and purified by a preparative TLC, from the fraction G. 
TLC was done on silica gel glass plate 20 x 20 cm. Once the sample (max 100 
mg) was deposited on the plate it was eluted with 85:7.5:7.5 
Hex/Acetone/acetic acid, then the plate was observed under the UV light in 
order to localize the desired compound (reveals as light-blue flame in the 365 
nm UV light). The silica containing the compound was then scratched from the 
plate and macerated four times in 90:10 CHCl3/MeOH for 30 minutes. The 
recovered palmitoleic acid (17.7 mg, 0.00000892%) was a colorless oil and its 
purity was determined by TLC with three different systems (DCM/Hex, 
Hex/EtOAc, Hex/Acetone/Acetic acid) and 2D TLC: 7x7 cm eluted first with 
70:30 DCM/Hex and then perpendicularly with 85:7.5:7.5 Hex/Acetone/acetic 
acid. Also, the compound revealed as a black flame with ceric sulfate. 
 
4.2.3.5 Isolation and purification of β-sitosterol (5) 
It was separated with good purity from fraction H by a gradient CC with 
11 g of silica gel as SP and a gradient of Hex/EtOAc. The compound presented 
itself as a whitish-yellow amorphous solid (271.3 mg, 0.00013668%) that 
crystalized in CHCl3. The compound purity was also determined by 2D TLC: 
7x7 cm and eluted first with a 7:3 Hex/EtOAc and then perpendicularly with a 
 33 
9:1 CHCl3/EtOAc. b-Sitosterol did not revealed at 254 and 365nm UV light, but 
it revealed as a purple flame with ceric sulfate. 
 
4.2.4 GC-MS analysis of leaf hexane extract and isolated compounds 
Hexane extract and compounds 1-7 were analyzed by GC-MS using an 
HP-5MS GC capillary column (30 m x 0.25 mm x 0.25 µm film thickness). 
Helium was used as carrier gas at a flow rate of 1.0 mL/min; the ion source 
and splitless injector were at a temperature of 230°C and 250°C, respectively 
and the volume of injection was 1-2 µL of a solution of 1 mg/mL of extract or 
isolated compounds in CHCl3. Oven temperature was programmed from 50°C 
to 285°C at a ramping rate of 2°C/min. Electron ionization energy was set at 
70 eV, and fragments from 1 to 3000 Da were collected. The instrumental 
conditions of the analysis are reported in the Table 4.2. 
 
Table 4.2 GC-MS experiment conditions 
Parameter Condition 
GC column HP-5MS pf 30m x 0.250mm x 0.25µM 
Carrier gas Helium, 1mL/min, constant flux 
Hoven 50°C-0min, 2°C/min-285°C-35min 
Injector 250°C, splitless 
Detector MSD 
Ionic source 230°C 
The reported results are referenced on the base of the NIST library 
version 1.7a. 
Were also calculated the relative retention indices (Equation 4.1) of the 
compounds.  
) = +,′.(0121341) − ,′.(1),′.(7) − ,′.(1) 8 × (100 × <) + (100 × >) 
Equation 4.1 Retention index for gradient limits in GC experiments 
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4.2.5 Fractionation of the leaf CHCl3/MeOH (1:1) extract 
Chloroform/methanol extract (87 g) was first analyzed by TLC under 
UV light and revealed with ceric sulphate. It was then decided to fractionate it 
by column chromatography using silica gel (2 Kg) as stationary phase and a 
gradient of hexane/ethyl acetate/MeOH/H2O. A total of 241 fractions were 
obtained and observed under UV light and with developing reagents. They 
were pooled for chromatographic similitude into 19 final fractions (Table 4.3). 
For biological assays the fractions were reunited into 8 macro-fractions in 
order to simplify their evaluation (Table 4.4). 
 
Table 4.3 Fractions of CHCl3/MeOH (1:1) extract 
Fractions Polarity 
Isolated 
compound 
1-12 A 100% Hexane 6 
13-24 B 100% Hex - 90:10 Hex/EtOAc - 
25-26 C 90:10 - 80:20 Hex/EtOAc - 
27-39 D 80.20 - 70:30 Hex/EtOAc 7-8 
40-66 E 70:30 - 50:50 Hex/EtOAc - 
67-72 F 50:50 - 30:70 Hex/EtOAc 
9-10 73-78 G 20:80 Hex/EtOAc 
79-102 H 20:80 Hex/EtOAc 
103-110 I 20:80 - 100% EtOAc - 
111-121 
122-132 
J 90:10 - 70:30 EtOAc/MeOH 11 
133-138 K 70:30 - 60:40 EtOAc/MeOH - 
139-150 L 60:40 - 50:50 EtOAc/MeOH - 
151-162 M 50:50 - 40:60 EtOAc/MeOH - 
163-174 N 40:60 - 30:70 EtOAc/MeOH - 
175-186 O 30:70 - 20:80 EtOAc/MeOH - 
187-210 P 20:80 - 10:90 EtOAc/MeOH - 
211-222 Q 100% MeOH - 95:5 MeOH/H2O - 
223-240 R 90:10 - 50:50 MeOH/H2O 
12 
241 S 50:50 MeOH/H2O 
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Table 4.4 Pooled fractions of CHCl3/MeOH (1:1) extract 
Pooled fraction Solubility Polarity 
1-24 1 Hexane/hot CHCl3 Lowest 
25-66 2 CHCl3 Low 
67-102 3 Acetone Medium 
103-121 4 Acetone Medium 
122-138 5 Acetone/MeOH Medium-high 
139-162 6 MeOH high 
163-240 7 MeOH high 
241 8 MeOH/H2O highest 
 
 
4.2.6 Methylation of pooled fraction 1 
Fraction 1 (27.3 mg) was added to a 20 mL vial and were dissolved in 
1 mL of toluene. Then it was added to the stirring solution 1 mL glyceryl 
triundecanoate as internal standard (0.1005 g in 25 mL toluene) and 2 mL of 
sulfuric acid 7% solution in MeOH. The vial was heated in a water bath at 80 
°C for 1.5 h then let cool at room temperature. To reaction was added 4 mL 
hexane and the mixture was stirred 1 minute in a vortex. The vial was keep 
until the separation of phases occurred. The organic phase was dried with 
Na2SO4 anhydrous and transferred into a 10 mL volumetric flask. To the 
aqueous phase was added other 4 mL of hexane and the extraction was 
repeated. The second organic phase was also dried with Na2SO4 anhydrous 
and added to the first one. The pooled organic phase was then brought to a 
final volume of 10 mL with hexane. 
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4.2.7 Isolation and purification of phytochemicals 
4.2.7.1 Isolation and purification of heneicosane (6) 
It was recovered from fraction A, a white wax-like precipitate (206.2 g, 
0.00010388%). The compound does not reveal under UV light and it was 
found pure with ceric sulfate, revealing as a brown spot. 
 
4.2.7.2 Isolation and purification of triacontanol (7) 
From fraction D, it was recovered a white crystalline solid. The solid 
was washed several times with hexane and cold chloroform in order to 
eliminate the other less polar components of the fraction. The white crystals 
were filtrated and air dried giving a white sticky solid which was not visible 
under UV light but revealed with ceric sulfate. It was obtained in high purity 
(55.0 mg, 0.00002771%).  
 
4.2.7.3 Isolation and purification of p-coumaric acid (8) 
From fractions F-H, it was recovered a white-yellowish amorph solid. 
The solid was washed several times with hexane and cold chloroform in order 
to eliminate the other less polar components of the fraction. The white-
yellowish solid was filtrated and air dried giving a whitish solid which was 
visible under UV light as a dark spot (254 nm) and revealed with ceric sulfate. 
It was obtained in high purity (6.6 mg, 0.0003%).  
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4.2.7.4 Isolation and purification of margaric acid (9) 
From fractions F-H, it was recovered a pinkish amorph solid. The solid 
was washed several times with methanol in order to eliminate the other more 
polar components of the fraction. After the solid was washed it was air dried 
giving a whitish solid which was not visible under UV light but revealed with 
ceric sulfate. It was recovered in low purity (12.4 mg, 0.0006%).  
 
4.2.7.5 Isolation and purification of caffeic acid (10) 
From fraction I it was recovered a greenish amorph solid precipitate. 
The solid was then separated from the other components of the fraction by 
preparative TLC. Then it was purified with CC, still retaining some 
decomposition byproducts. Once the greenish solid was dried in vacuo it gave 
a green solid which was visible under UV light as a dark spot (254 nm) and 
revealed with ceric sulfate. It was obtained in high purity (3.0 mg, 0.0002%).  
 
4.2.7.6 Isolation and purification of daucosterol (11) 
The compound precipitated from fraction J as a white solid and it was 
washed with methanol several times, submerging the methanol suspension of 
the dirty compound in an ultrasounds bath for 15 minutes. The procedure was 
repeated until the solid resulted completely white and the methanol colorless. 
It was recovered with high purity (272.0 mg, 0.00013703%). 
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4.2.7.7 Isolation and purification of ΚCl (12) 
Potassium chloride precipitated during the drying of the whole extract, 
and it was washed first first with CHCl3 and then with MeOH until it was white. 
The process was repeated every time that a new volume of the (10 L) extract 
was concentrated by rotatory evaporation. Then the solid was recovered from 
the flask using methanol and an ultrasounds bath. The solid was then filtrated 
in vacuo resulting in 2.2787 g (0.00114796%). The compound does not reveal 
under the UV light or with ceric sulfate. 
 
4.2.7.8 X-ray analysis of KCl (12) 
 
 
For the characterization of KCl isolated from the CHCl3/MeOH extract 
an X-ray diffraction was necessary. The analysis was conducted first with the 
pure dusted crystalline compound confronting with the in-house database the 
obtained diffractogram (exploring XRD analysis).  
 
Figure 4.1 Example of XRD analysis 
 39 
Table 4.5 Exploring XRD analysis conditions 
 
The conditions for the IS-XRD analysis are reported in table 4.5. Once 
a matching compound was found its identity was confirmed by the addiction of 
an internal standard to the pure compound 12 (IS-XRD analysis). The 
conditions for this experiment are reported in table 4.6. 
 
Table 4.6 IS-XRD analysis conditions 
 
  
Experimental Condition of Exploring XDR Analysis 
2θ Range 5°- 90° 
Step  0.050° 
Step time 1.1 seconds 
Temperature 25°C 
Experimental Condition of IS-XDR Analysis 
2θ Range 5°- 90° 
Step  0.050° 
Step time 2.0 seconds 
Radiation of X-ray Tube (CuKα) λ = 1.5418 (average α1 and α2) 
Compound 12 crystalline solid 93.23% 
KCl (IS) 6.76% 
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4.2.8 Fractionation of the leaf dry aqueous extract 
The dry aqueous extract (972.3mg) was first analyzed by TLC (normal 
and reverse phase) observing the chromatographic plates under UV light and 
revealed with ceric sulfate. It was then decided to fractionate it by flash 
chromatography using a C18 reverse phase cartridge as stationary phase and 
a gradient of MeOH/H2O as mobile phase. A total of 6 soluble fractions plus a 
part of the extract that resulted non-soluble in the hydro-alcoholic eluent were 
obtained and observed under UV light and with the developing reagents. They 
were pooled for chromatographic similitude into 5 final fractions (Table 4.7). 
 
Table 4.7 Fractions of the dry aqueous extract (1:1) 
Pooled fraction Polarity 
1 A 50:50 H2O/MeOH 
2 B 60:40 H2O/MeOH 
3 C 70:30 H2O/MeOH 
4-6 D 80:20-100% H2O/MeOH 
7 E H2O soluble 
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4.3 Derivatization of the isolated compounds 
4.3.1 Acetylation of β-sitosterol (5) 
 
 
 
Figure 4.2 Acetylation of β-sitosterol 
 
β-sitosterol (25.3 mg, 0.06 mmol) was added in a 7 mL vial, then 0.5 
mL of pyridine was poured into the vial and the mixture was maintained in 
constant agitation. At this point 0.5 mL of acetic anhydride were added drop 
wise to the stirring solution (final concentration: 0.06 M), then the reaction was 
left stirring overnight at room temperature (r.t.). The reaction mixture was then 
diluted in 10 mL CHCl3 and washed four times with a 10 mL HCl 10% solution 
to eliminate the pyridine. The organic fraction was then dried with anhydrous 
sodium sulfate and concentrated under reduced pressure to give 27.3 mg 
(0.06 mmol) of acetylated product. The yield of the reaction was > 99%. A 
schematic representation of the reaction is shown in figure 4.2. 
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4.3.2 Acetylation of daucosterol (11) 
 
 
Figure 4.3 Acetylation of β-sitosteryl β-D-glucopyranoside (daucosterol) 
 
Daucosterol (29.7 mg, 0.05 mmol) was added in a 7 mL vial. Then 0.3 
mL of pyridine was poured into the vial and the mixture was maintained in 
constant agitation, until the solid was completely solubilized. At this point 0.7 
mL of acetic anhydride were added drop wise to the stirring solution (final 
concentration 0.05 M), then the reaction mixture was left stirring overnight at 
room temperature (r.t.). The reaction mixture was then diluted in 10 mL CHCl3 
and washed four times with a 10 mL HCl 10% solution to eliminate the pyridine. 
The organic fraction was then dried with anhydrous sodium sulfate and 
concentrated under reduced pressure to give 33.8 mg (0.05 mmol) of 
acetylated product. The yield of the reaction was of 91%. A schematic 
representation of the reaction is shown in figure 4.3. 
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4.3.3 Methylation of oleic acid (4) 
 
 
Figure 4.4 Methylation of oleic acid (C18:1, Δ9) 
 
Oleic acid (3.3 mg, 0.01 mmol) was added in a 7 mL vial. Then 0.1 mL 
of toluene was poured into the vial and the mixture was maintained in constant 
agitation, until the solid was completely solubilized. At this point 0.1 mL of a 
solution of H2SO4 in MeOH at 10% were added drop wise to the stirring 
solution (final concentration 0.06 M), then the reaction mixture was left stirring 
overnight at room temperature (r.t.). The reaction mixture was then diluted in 
10 mL EtOAc and washed four times with a 10 mL NaCl 5% solution, then it 
was washed once with NaHCO3 to neutralize the pH. The organic fraction was 
then dried with anhydrous sodium sulfate and concentrated under reduced 
pressure to give 3.8 mg (0.01 mmol) of acetylated product. The yield of the 
reaction was of >99%. A schematic representation of the reaction is shown in 
figure 4.4. 
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4.4 Metabolomics 
4.4.1 UPLC-QTOF-MS analysis 
Hexane, CHCl3/MeOH (1:1), dry and fresh aqueous extracts were 
solubilized in a mixture of MeOH and H2O (1:1) HPLC grade by sonicating. 
Samples were then centrifuged twice for 5 minutes at 10,000 revolutions per 
minute (rpm) and then the solutions were filtered through 2.2 µm syringe filters.  
Once the solutions were ready, they were injected by an automatic 
sampler into the column of UPLC equipment. The extracts were eluted with a 
gradient of H2O and methanol, for 11 minutes with constant flow and pressure 
(Table 4.8). 
 
Table 4.8 UPLC elution parameters. 
Time H2O MeOH Flow Pressure 
6.00 0.00 % 100.00 % 0.250 mL/min 900.00 bar 
10.00 0.00 % 100.00 % 0.250 mL/min 900.00 bar 
11.00 70.00 % 30.00 % 0.200 mL/min 900.00 bar 
 
The retrieved data was first analyzed by the equipment library METLIN. 
Then all the compounds that were not possible to identify were then 
investigated throughout various plant natural products databases. They were 
finally identified by comparation of their molecular weights with the reported 
ones. 
 
4.4.2 Statistical analysis 
Data obtained from UPLC-Q/TOF-MS analysis was submitted in the 
platform MetaboAnalyst 4.0. The modules employed were the Statistical 
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Analysis, which comprises various statistical and machine learning methods 
and the Integrating Enrichment Analysis and Pathway Topology Analysis for 
the metabolic pathway visualization. Each compound of the four extracts was 
reported on a table with their abundances in triplicate, in a dummy variable file 
fashion. The latter contains an abundance value or a zero, indicating the 
presence or the absence of a compound from a certain extract. In base of their 
abundance the program generates a series of scores which are then used to 
obtain a graphical comparation of the extracts. Once the table of the 
compounds was submitted the data was normalized using the default 
normalization parameters of the program. Different set of normalization 
parameters were tried in order to give the best result. At the end a logarithmic 
normalization was selected, together with the mean centering of the data. 
Also, a second table containing the compound classes was created and 
submitted to the program. 
After normalization the data finally underwent various statistical 
analysis: principal component analysis (PCA), analysis of variance (ANOVA) 
and metabolic pathways analysis. The latter was also used in the validation of 
cytotoxicity results. 
 
4.4.2.1 Analysis of variance (ANOVA) 
The analysis of variance or ANOVA (71) is a statistical test with the 
objective of determining the difference between two or more groups of 
variables. ANOVA checks the impact of one or more factors by comparing the 
means of different samples. It consists first in the calculation of the comparing 
factors: number of groups, sum of variables, average of variables and variance 
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among each group variables. Then these values are used “between group 
variability” and “within group variability” (Figure 4.5), which are the main 
indicators of the presence or absence of a difference among the samples. 
 
 
Figure 4.5 Variance between groups and within group for a null hypothesis (a) and a non-
null hypothesis (b) 
 
To calculate these values the means (µn) and grand mean (µ, mean of 
sample means) of each sample were calculated and used to obtain their 
squared standard deviations (SS). The SS were also multiplied by each 
sample size in order to give more weight to the larger samples. This was done 
for both variabilities obtaining the sum-of-squares for between-groups and 
within-group (SSb and SSw). Then the degrees of freedom are calculated for 
between (dfb) and within (dfw) group variabilities which are the number of 
samples means and the sum of the sample sizes minus the number of samples 
respectively. Then each SS is divided by its own df to obtain the mean square 
for within (MSw) and between (MSb) groups variabilities. All these calculated 
variables are a statistical estimation of the difference among the considered 
samples. This difference is also represented, in more general way, by two 
variables which are F-ratio (F) also called F-statistic and F-critical (Fcrit). F is 
the ratio of between groups and within group variabilities, instead Fcrit is 
considered as the cut-off value of the significance level (α). To represent Fcrit 
the F values of multiple experiments must be plotted into a diagram called F-
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distribution (Figure 4.6). The Fcrit value represent the beginning of an area of 
the plot called critical region which represent the probability of a null 
hypothesis based on α (0.05). Therefore, for a hypothesis to be null the value 
of F must be lower than the value of F-critical and fall in the critical region, 
while a non-null hypothesis must have and F with a higher value. Another way 
to evaluate the ANOVA result is by checking the p-value, if it is lower than the 
selected α value the null hypothesis is rejected. 
 
 
Figure 4.6 F-distribution with F-critical and critical area 
 
A One-Way, Two-Way and Three-Way ANOVA were used in the 
statistical manipulation of the cytotoxicity data since the experiments were 
conducted with the same conditions and on the same population. For the 
interpretation of the One-Way ANOVA results a t-test was employed, because 
the statistical analysis only gives as a result that at least two groups of samples 
are different from one another. The t-test allows a much specific comparation 
of two selected samples, giving their difference with one another. The term 
used to determine this aspect is the p-value calculated for both edges of the 
distribution or “tails”. If the p-value is lower than α level selected (0.05) than 
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the two compared samples are probable to belong to two entirely different 
populations. The magnitude of their difference depends on the extent of their 
numerical variance (72). In the metabolomic study the ANOVA was performed 
by the open access web platform MetaboAnalyst v4.0 (73). And the results 
were represented in various ways, the most intuitive being the hierarchical 
clustering (dendrogram and heatmap). The latter was obtained through the 
measure of the differences and similitudes among the extracts, which was 
given by the Euclidean measure and the Ward clustering algorithm. All results 
of the cytotoxicity assays were processed through ANOVA analysis performed 
with the software Prism v8.2.1. 
 
4.4.2.2 Principal component analysis (PCA) 
The principal component analysis (PCA) is a statistical method often 
employed in unsupervised metabolomic approaches. It consists in a 
multivariate analysis that allows the visualization of the relationships among 
large data sets. Data needs to be normalized and centered (often mean-
centered) before the statistical analysis. Then the values are transformed into 
a set of linearly correlated variables called principal components. These 
components are defined so that each one of them contains the highest level 
possible of variance. This way the system is described by the lowest number 
of orthogonal coordinates it requires. The results of the analysis are showed 
in the form of two- or three-dimensional plot of the generated component 
scores (factor scores) against the orthogonal components. The simplicity of 
results allows a more direct and intuitive analysis of the system’s differences. 
PCA can be used for supervised and reinforcement learning, such as 
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classification or regression, clustering and dimensionality reduction. It can also 
detect abnormalities in a large set of data and predict structured object, which 
is used in machine learning and data mining. Mostly PCA is employed in 
explorative data analysis, like in this work, and to make predictive models.  
 
4.4.2.3 Pathway analysis 
In the pathway analysis the identified compounds of a sample or 
extract, either by their names or IDs (KEGG, HMDB and PubChem), are 
confronted with the metabolites of another similar organism. In the database 
are also reported the biosynthetic and metabolic pathways of each metabolite 
for the selected organism. When an identified compound matches one in the 
database, its biosynthetic pathway is also shown. This generates a plot 
reporting the matched metabolites over their pathway impact. The latter 
reflects the number of compounds matched and the compound identity. The 
more identified compounds match the metabolites in the database and the 
more central is the role of the compound in the organism metabolism, the 
higher is the final score. The result of the analysis is a two-dimensional plot, 
reporting each identified metabolic pathway as a dot. The dots with higher 
score are bigger and shifted at higher pathway impact values and are 
considered the main pathways represented by the identified compounds. 
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4.5 Biological assays 
 
The antibacterial activity assay of phytochemicals and raw extracts 
were done in the Department of Gastroenterology of the University Hospital of 
the UANL. Instead the cytotoxic activity of the raw extracts was done in the 
Faculty of Pharmacy, Universidad Autónoma del Estado de Morelos. At last 
the mechanism of action assay was done in the laboratory of Genetic 
Engineering of the Postgraduate School of the UANL. 
 
4.5.1 Bacterial strains and inoculum preparation 
The antibacterial essays were performed using nine drug-resistant 
clinically isolated strains. The Gram-negative resistant bacteria are 
carbapenem resistant Acinetobacter baumannii (12-666), Escherichia coli 
producer of ESBL (14-2081), carbapenems resistant Pseudomonas 
aeruginosa (13-1391), oxacillin resistant Klebsiella pneumoniae (OXA-48), K. 
pneumoniae NDM-1+ (14-3335) resistant to carbapenems, and wide spectrum 
cephalosporins, K. pneumoniae producer of ESBL (14-2081). Instead the 
Gram-positive resistant bacteria are methicillin resistant Staphylococcus 
aureus (14-2095), linezolid resistant Staphylococcus epidermidis (14-583), 
vancomycin resistant Enterococcus faecium (10-984). Also, five sensitive 
strains purchased from the American type culture collection (ATCC) were 
employed. The Gram-negative are E. coli (ATCC 25922), P. aeruginosa 
(ATCC 9027), K. pneumoniae (ATCC 13883). Meanwhile the Gram-positive 
sensitive bacteria are: S. aureus (ATCC 25923), and E. faecium (ATCC 
29212). 
 51 
The strains were inoculated into plates prepared with 5% blood agar 
and cultured for 24 hours, with the exception of the carbapenem resistant P. 
aeruginosa and S. epidermidis strains, which were left for 48 hours (Figure 
4.7).  
 
 
Figure 4.7 Example of inoculum of E. faecium in agar blood 
 
For the preparation of the inoculum for the assay, three to five colonies 
from each culture were transferred to tubes with sterile saline solution, and the 
turbidity was adjusted to McFarland's 0.5 (1.5 x 108 CFU/ml). Then 10 μl were 
then transferred into 11 ml Mueller Hinton broth to reach a concentration of 5 
x 105 CFU/ml (74), according to the National Committee for Clinical Laboratory 
Standard (NCCLS) guidelines (75).  
 
4.5.2 Antibacterial activity assay 
The antibacterial activity was determined by the microdilution method. 
The essay was performed in 96-well microplates, adding 100 µL of culture 
medium in each well of the plate. Then in first and second well of the row A, 
were added 100 µL of the work solution (in duplicate) containing raw extracts, 
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extract fractions, isolated compounds or positive control (levofloxacin) with a 
concentration of 4X (2000µg/mL or 800µg/mL). The content of the wells was 
then mixed with multichannel micropipette, and from this mixture 100 µL were 
transferred to row B to produce a dilution 1:2, and this was repeated until 
reaching the row G, discarding the last 100 µL. Later 100 µL were taken from 
the tube with bacterial suspension previously adjusted to 0.5 McFarland and 
added to the wells with or without sample, for the negative and positive 
controls. 
 
ß 500 or 200 µg/mL 
ß 250 or 100 µg/mL 
ß 125 or 50 µg/mL 
ß 62.5 or 25 µg/mL 
ß 31.25 or 12.5 µg/mL 
ß 15.63 or 6.25 µg/mL 
ß 7.81 or 3.13 µg/mL 
ß Medium sterility control 
 
The microplate was then placed in the incubator at 37°C for 24 to 48 h. 
At the end of the incubation time the growth or inhibition of the bacteria was 
evaluated visually, taking as inhibition the wells where nor turbidity nor 
bacterial bottom deposition were observed. Each concentration was evaluated 
in duplicate. Levofloxacin was used as reference standard for the resistant 
strains while ampicillin (8 µg/mL) was used as positive control for the sensible 
strains. The minimum inhibitory concentrations (MICs) were determined (76). 
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4.5.3 Cell lines growth and harvest 
For the cytotoxic assays were used the following cellular lines obtained 
from the American Type Culture Collection (ATCC): liver cancer cells Hep3B 
and HepG2, lung cancer cells A549, cervix cancer cells HeLa, breast cancer 
cells MCF7, prostate cancer cells PC3, and normal immortalized hepatocytes 
IHH. Cells were cultured in RPMI 1640 or EMEM medium, supplemented with 
10% (v/v) inactivated fetal bovine serum, 100 U/mL penicillin and 100 μg/mL 
streptomycin sulfate, 2 μg/mL glutamine, 0.25 μg/mL amphotericin B and the 
needed growth factors. Cells were maintained in a humidified atmosphere 
(95% humidity) with 5% CO2 at 37°C for 24 h prior to the addition of the 
extracts, fractions or compounds (70). Right before treatment cells were 
removed from the tissue culture flasks by treatment with trypsin and diluted 
with fresh media. 
 
4.5.4 Cytotoxic activity assay 
The cytotoxic activities were determined using the metabolism-
dependent dye Owen’s reagent (MTS) or WST1 in a microculture method. Cell 
suspensions, containing 5000 or 7500 cells per well, were added into 96-well 
microplates, and incubated at 37°C for 24h in a 5% CO2 atmosphere to reach 
exponential growth. After 24h, 100 μL of tested compounds, raw extracts or 
positive control at various concentrations were added to each well starting 
from 100 μg/mL. The cultures were exposed to compounds for 48h. After 
incubation time, cells were stained by the addition of 40µL of MTS or WST1. 
After 2 hours of incubation at 37°C in a humidified atmosphere (95% humidity) 
with 5% CO2 the absorbance at 490nm was read in a microplate reader. The 
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inhibitory concentration at 50% (IC50) was determined (77). Paclitaxel was 
used as positive control. Extracts and fractions were considered active when 
their IC50 gave £ 30 µg/mL. This threshold was selected in accordance to the 
National Committee for Clinical Laboratory Standards (NCCLS) guidelines. 
The latter also stipulates that extracts shall be tested at a centration not 
exceeding 1 mg/mL (78). 
 
4.5.5 Biodirected cytotoxicity screening 
The biodirected cytotoxicity screening was done by WST1 cytotoxic 
assay. PC3 and MCF7 cells were treated for 48h with 100, 50 and 25 µg/mL 
of each fraction of CHCl3/MeOH extract. The percentage of viable cells per 
well was then obtained. 
 
4.5.6 Microarray assay 
PC3 and MCF7 cells were treated for 24h with the selected compound 
at its IC50. Untreated cells were used for the comparation of the gene 
expression after treatment. Total ribonucleic acid (RNA) isolation was pursued 
using TRIzolTM Reagent (Invitrogen), following manufacturer instructions. The 
quality control of RNA was determined by using agarose gel (1%) and total 
RNA was quantified in an Eppendorf 6131 biophotometer (Eppendorf, 
Hauppauge, NY, USA). RNA quantity was adjusted to 20 µg for both treated 
and untreated controls. The modified complementary DNA (cDNA possessing 
the nucleotide aminoallyl-uridine) was synthesized using the amino-allyl cDNA 
labeling kit. The fluorescent dyes Cy3 and Cy5 from the CyDye Post-Labeling 
Reactive Dye Packs were used for labeling the cDNA. Each vial of fluorescent 
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dye was dissolved in 3 µL of DMSO and mixed with one specific cDNA. A 
NucAway column were used to eliminate the excess of unbound fluorophore 
(79–83).  
The microarray hybridization was performed on a 35K human genes 
chip using the procedure described in the protocol by MYcroarray Company 
(Ann Arbor, MI, USA). The procedure took place in a hybridization chamber 
G2534A (Agilent, Santa Clara, CA, USA), fluorophore incorporation efficiency 
was analyzed measuring absorbance at 555 nm for Cy3 and 647 nm for Cy5 
using Gene Pix 4000B scanner. Data was then submitted to statistical analysis 
performed using the GenArise package in order to obtain Zscore values, which 
were negative or positive according to down- or up-regulated genes 
expression after treatment with the compound. Genes with Zscore ≥ +2 and 
Zscore ≤ -2 were selected to carry out the gene expression analysis. Both lists 
of genes were analyzed separately for the biological pathways identification, 
using bioinformatics tools such as Database for Annotation, Visualization and 
Integrated Discovery (DAVID) version 6.8. The database tools employed in 
the analysis were: Functional Annotation and Gene Functional Classification 
(83, 84).  
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4.6 In silico study 
4.6.1 Explorative docking 
The crystalline structure of the target protein was retrieved from the 
Protein Data Bank (85). Incomplete protein structures were fixed through the 
generation of theoretical models using online platforms such as I-TASSER, 
Galaxy WEB and SWISS-MODEL (86–88). The obtained models were 
completed with their cofactors (if possible) and submitted to a brief molecular 
dynamic of 2 ns, using the software Maestro release 2019-3 (Schrödinger) 
(89). The 3D model of the ligand was drawn using the molecular builder 
Avogadro 1.2.0 (90). These files were then opened with the opensource 
molecular modeling program UCSF Chimera (91), and were both prepared for 
the molecular docking. Using the Docking Preparation wizard (DockPrep) 
available in the program the functional groups of target and ligand were 
determined, and the polar and non-polar hydrogens were added. Small protein 
chain gaps or missing residues were replaces using the Dunbrack 2010 
rotamers library (92). AutoDock Vina version 1.1.2 plug-in was used in 
Chimera for the docking experiments. The opal web service (server: 
http://nbcr-222.ucsd.edu/opal2/services/vina_1.1.2) was used as host for the 
docking simulations. The resulting docked structures of the ligand were then 
rewritten separately as .pdb files for a simpler handling and were processed 
in the Maestro suit (Figure 4.8). 
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Figure 4.8 Example of Docking results viewed in Maestro: docked ligand structures in 
protein ribbons (left); docked ligand structures in the active site cavity represented as a 
molecular surface (right) 
 
4.6.2 Molecular dynamics (MD) 
The pdb files of protein and docked ligand structures were processed 
by the software Maestro. First the structures were preprocessed with the 
preprocess wizard and the protein structure fixed and its energy was 
minimized. One docked ligand structure was selected in base of its score, site 
of binding and protein interaction. The best docked ligand and protein 
structures were then merged, and the resulting file was processed with the 
molecular builder wizard of the Desmond suit of Maestro. The ligand-protein 
complex was enclosed into an orthorhombic boundary box and solvated 
adding water molecules in the SPC model. The model represents the 
hydrogens and the oxygen of the water molecules as charged sphere. Na+ 
ions were used to neutralize eventual residual charges of the protein. 
Meanwhile both Na+ and Cl- ions were added to a concentration of 0.15 M in 
order to generate a physiological-like salinity. If the protein was of the 
transmembrane type, a membrane was generated before solvation using 
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phosphatidyl choline (POPC; 300 K) as phospholipids. The resulting file was 
saved into a cms format.  
Using the Desmond’s molecular dynamics wizard, the molecular 
dynamics conditions were set. The duration of the simulation was set to 10 ns, 
the recording interval for the trajectory was every 10 ps and the consequent 
approximate number of frames was 1000. The temperature was set to 310.15 
K (corporeal temperature), while the system’s pressure to 1.013225 bars.  
To maintain these conditions Nose-Hoover chain algorithm and 
Martyna-Tobias chain algorithm were used as thermostat and barostat 
respectively. The Coulombic interaction was calculated by the short-range 
method and the cutoff was set to 9.0 Å. Finally the bonded RESPA integration 
was performed with time step of 2.0 fs (near: 2.00 and far: 6.00) (93). Table 
4.9 reports all the settings employed in the MD simulations. 
 
Table 4.9 MD’s settings 
System Builder 
Na+ and Cl- concentration 0.15 M 
Membrane POPC 300K 
Molecular Dynamic 
Simulation time 10 ns 
Trajectory recording interval 10 ps 
Frames number 1000 
Temperature 310.15 K 
Pressure 1.01325 bar 
Coulombic cutoff 9.0 Å 
RESPA time step 2.0 fs 
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4.6.3 Cluster analysis and binding energy (∆Ebound) determination 
Results of molecular dynamics were processed with the Desmond 
trajectory clustering wizard. The output cms file was clustered to a maximum 
of 5 clusters for each target protein, which were selected and exported from 
the trajectory movie. The clusters with the higher number of members were 
considered as the representative for each ligand-protein complex. Also, using 
the simulation event analysis and simulation quality analysis wizards the 
goodness of the results was checked. The variation of volume (Å3), 
temperature (K), pressure (bar), potential energy and total energy (kcal/mol) 
of the system were analyzed for their average, standard deviation and slope 
(ps-1). The results were also plotted in order to check visually the quality of the 
analysis (Figure 4.10 A).  
 
 
Table 4.10 Example of MDs parameters monitored during the simulation. A) From top to 
bottom: total energy, potential energy, temperature, pressure, volume (simulation time: 0-
10,000 ps). B) Top: protein residues movement (Å), RMSF; bottom: protein backbone (Cα) 
movement (Å), RMSD. 
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Other properties of the system that were checked are the coulomb and 
van der Waals interaction energies, root-mean-square deviation (RMSD) of 
atomic positions and root-mean-square fluctuation (RMSF) of atomic 
positions. In this specific case it was decided to monitor with the RMSD the 
movement of the protein backbone (Cα) and with the RMSF the movement of 
the protein residues. The RMSD and RMSF were graphed in order to visualize 
the average movement of the system over the simulation time (Figure 6.10 B). 
After the more representative cluster was selected, the electrostatic and van 
der Waals (vdW) energy for the bound and free ligand were calculated using 
the Desmond simulation event analysis wizard. These parameters were 
considered as the ligand-protein (bound) and ligand-solvent (free) interaction 
energies for both coulombic ( !"#$"  and 	!"%$" ), and vdW ( !"#&'( and !"%&'( ) 
parameters. Finally, the binding energy (∆Ebound) was calculated with the linear 
interaction energy (LIE) equation (Equation 4.2). 
 
∆!A301' = BC!"#&'( − !"%&'(D + EC!"#$" − !"%$"D + F 
Equation 4.2 Linear interaction energy (LIE) equation 
 
In the equation α, β and γ are scaling factors which have the default 
values of 0.16, 0.5 and 0. The LIE equation is used in cheminformatics to find 
a suitable compounds for disease-related targets or to predict the goodness 
of a ligand-protein interaction (94). 
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CHAPTER 5 
5. RESULTS AND DISCUSSION 
 
 
5.1 Phytochemistry 
5.1.1 Preparation of the vegetal material 
The first step in the preparation of the vegetal material was the drying 
of leaves and roots in the darkness. In particular the leaves were then cut into 
small pieces to allow a faster dehydration of the very juicy and water reach 
tissues. Instead the roots were left to dry almost intact to reduce the oxidation 
of its components. The drying process was fundamental in the prevention of 
the growth of microorganisms on the plant samples which would have modified 
the metabolites content of the plant, leading to a wrong identification of the 
plant’s phytochemical composition. Also, the drying process eliminates the 
water from the material, fixes the phytochemicals and reduces the probability 
of molding of the vegetal material. The leaves were allowed to dry for 1 month 
at room temperature and away from the sun light. The low temperature and 
the dark conditions were of outmost importance, since the plant composition 
was unknown. In fact, heating or exposing to the light the vegetal material 
could have caused the degradation of sensible and important molecules.  
Some plant’s leaves were dried and were blended fresh in distilled 
water. This was done in the hypothesis that some of the compounds of the 
plant could have been decomposed during the drying process. This might 
have happened throughout oxidation by the oxygen present in the air or the 
 62 
reaction of some components with each other. These reactions could be 
explained by the growing concentration of the compounds in the tissues while 
drying or simply by the exposure to the atmosphere, when the cellular 
structures were broken in the preparation of the vegetal material. So, by 
blending the leaves fresh and conserving the lyophilized extract at 4 °C, it was 
ensured the stabilization of the extracted molecules. 
The double grounding of the dried leaves and roots, first grounded into 
a coffee grinder and then into a blender, was of outmost importance to reduce 
as much as possible the particles size. This will give a more intimate contact 
between the solvent and the vegetal material during the maceration and allow 
the solvent to penetrate the cellular structures to maximize the extraction.  
 
5.1.2 The hexane maceration 
The first volatile solvent extract was made in hexane with the purpose 
of defating the vegetal material. This solvent, being very non-polar, has the 
ability of extracting the majority of the non-polar metabolites, such as fatty 
acids, triglycerides, terpenoids, steroids, between others. So, this maceration 
had the objective of simplify the sequent and much more complex extract. The 
molecules that were isolated from the fractionation of the leaves extract were 
five, from compound 1 to 5 and their physical, chemical and spectroscopic 
properties are described in the next paragraphs. Instead for the roots, since 
no chromatographic separation was planned just a small quantity of material 
was macerated. 
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5.1.3 Leaves isolated and purified phytochemicals 
5.1.3.1 Physic and spectroscopic data of nonacosane (1) 
 
 
Figure 5.1 Structure of nonacosane (1) 
 
Compound 1 (Figure 5.1) was found to be soluble in nonpolar solvents 
like hexane or CHCl3 and its solubilization was facilitated by heating the 
solvent. It had a low melting point (mp) of 43-46°C and its molecular formula 
is C29H60. 
IR (cm-1): 2800-3000, 1485, 750. 1H NMR (400 MHz, CDCl3) d (ppm): 
0.88 (t, J=6.8 Hz, 6H, 2Me), 1.25 (s, 54H). 13C NMR (100 MHz, CDCl3) d (ppm): 
14.28 (2Me), 22.86 (C-2;C-22), 29.53 (C-4;C-20), 29.86 (21C), 32.09 (C-3;C-
21). GC-MS Rt (min): 102.298; (EI) m/z: 408 (M+•), 57 (100%), 71 (80%), 85 
(70%), 43 (50%), 99 (25%). 
 
5.1.3.1.1 Structural elucidation of nonacosane (1) 
 
Figure 5.2 IR spectrum of nonacosane (1) 
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The IR spectrum (Figure 5.2) of this compound showed only 
hydrocarbon signals: the aliphatic C-H stretching from 2800 to 3000 cm-1, and 
the CH2 scissoring at 1485 cm-1 and rocking at 750 cm-1, indicative of long 
carbon chain.  
 
 
Figure 5.3 EI/MS spectrum of nonacosane (1) 
 
The electron ionization mass spectrum (Figure 5.3) of nonacosane is 
typical of a long chain alkane. This is clear from the constant difference of 14 
between the various ion peaks. This loss doesn’t represent an actual weight 
but indicate instead the repetitive loss of a 28 Da fragment. This is 
characteristic of this class of molecules. Among the important peaks of the 
spectrum are the molecular ion (M+•), with a weight of 408 m/z and the base 
peak of 57 m/z also characteristic of alkanes. The identity of the molecule was 
also confirmed by comparation of the spectrum with the NIST library. 
The 1H NMR spectrum (Figure 5.4) showed signals typical of alkanes 
molecules, with an upfield triplet that integer for 6 hydrogens at 0.88 ppm 
(J=6.8 Hz, 2Me) and a less downfield singlet that integer for the other 54 
protons. The absence of any other signal was indicative of the alkane nature 
of the molecule.  
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The 13C NMR spectrum (Figure 5.5) also showed an alkane pattern with 
very few signals, which were related to a pair of carbons each: the terminal 
methyl groups at 14.28 ppm, and all the other carbons following them in chain, 
at 22.86 ppm (C-2 and C-22), 29.53 ppm (C-4, C-20) and 32.09 ppm (C-3, C-
21). Then it was present a much more intense signal at 1.25 ppm related to all 
the other carbons of the molecule (21C).
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Figure 5.4 1H NMR spectrum (400MHz, CDCl3) of nonacosane (1) 
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Figure 5.5 13C NMR spectrum (100MHz, CDCl3) of nonacosane (1) 
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5.1.3.2 Physic and spectroscopic data of hexatriacontanyl stearate (2) 
 
 
 
Figure 5.6 Structure of hexatriacontanyl stearate (2) 
 
This long chain wax (Figure 5.6) was very soluble in CHCl3 and partially 
soluble in hexane. It had mp of 73-75°C and its molecular formula is C54H108O2. 
IR (cm-1): 2800-3000, 1750, 1485, 1185, 750. 1H NMR (400 MHz, 
CDCl3) d (ppm): 0.87 (t, J=6.7 Hz, 6H, 2Me), 1.25 (s, 94H), 1.61 (p, J=6.9 Hz, 
4H), 2.28 (t, J=7.5 Hz, 2H), 4.05 (t, J=6.7 Hz, 2H). 13C NMR (100MHz, CDCl3) 
d (ppm): 14.12 (2Me), 22.70 (C-17;C-35’), 25.05 (C-34’), 25.95 (C-16), 28.67 
(C-15), 29.37 (C-32’;C-33’), 29.71 (40C), 31.94 (C-2’;C-3), 34.44 (C-2), 64.40 
(C-1’), 174.01 (C-1). 
 
5.1.3.2.1 Structural elucidation of hexatriacontanyl stearate (2) 
The IR spectrum (Figure 5.7) of the molecule showed aliphatic signals 
between 2800 and 3000 cm-1 and relative CH2 scissoring and rocking 
respectively at 1485 and 750 cm-1. Then it showed a carbonyl signal at 1750 
cm-1 and a C-O stretching at 1185 cm-1, indicating a long chain ester. 
The 1H NMR spectrum (Figure 5.8) showed signals typical of long chain 
esters, with a upfield triplet at 0.87 ppm (J= 6.7, 6H, 2Me) that integer for 6 
hydrogens and a more downfield singlet that integer for the other 94 protons 
(1.25 ppm), typical of long chains of CH2. Then a triplet at 2.28 ppm (J=7.5 Hz, 
2H, H-2), is indicative of the presence of a carbonyl group attached to a long 
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chain of carbons and at last, the proton signal indicative of the presence of an 
oxygen directly attached to a CH2 is the triplet at 4.05 ppm (J=6.7 Hz, 2H, H-
1) and a pentaplet at 1.61 ppm (J=6.9 Hz, 4H, H-3; H2’) relative the hydrogens 
3 and 2’. The 13C NMR spectrum (Figure 5.9) also showed a long chain ester 
molecule pattern with very few signals in the downfield region and a lot of 
signals in the upfield region of the spectrum. A very intense signal at 29.71 
ppm corresponds to the majority of the CH2 of the molecule. But the signals 
that were decisive to characterize the molecule are the one at 65.40 ppm 
relative to the carbon attached to the oxygen and the one at 174.01 ppm which 
is characteristic of esters’ carbonyl groups. 
 
 
Figure 5.7 IR spectrum of hexatriacontanyl stearate (2) 
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Figure 5.8 1H NMR spectrum (400MHz, CDCl3) of hexatriacontanyl stearate (2) 
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Figure 5.9 13C NMR spectrum (100MHz, CDCl3) of hexatriacontanyl stearate (2) 
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5.1.3.3 Physic and spectroscopic data of hexacosanol (3) 
 
 
 
Figure 5.10 Structure of hexacosanol (3) 
 
The alcohol (Figure 5.10) gave crystals in small flat crystals flakes with 
a chromium shade. It resulted to be very soluble in CHCl3 but less soluble in 
other nonpolar solvents. The compound resulted to have mp of 76-77°C and 
its molecular formula is C23H48O. 
IR (cm-1): 3300, 2800-3000, 1485, 11050, 750. 1H NMR (400 MHz, 
CDCl3) d (ppm): 0.88 (t, J=6.8 Hz, 3H), 1.25 (s, 46H), 1.57 (p, J=13.2, 6.7 Hz, 
2H), 3.64 (t, J=6.6 Hz, 2H). 13C NMR (100MHz, CDCl3) d (ppm): 14.12 (CH3), 
22.70 (C-25), 25.75 (C-24), 29.37 (C-23), 29.44 (C-2), 29.71 (18C), 31.93 (C-
3), 32.83 (C-2), 63.12 (C-1). 
 
5.1.3.3.1 Structural elucidation of hexacosanol (3) 
The IR spectrum (Figure 5.11) of the compound showed an O-H 
stretching signal at 3300 cm-1 and also it was visible a C-O stretching at 
1050cm-1. The rest of the signals were all aliphatic C-H stretching (from 2800 
to 3000 cm-1) and bending (scissoring: 1485 cm-1 and rocking: 750 cm-1). All 
the signals were indicative of a long carbon chain alcohol. 
The 1H NMR spectrum (Figure 5.12) showed signals typical of long 
chain alcohol, with an upfield triplet at 0.88 ppm (J=6.8 Hz, 3H, Me) that integer 
for the terminal methyl group and a more downfield singlet that integer for the 
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other 46 protons (1.25 ppm), typical of long chains of CH2. Then a double 
pentaplet at 1.57 ppm (J=11.3, 6.8 Hz, 2H, H-2) followed by a triplet at 3.64 
ppm (J=6.6 Hz, 2H, H-1), are indicative of the presence of an oxygen attached 
to a long chain of carbons. The absence of any other signal showed that 
oxygen doesn’t have any substituent and that the molecule is an alcohol. The 
13C NMR spectrum (Figure 5.13) also showed a long chain alcohol molecule 
pattern with very few signals in the downfield region and a lot of signals in the 
upfield region of the spectrum. A very intense signal at 29.71 ppm is related to 
the majority of the CH2 of the molecule. But the signal that was decisive to 
characterize the molecule was the one at 63.12 ppm relative to the carbon 
attached to the oxygen which is characteristic of alcohols. 
 
 
 
Figure 5.11 IR spectrum of hexacosanol (3) 
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Figure 5.12 1H NMR spectrum (400MHz, CDCl3) of hexacosanol (3)l 
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1 
Figure 5.13 13C NMR spectrum (100MHz, CDCl3) of hexacosanol (3) 
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5.1.3.4 Physic and spectroscopic data of oleic acid (4) 
 
 
 
Figure 5.14 Structure of oleic acid (4) 
 
This fatty acid (Figure 5.14) was very soluble in CHCl3 and in the 
majority of the other nonpolar solvents. It had mp < 25°C, it is transparent, 
colorless oil and its molecular formula is C18H34O2 (18:1∆9). The spectroscopic 
data of compound 4 is shown in Table 5.1. 
 
Table 5.1 Spectroscopic data of oleic acid (4) 
n 
1H NMR (500 
MHz, CDCl3) δ 
(ppm), (95) 
1H NMR (400 MHz, 
CDCl3) δ (ppm), 4 
13C NMR 
(125MHz, CDCl3) 
δ (ppm), (95) 
13C NMR 
(100MHz, CDCl3) 
δ (ppm), 4 
1 - - 180.2065 179.02 
2 2.3495 t 2.35 (t, J=7.5 Hz, 2H) 34.0529 33.91 
3 1.6326 p 1.63 (p, J=7.3 Hz, 2H) 31.7903 31.93 
4 - - 29.7376 31.91 
5 - - 29.6750 - 
6 - - 29.1471 - 
7 - - 29.0665 - 
8 2.0125 q 2.01 (psq, J=6.4 Hz, 2H) 27.2225 27.22 
9 5.3546 q 5.35 (m, 1H) 130.0219 130.02 
10 5.3397 q 5.34 (m, 1H) 129.7343 129.72 
11 2.0125 q 2.01 (psq, J=6.4 Hz, 2H) 27.1518 27.16 
12 - - 29.0299 - 
13 - - 29.0003 - 
14 - - 24.6533 24.70 
15 - - 22.6721 22.68 
16 0.8834 0.88 (t, J=6.7 Hz, 3H) 14.1286 14.11 
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5.1.3.4.1 Structural elucidation of oleic acid (4) 
The 1H NMR spectrum (Figure 5.15) showed signals typical of 
unsaturated long chain molecule, with a upfield triplet at 0.88 ppm (J=6.7 Hz, 
3H, Me) that integer for the terminal methyl group and a more downfield 
multiplet that integer for other 18 protons (1.28 ppm), typical of long chains of 
CH2. Then a pentaplet at 1.63 ppm (J=7.3 Hz, 2H, H-3) followed by a pseudo 
quartet at 2.01 ppm (J=6.4 Hz, 4H, H-8 and H-11), which are relative to the 
CH2 in β to the carboxyl group and the two allylic CH2 positions of the molecule 
respectively. At 2.35 ppm there is a triplet (J=7.5 Hz, 2H, H-2), that is due to 
the protons in the  a position with respect on the carboxyl group and was 
consequently indicative of a carboxylic acid. The last signals are two multiplets 
at 5.35 ppm (m, 1H, H-9) and 5.34 ppm (m, 1H, H-10) typical of 
monounsaturated fatty acids.  
The 13C NMR spectrum (Figure 5.16) also showed a long chain fatty 
acid pattern with very few characteristic signals in the downfield region: at 
179.02 ppm (the Sp2 carbon of the carboxylic group, C-1) and at 130.02 ppm 
and 129.72 ppm (the Sp2 carbons of the double bond of the molecule, C-9 and 
C-10). There were instead a lot of signals in the upfield region of the spectrum 
(Figure 5.17): at 33.91 ppm (the carbon in α to the carboxyl group, C-2), at 
31.93 ppm (the carbon in  β to the carboxyl group, C-3). Then between 29.00 
ppm and 29.80 ppm there is a region intensively populated of signals which 
correspond to the majority of the CH2 of the molecule and its characteristic of 
monounsaturated fatty acids. Following at 27.22 ppm and 27.16 ppm are the 
signals relative to the allylic carbons (C-8 and C-11) and at 24.70 ppm, 22.68 
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ppm and 14.11 ppm there are the final carbons of the chain of the acid, 
respectively C-14, C-15 and the terminal methyl group C-16.  
The molecule was also analyzed using 2D NMR experiments: 1H-
1HCOSY, 1H-13C HSQC, 1H-13C HMBC and 1H-1H NOESY. All the spectra 
confirmed the same molecule and in particular the HSQC experiment was 
important for the precise assignation of all the signals of the molecule (Figure 
5.18). 
All the assigned signals were also confirmed from the literature (95), 
although the inconsistence between the integration of some of the protons in 
the 1H NMR spectrum (specifically the allylic and vinylic protons) still rise some 
doubts about the purity of the sample. This last one was confirmed by GC-MS 
analysis, but the current hypothesis is that the sample is probably a mixture of 
the cis and trans isomers of the monounsaturated fatty acid. 
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Figure 5.15 1H NMR spectrum (400MHz, CDCl3) of oleic acid (4) 
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Figure 5.16 13C NMR spectrum (100MHz, CDCl3) of oleic acid (4) 
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Figure 5.17 13C NMR spectrum (100MHz, CDCl3) of oleic acid (4) - expansion 
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Figure 5.18 1H-13C HSQC spectrum (400MHz, CDCl3) of oleic acid (4) 
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5.1.3.5 Physic and spectroscopic data of β-sitosterol (5) 
 
 
 
Figure 5.19 Structure of β-sitosterol (5) 
 
Compound 5 (Figure 5.19) was separated in large amounts from its 
fraction and after purification by CC it was found to crystalize into colorless-
yellowish needles. The pure steroid has a strong tea odor. It resulted to be 
very soluble in CHCl3 but less soluble in other nonpolar solvents, unless other 
components of its native fraction were dissolved first. The compound resulted 
to have mp of 138-140°C and its molecular formula is C29H50O. The following 
spectral data for compound 5 were also confronted with the literature (Table 
5.2). 
1H NMR (400 MHz, CDCl3) d (ppm): 0.68 (s, 3H), 0.81 (d, J=6.9 Hz, 
3H), 0.83 (d, J=7.4 Hz, 3H), 0.84 (t, J=7.4 Hz, 3H), 0.92 (d J=6.6 Hz, 3H), 1.01 
(s, 3H), 1.68 (de, J=7.4, 6.8 Hz, 1H), 1.84 (m, 3H), 1.99 (m, 2H), 2.29 (ddd, 
J=20.9, 13.3, 2.6 Hz, 2H), 3.52 (m, 1H), 5.35 (psd, J=5.5Hz, 1H). 13C NMR 
(100MHz, CDCl3) d (ppm): 11.87 ppm (C-18), 11.99 ppm (C-29), 18.79 ppm 
(C-21), 19.04 ppm (C-27), 19.41 (C-19), 19.83 ppm (C-26), 21.10 (C-11), 
23.08 (C-28), 24.31 (C-15), 26.09 (C-23), 28.26 (C-16), 29.17 (C-25), 31.68 
(C-2), 31.91 (C-8), 31.93 (C-7), 33.96 (C-22), 36.16 (C-20), 36.52 (C-10), 
37.26 (C-1), 39.79 (C-12), 42.32 (C-4), 42.33 (C-13), 45.84 (C-24), 50.14 (C-
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9), 56.07 (C-17), 56.78 (C-14), 71.82 (C-3), 121.72 (C-6), 140.76 (C-5). GC-
MS Rt (min): 115.146; (EI) m/z: 414 (M+•), 396 (50%), 329 (50%), 273 (25%), 
255 (25%). 
 
5.1.3.5.1 Structural elucidation of β-sitosterol (5) 
 
 
Figure 5.20 EI/MS of β-sitosterol (5) and characteristic fragmentations 
 
The EI/MS spectrum of compound 5 showed loss of 18 units from the 
molecular ion (m/z: 414), which is characteristic of secondary alcohols. This 
fragmentation generates the radical cation with m/z 396 important for the 
structure elucidation. Other fragmentations of particular relevance are the 
partial loss of the side chain, as a radical of 85 Da, giving as result a cation 
with m/z 329. Also, the total loss of the side chain, as a radical of 141 Da giving 
the cation with m/z 273 is characteristic of sterols. The last cation of m/z 255 
m/z: 414.39 (100.0%)
HO
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H H
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can be generated as well from the radical cation of 396 m/z, which gives as 
well important information over the molecule’s structure. The mass spectrum 
and the most important fragments in the process of confirmation of the sterol 
are reported in figure 5.20. The NIST library was also used to counter check 
the obtained results. 
The 1H NMR spectrum (Figure 5.21) showed signals typical of a steroid, 
with a lot of signals in the upfield region. They are given from all the protons 
of the aliphatic hydrogens of the four rings and substituents of the molecule. 
The most important and simpler to recognize are the signals relative to all the 
CH3 of the compound, which give very intense, of small multiplicity and upfield 
signals: the singlet at 0.68 ppm (3H, Me-18), the doublet at 0.81 ppm (J=6.9 
Hz, 3H, Me-27), the doublet at 0.83 ppm (J=7.4 Hz, 3H, Me-26), the triplet at 
0.84 (J=7.4 Hz, 3H, Me-29), the doublet of 0.92 ppm (J=6.6 Hz, 3H, Me-21) 
and the singlet at 1.01 ppm (3H, Me-19). Other signals that were assigned are 
some more downfield signals: the double heptaplet at 1.68 ppm (J=7.4, 6.8 
Hz, 1H, H-25), a multiplet that integer for three protons at 1.84 ppm (H-1a, H-
2b and H-16a), as visible from the HSQC spectrum. Then follow another 
multiplet that integer for other two protons at 1.99 ppm (H-2a and H-12a) also 
confirmed by the HSQC spectrum, the signal at 2.29 ppm (ddd, J=20.9, 13.3, 
2.6 Hz, 2H, H-4). The multiplet relative to the proton germinal to the hydroxyl 
group at 3.52 ppm (m, 1H, H-3), the position of the latter was also confirmed 
by the HMBC experiment was the 3J correlation between H-3 and C-5 was 
also observed. Then it is followed by the most shielded signal of the vinylic 
hydrogen at 5.35 ppm (psd, J=5.5 Hz, 1H, H-6) and the position of the double 
bond was also confirmed by 3J correlation between H6 and C-10 and H-3 and 
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C-5; these last signals in particular were the decisive ones in the 
characterization of the type of sterol analyzed.  
The 13C NMR spectrum (Figure 5.22) also showed a steroid pattern with 
very few signals in the downfield region: a quaternary carbon at 140.76 ppm 
(C-5), the vinylic carbon at 121.72 ppm (C-6), these two signals were decisive 
for the characterization of the sterol, because confirmed the presence of the 
double bond and its position in the molecule (as shown by the HMBC 
correlations). Then there is the carbon directly attached to the hydroxyl group 
at 71.82 ppm (C-3), which also was important to confirm the presence of a 
hydroxyl group (as shown by the HMBC correlations). In contrast to the 
downfield region, there were a lot of signals in the upfield region of the 
spectrum (Figure 5.23) which were all relative to the protons of the steroid 
rings and lateral chain. Especially simple to recognize were the methyl 
carbons at 11.87 ppm (C-19), 11.99 ppm (C-29), 18.79 ppm (C-21), 19.04 ppm 
(C-27), 19.41 (C-18) and 19.83 ppm (C-26). These signals are the most 
shielded of the spectrum and are characteristic of steroid molecules. It was 
also taken a 1D DEPT135 spectrum (Figure 5.24) which was useful to 
individuate some overlapping signals like the ones at 31.93 and 31.91 ppm 
(C-7 and C-8). The assigned signals were also confirmed from the literature 
(96). 
The molecule was also analyzed using 2D NMR experiments: 1H-
1HCOSY, 1H-13C HSQC, 1H-13C HMBC (Figure 5.25) and 1H-1H NOESY. All 
the spectra confirmed the same molecule and in particular the NOESY 
experiment was important for the determination of the stereocenters 
configuration (Figure 5.26). In fact, from the NOESY spectrum was possible to 
 87 
observe the lack of correlation between the H3 and any other methyl group of 
the molecule. The most important being Me-18 and Me-19 which are clearly 
pointing on the opposite diastereotopic face of the molecule. The 
configurations of these groups with respect to the one of the H3, confirms the 
configuration for all the stereocenters of the steroid as the β stereoisomer of 
the sitosterol. 
 
Table 5.2 Spectroscopic data of β-sitosterol (5) 
n 
1H NMR (400 
MHz, CDCl3) 
δ (ppm), (96) 
1H NMR (400 MHz, 
CDCl3) δ (ppm), 5 
13C NMR 
(100MHz, CDCl3) 
δ (ppm), (96) 
13C NMR 
(100MHz, CDCl3) 
δ (ppm), 5 
1a - 1.84 m 37.2 37.26 
1b - - 
2a - 1.99 m 
31.6 31.68 
2b - 1.84 m 
3 3.52 m 3.52 m 71.8 71.82 
4 - 
2.29 (ddd, J=20.9, 13.3, 
2.6 Hz, 2H) 
42.3 42.32 
5 - - 140.7 140.76 
6 5.35 dt 5.35 (psd, J=5.5 Hz, 1H) 121.7 121.72 
7 - - 31.9 31.93 
8 - - 31.9 31.91 
9 - - 50.1 50.14 
10 - - 36.5 36.52 
11 - - 21.1 21.10 
12a - 1.99 m 
39.8 39.79 
12b - - 
13 - - 42.3 42.33 
14 - - 56.8 56.78 
15 - - 24.3 24.31 
16a - 1.84 m 
28.2 28.26 
16b - - 
17 - - 56.0 56.07 
18 0.68 s 0.68 s 11.9 11.87 
19 1.01 s 1.01 s 19.4 19.41 
20 - - 36.1 36.16 
21 0.92 d 0.92 (d J=6.6 Hz, 3H) 18.8 18.79 
22 - - 33.9 33.96 
23 - - 26.0 26.09 
24 - - 45.8 45.84 
25 - 
1.68 (dh, J=7.4, 6.8 Hz, 
1H) 
29.1 29.17 
26 0.83 d 0.83 (d, J=7.4 Hz, 3H) 19.8 19.83 
27 0.81 d 0.81 (d, J=6.9 Hz, 3H) 19.0 19.04 
28 - - 23.0 23.08 
29 0.84 t 0.84 (t, J=7.4 Hz, 3H) 12.0 11.99 
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Figure 5.21 1H NMR spectrum (400MHz, CDCl3) of β-sitosterol (5) 
 
6 
3 
4 
Me-18 
Me-21 
Me-29 
Me-26 
Me-27 
Me-19 
1a, 2b, 16a 
2a, 12a 
2
3
4
5
10
1
6
7
8
9 14
13
12
11
15
16
17
HO
19
H
18
20
21
22
23
24 25
26
27
28
29
H
H H
 89 
  
Figure 5.22 13C NMR spectrum (100MHz, CDCl3) of β-sitosterol (5) 
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Figure 5.23 13C NMR spectrum (100MHz, CDCl3) of β-sitosterol (5) – expansion 
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Figure 5.24 1D DEPT135 spectrum (100MHz, CDCl3) of β-sitosterol (5) - expansion 
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Figure 5.25 1H-13C HMBC spectrum (400MHz, CDCl3) of β-sitosterol (5)  
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Figure 5.26 1H-1H NOESY spectrum (400MHz, CDCl3) of β-sitosterol (5) 
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5.1.3.6 Physic and spectroscopic data of  β-sitosteryl acetate (5a) 
 
 
 
Figure 5.27 Structure of β-sitosteryl acetate (5a) 
 
Compound 5a (Figure 5.27) present itself as a white solid which 
crystalize in CHCl3. It was found to be perfectly soluble in CHCl3, less in other 
non-polar solvents, like the natural product (5) from which it was derived it 
does not reveal under the UV light, it is just barely visible as a black shadow 
at 254 nm. It has mp of 126-128 °C and a molecular formula of C31H52O2. The 
following spectral data for compound 5a were also confronted with the 
literature (Table 5.3). 
1H NMR (400 MHz, CDCl3) d (ppm): 0.70 (s, 3H), 0.84 (d, J=6.7 Hz, 
3H), 0.85 (d, J=7.7 Hz, 3H), 0.86 (t, J=7.7 Hz, 3H), 0.94 (d, J=6.4 Hz, 3H), 
1.04 (s, 3H), 2.05 (s, 3H), 2.34 (d, J=7.7 Hz, 2H), 4.62 (m, 1H), 5.40 (psd, 
J=5.0 Hz, 1H). 13C NMR (100MHz, CDCl3) d (ppm): 11.86 ppm (C-18), 11.99 
ppm (C-29), 18.79 ppm (C-21), 19.04 ppm (C-25), 19.32 (C-19), 19.82 ppm 
(C-26), 21.04 (C-11), 21.45 (C-31), 23.08 (C-28), 24.30 (C-15), 26.09 (C-23), 
27.78 (C-16), 28.25 (C-2), 29.17 (C-27), 31.87 (C-8), 31.91 (C-7), 33.95 (C-
22), 36.16 (C-20), 36.66 (C-10), 37.00 (C-1), 38.13 (C-4), 39.73 (C-12), 42.32 
(C-13), 45.85 (C-24), 50.04 (C-9), 56.05 (C-17), 56.70 (C-14), 73.99 (C-3), 
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122.64 (C-6), 139.66 (C-5), 170.53 (C-31). GC-MS Rt (min): 118.70; (EI) m/z: 
456 (M+•), 413 (1%), 396 (100%), 329 (1%), 273 (15%), 255 (15%). 
 
5.1.3.6.1 Structural elucidation of β-sitosteryl acetate (5a) 
 
 
 
 
Figure 5.28 EI/MS of β-sitosteryl acetate (5a) and characteristic fragmentations 
 
Fragmentation of the acetyl sitosterol gave rise to the same loss of its 
raw material the β-sitosterol. In fact, we can find the same peaks but with 
different intensities. This is due to the easier loss of the acetyl group in form of 
acylium cation or in for of neutral acetic acid. The fragmentations have very 
different probabilities of taking place and the cause of this is the different 
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stability of their products. The radical cation with m/z 396 (base peak) is the 
most probable product of the fragmentation, because the side product of the 
process is a neutral molecule of acetic acid. Instead the formation of the cation 
with m/z 413 is very improbable, because of the high electronegativity of the 
oxygen which cannot retain the positive charge. The rest of the important 
fragments are the result of the loss of the side chain of the sterol, much like in 
the β-sitosterol (329, 275 y 255). Fragments and mass spectrum are reported 
in the figure 5.28. 
The 1H NMR spectrum (Figure 5.29) showed signals typical of a steroid, 
with a lot of signals in the upfield region. These signals are given from all the 
protons of the aliphatic hydrogens of the four rings and substituents of the 
molecule, as it was also seen in the previous steroidal molecules. The most 
important and simpler to recognize are the signals relative to all the CH3 of the 
compound, which give very intense, of small multiplicity and upfield signals: 
the singlet at 0.70 ppm (3H, Me-18), the doublet at 0.84 ppm (J=6.9 Hz, 3H, 
Me-27), the doublet at 0.86 ppm (J=7.4 Hz, 3H, Me-26), the triplet at 0.85 
(J=7.4 Hz, 3H, Me-29), the doublet of 0.94 ppm (J=6.6 Hz, 3H, Me-21) and the 
singlet at 1.04 ppm (3H, Me-19). Other signals that were assigned are some 
more downfield signals: the singlet at 2.05 ppm (3H, Me-31), the latter is 
characteristic of an acetyl group and it confirmed the acetylation of the 
molecule. Then a multiplet at 4.62 ppm (m, 1H, H-3) relative to the proton 
germinal to the acetyl group and then the most shielded signal of the vinylic 
hydrogen at 5.40 ppm (psd, J=5.0 Hz, 1H, H-6); these last signals in particular 
were the decisive ones in the characterization of the type of sterol analyzed.  
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The 13C NMR spectrum (Figure 5.30) also showed a steroid pattern with 
very few signals in the downfield region: two Sp2 quaternary carbons at 170.53 
ppm (C-30) and at 139.66 ppm (C-5), relative to the carbonyl of the acetyl 
group and the totally substituted vinylic carbon respectively. Then the tertiary 
vinylic carbon at 122.64 ppm (C-6), these three signals were decisive for the 
characterization of the acetylated sterol, because confirmed the presence of 
the double bond and that its position in the molecule did not change through 
the reaction. If the position of the double bond was different, the signals of the 
carbons C-5 and C-6 would have been also less shielded than they are as 
shown in the literature and was also confirmed the presence of the acetyl 
group bound to the molecule. Then there is the carbon directly attached to the 
acetyl group at 73.99 ppm (C-3), which also was important to confirm the 
presence of an esterified hydroxyl group. In contrast to the downfield region, 
there were a lot of signals in the upfield region of the spectrum which were all 
relative to the protons of the steroid rings and lateral chain. Especially fast to 
recognize were the methyl carbons at 11.86 ppm (C-18), 11.99 ppm (C-29), 
18.82 ppm (C-21), 19.04 (C-19), 19.32 ppm (C-26) and 29.17 ppm (C-27). 
These signals are the most shielded of the spectrum and are characteristic of 
steroid molecules (Figure 7.31). It was also taken a 1D DEPT135 spectrum 
(Figure 5.32) which was useful to discriminate between carbons carrying an 
even or an odd number of hydrogens. The assigned signals were also 
confirmed from the literature (78). 
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Table 5.3 Spectroscopic data of β-sitosteryl acetate (5a) 
n 
1H NMR (400 MHz, 
CDCl3) d (ppm), (97) 
1H NMR (400 MHz, 
CDCl3) d (ppm), 5a 
13C NMR 
(100MHz, 
CDCl3) d 
(ppm), (97) 
13C NMR 
(100MHz, 
CDCl3) d 
(ppm), 5a 
1 - - 36.9 37.00 
2 - - 29.0  
3 4.62 m 4.62 (m, 1H) 73.7 73.99 
4 - 2.34 (m, 2H) 38.1 38.13 
5 - - 139.7 139.66 
6 5.36 (t, J=5.4 Hz, 1H) 5.40 (psd, J=5.0 Hz, 1H) 122.5 122.64 
7 - - 31.9 31.91 
8 - - 31.87 
9 - - 50.0 50.04 
10 - - 36.5 36.66 
11 - - 21.0 21.04 
12 - - 39.7 39.73 
13 - - 42.3 42.32 
14 - - 56.7 56.70 
15 - - 24.9 24.30 
16 - - 28.2 27.78 
17 - - 56.0 56.05 
18 0.77 s 0.70 s 11.8 11.86 
19 0.99 s 1.04 s 19.0 19.04 
20 - - 36.1 36.16 
21 0.87 d 0.94 (d, J=6.4 Hz, 3H) 19.8 19.82 
22 - - 34.4 33.95 
23 - - 27.1 26.09 
24 - - 45.8 45.85 
25 - - 23.0 18.79 
26 - 0.85 (d, J=7.7 Hz, 3H) 19.3 19.32 
27 - 0.84 (d, J=6.7 Hz, 3H) 29.6 29.17 
28 - - 18.7 23.08 
29 0.84 (t, J=6.6 Hz, 3H) 0.86 (t, J=7.7 Hz, 3H) 11.9 11.99 
30 - - 170.9 170.53 
31 2.04 s 2.05s - 21.45 
 
 99 
  
Figure 5.29 1H NMR spectrum (400MHz, CDCl3) of β-sitosteryl acetate (5a) 
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Figure 5.30 13C NMR spectrum (100MHz, CDCl3) of β-sitosteryl acetate (5a) 
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Figure 5.31 13C NMR spectrum (100MHz, CDCl3) of β-sitosteryl acetate (5a) - expansion 
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Figure 5.32 1D DEPT135 spectrum (100MHz, CDCl3) of β-sitosteryl acetate (5a) 
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5.1.4 The chloroform/methanol (1:1) extraction 
The second extract was made with chloroform/methanol (1:1) using the 
previously defatted vegetal material. This mixture of solvents, being of medium 
polarity, has the ability of extracting a broader spectrum of metabolites then 
the single solvents should have. Some of those metabolites comprehend polar 
terpenoids compounds, coumarins, lignans, alkaloids, polyphenolic 
compounds, glycosylated compounds and sugars. So, this maceration had the 
objective of extracting the majority of the natural products, intended as 
secondary metabolites of the plant. The molecules that were isolated from the 
fractionation of this extract were seven: compound 6 to 12 and their physical, 
chemical and spectroscopic properties are described in the next paragraphs. 
 
5.1.4.1 Physic and spectroscopic data of heneicosane (6) 
 
 
Figure 5.33 Structure of heneicosane (6) 
 
The alkane 6 (Figure 5.33) precipitated as a white amorphous solid. It 
is soluble in CHCl3 and hexane but less soluble in other nonpolar solvents and 
it always needs to be heated to be solubilized completely. The compound had 
mp of 43-45°C and its molecular formula is C21H44. 
1H NMR (400 MHz, CDCl3) d (ppm): 0.88 (t, J=6.7 Hz, 3H), 1.25 (s, 
37H). 13C NMR (100MHz, CDCl3) d (ppm): 14.14 (2CH3), 22.71 (C-2 and C-
19), 29.38 (C-4 and C-17), 29.68 (C-5 and C-16), 29.72 (11C), 31.95 (C-3 and 
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C-18). GC-MS Rt (min): 71.609; (EI) m/z: 296 (M+•), 57 (100%), 71 (85%), 85 
(75%), 43 (40%). 
 
5.1.4.1.1 Structural elucidation of heneicosane (6) 
The mass spectrum of compound 6 (Figure 5.34) showed the classic 
pattern of a long chain alkane, with differences of 14 Da between almost all 
the peaks. The molecule identification was confirmed by confrontation with the 
NIST database. 
 
 
Figure 5.34 EI/MS spectrum of heneicosane (6) 
 
The 1H NMR spectrum (Figure 5.35) showed signals typical of long 
chain alkane, with a upfield triplet at 0.88 ppm (J=6.7 Hz, 6H, 2Me) that integer 
for the terminal methyl groups and a more downfield singlet that integer for the 
other 36 protons (1.25 ppm), typical of long chains of CH2. The absence of any 
other signal showed that the molecule was an alkane with no substituents or 
ramifications. The 13C NMR spectrum (Figure 5.36) also showed a long chain 
alkane molecule pattern with very few signals in the downfield region and a lot 
of signals in the upfield region of the spectrum. A intense signal at 29.72 ppm 
corresponds to the majority of the CH2 of the molecule (10C). Then there were 
a series of signal which were relative to two carbons each and started with the 
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two methyl groups at 14.14 ppm and continued with the carbons following up 
the chain at 22.71 ppm (C-2 and C-19), 29.38 ppm (C-4 and C-17), 29.68 ppm 
(C-5 and C-16) and 31.95 ppm (C-3 and C-18). The absence of other signals 
was indicative of an alkane molecule. 
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Figure 5.35 1H NMR spectrum (400MHz, CDCl3) of heneicosane (6) 
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Figure 5.36 13C NMR spectrum (100MHz, CDCl3) of heneicosane (6) 
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5.1.4.2 Physic and spectroscopic data of triacontanol (7) 
 
 
 
Figure 5.37 Structure of triacontanol (7) 
 
The alcohol (Figure 5.37) crystallizes in small flat crystals flakes with a 
chromium shade, but once it was completely dry it looked like an amorphous 
white solid with the consistence of plastic. It resulted to be completely insoluble 
in the majority of solvents but slightly soluble in pyridine, with a higher solubility 
when the solvent was heated up. The compound has mp of 77-78°C and its 
molecular formula is C30H62O. 
1H NMR (400 MHz, Py-5d) d (ppm): 0.87 (t, J=6.5 Hz, 3H), 1.33 (s, 
53H), 1.52 (p, J=7.1 Hz, 2H), 1.75 (p, J=6.8 Hz, 2H), 3.87 (t, J=6.5 Hz, 2H). 
13C NMR (100MHz, Py-5d) d (ppm): 13.99 (CH3), 22.67 (C-25), 26.31 (C-24), 
29.34 (C-23), 29.74 (C-2), 31.87 (23C), 33.56 (C-3), 61.92 (C-1). 
 
5.1.4.2.1 Structural elucidation of triacontanol (7) 
The EI mass spectrum of the alcohol has the classic long chain alkane 
molecule pattern, like the ones already mentioned in this section. But looking 
at the spectrum is noticeable at first sight that it’s missing the molecular ion. 
This is not uncommon in EI spectra were most of the time the energy is too 
high for the molecule to bear and it is fragmented completely. In any case the 
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first peak of m/z of 420 is exactly 18 Da lighter than the molecular ion would 
have been (438 m/z). The mass spectrum is showed in figure 5.38. 
 
 
Figure 5.38 EI/MS of triacontanol (7) 
 
The 1H NMR spectrum (Figure 5.39) showed signals typical of long 
chain alcohol, with a upfield triplet at 0.87 ppm (J=6.5 Hz, 3H, Me) that integer 
for the terminal methyl group and a more downfield singlet that integer for the 
other 64 protons (1.33 ppm), typical of long chains of CH2. Then two pentaplets 
at 1.52 ppm (J=7.1 Hz, 2H, H-3) and 1.75 ppm (J=6.8 Hz, 2H, H-2) followed 
by a triplet at 3.87 ppm (J=6.5 Hz, 2H, H-1), which are indicative of the 
presence of an oxygen attached to a long chain of carbons. The absence of 
any other signal showed that the oxygen doesn’t have any substituent and that 
the molecule is in fact an alcohol. The 13C NMR spectrum (Figure 5.40) also 
showed a long chain alcohol molecule pattern with very few signals in the 
downfield region and a lot of signals in the upfield region of the spectrum. A 
very intense signal at 29.73 ppm corresponds to the majority of the CH2 of the 
molecule. But the signal that was decisive to characterize the molecule was 
the one at 61.92 ppm relative to the carbon attached to the oxygen which is 
characteristic of alcohols. 
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Figure 5.39 1H NMR spectrum (400MHz, Py-5d) of triacontanol (7) 
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Figure 5.40 13C NMR spectrum (100MHz, Py-5d) of triacontanol (7) 
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5.1.4.3 Physic and spectroscopic data of p-coumaric acid (8) 
 
 
Figure 5.41 Structure of p-coumaric acid (8) 
 
Compound 8 (Figure 5.41) present itself as a white yellowish amorph 
solid which precipitate in hexane and cold chloroform. It was soluble in 
acetone, and insoluble in nonpolar solvents, and it reveal under the UV light 
(254 and 365 nm) as a dark spot. Also, after staining with ceric sulfate it was 
observed as a dark spot on the TLC. It has mp of 213-215 °C and molecular 
formula of C9H8O3.  
1H NMR (400 MHz, acetone) d (ppm): 6.35 (d, J=15.9 Hz, 1H), 6.95 (d, 
J=8.7 Hz, 2H), 7.57 (d, J=8.7 Hz, 2H), 7.63 (d, J=15.9 Hz, 1H). 13C NMR 
(100MHz, acetone) d (ppm): 114.90 (C-6), 115.79 (C-2), 126.19 (C-3), 129.99 
(C-1), 144.67 (C-5), 159.61 (C-4), 167.35 (C-7). 
 
5.1.4.3.1 Structural elucidation of p-coumaric acid (8) 
The 1H NMR spectrum (Figure 5.42) showed signals typical of phenyl 
propionic acids, with only four downfield doublets. The signals are part of two 
AB/AX not correlating systems, clearly visible from the roof effect from which 
each couple of signals is affected. The first comprehends a doublet at 6.35 
ppm (J=15.9 Hz, 1H) and the most downfield signal at 7.63 ppm (d, J=15.9 
Hz, 1H). The coupling constant J of 15.9 Hz found in these signals also reveals 
the trans configuration of the doble bond of molecule. The second system 
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contains the more intense doublets at 6.95 (J=8.7 Hz, 2H) and at 7.43 (J=8.7 
Hz, 2H) which are characteristic of p substituted aromatic ring that still retains 
a symmetry axis. The 13C NMR spectrum (Figure 5.43) showed a phenyl 
propionic molecule pattern with very few signals all in the downfield region. 
The most typical signals were at 114.90 ppm and 144.67 ppm for the olefinic 
carbons and at 115.79 ppm and 129.99 ppm for the aromatic carbons. The 
latter integrate for two nuclei each, corresponding to the two pairs of symmetric 
Sp2 carbons of the ring. The signals at 126.19 ppm and at 159.61 ppm are 
produced by the tetrasubstituted carbon bonded of the olefin and to the 
hydroxyl group respectively. The less shielded signal at 167.35 ppm belongs 
instead to the Sp2 carbon of the carbonyl group. All The 2D NMR spectra also 
confirmed the identity of the molecule (Figure 5.44 to 5.46), particularly the 1H-
1H NOESY spectrum (Figure 5.47) confirmed the spatial configuration of the 
olefin.  
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Figure 5.42 1H NMR spectrum (400MHz, Acetone-6d) of p-coumaric acid (8) 
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Figure 5.43 13C NMR spectrum (100MHz, Acetone-6d) of p-coumaric acid (8) 
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Figure 5.44 1H-13C HSQC NMR spectrum (400MHz, Acetone-6d) of p-coumaric acid (8) 
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Figure 5.45 1H-1H COSY NMR spectrum (400MHz, Acetone-6d) of p-coumaric acid (8) 
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Figure 5.46 1H-13C HMBC NMR spectrum (400MHz, Acetone-6d) of p-coumaric acid (8) 
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Figure 5.47 1H-1H NOESY NMR spectrum (400MHz, Acetone-6d) of p-coumaric acid (8) 
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5.1.4.4 Physic and spectroscopic data of margaric acid (9) 
 
 
Figure 5.48 Structure of margaric acid (9) 
 
Compound 9 (Figure 5.48) present itself as a rose amorphous solid 
which precipitate in chloroform. It was found to be soluble in pyridine, and 
insoluble in nonpolar solvents. It was observed as a dark spot on a TLC after 
staining with ceric sulfate. It has mp of 80-82 °C and molecular formula 
C17H34O2. 
1H NMR (400 MHz, Py-5d) d (ppm): 0.87 (t, J=7.2 Hz, 3H), 1.33 (s, 
22H), 1.42 (q, J=7.5 Hz, 4H), 1.83 (t, J=7.6 Hz, 2H), 2.55 (t, J=7.5 Hz, 2H). 13C 
NMR (100MHz, Py-5d) d (ppm): 14.04 (CH3), 22.70 (C-17), 25.43 (C-16), 
29.38 (C-15), 29.48 (C-14), 29.60 (C-13), 29.69 (C-12), 29.76 (7C), 31.89 (C-
3), 34.67 (C-2), 175.75 (C-1). 
 
5.1.4.4.1 Structural elucidation of margaric acid (9) 
The 1H NMR spectrum (Figure 5.49) showed signals typical of a 
carboxylic acid, with only few upfield signals. Much like the other identified 
carboxylic acids from this plant the principal signals are the ones from the long 
carbon chain. At 0.87 ppm (t, J=7.2 Hz) a typical signal of CH3 at the end of 
the chain, followed by a singlet at 1.33 ppm which integer for 22 hydrogens, 
then there are three signals at 1.42 ppm (q, J=7.5 Hz, 4H), 1.83 ppm (t, J=7.6 
Hz, 2H), 2.55 ppm (t, J=7.5 Hz, 2H), which are the protons next to the 
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carboxylic group and are characteristic of acids. The 13C NMR spectrum 
(Figure 5.50) showed a carboxylic acid pattern. The signals for the 
characterization of the molecule were the one at 29.76 ppm which is the sum 
of seven carbons of the molecule, typical of a long chain of carbons, and the 
one at 175.75 ppm indicative of a free carboxylic acid. 
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Figure 5.49 1H NMR spectrum (400MHz, Py-5d) of margaric acid (9) 
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Figure 5.50 13C NMR spectrum (100MHz, Py-5d) of margaric acid (9) 
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5.1.4.5 Physic and spectroscopic data of caffeic acid (10) 
 
 
Figure 5.51 Structure of caffeic acid (10) 
 
Compound 10 (Figure 5.51) is a greenish amorph solid which 
precipitate in chloroform. It was soluble in methanol, and insoluble in less polar 
solvents. It was visible under the UV light at 254 and 365 nm as a dark spot, 
it was observed as a brown spot on a TLC after staining with ceric sulfate. It 
has mp of 225-227 °C and molecular formula of C9H8O4. The identity of the 
molecule was confirmed by the literature (98). 
1H NMR (400 MHz, MeOD) d (ppm): 6.20 (d, J=15.9 Hz, 1H), 6.67 (d, 
8.2Hz, 1H), 6.85 (dd, J=8.3, 2.1 Hz, 1H), 6.95 (d, J=2.1 Hz, 1H), 7.50 (d, 
J=15.9 Hz, 1H). 13C NMR (100MHz, Py-5d) d (ppm): 113.31 (C-8), 113.77 (C-
6), 115.09 (C-3), 121.61 (C-2), 126.27 (C-1), 145.42 (C-5), 145.96 (C-7), 
148.28 (C-4), 167.60 (C-9). 
 
5.1.4.5.1 Structural elucidation of caffeic acid (10) 
The 1H NMR spectrum (Figure 5.52) showed signals typical of phenyl 
propionic acids, with only four downfield doublets. Two of the signals are part 
of AX system. It comprehends two doublets one at 6.20 ppm (J=15.9 Hz, 1H) 
and the other at 7.50 ppm (d, J=15.9 Hz, 1H). The coupling constant J of 15.9 
Hz found in these signals revealed the trans configuration of the molecule. The 
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other signals comprehend two doublets at 6.67 ppm (J=8.2 Hz, 2H) and at 
6.95 ppm (J=2.1 Hz, 2H) which are for the protons in position 3 and 6 
respectively, and a doublet of a doublet at 6.85 ppm (dd, J=8.3, 2.1 Hz, 1H) 
due to the proton in position 2. The larger coupling constant generated by the 
vicinal proton H3 and the smaller one produced by the H6. The five signals are 
typical of an aromatic ring non-symmetrically substituted, and one of the 
substituents is an olefin. The 13C NMR spectrum (Figure 5.53) showed a 
phenyl propionic molecule pattern with very few signals in the downfield 
region. The first typical signals were the two of similar intensities at 113.31 
ppm and 145.96 ppm for the olefinic carbons and at 126.27 ppm, 145.42 and 
148.28 ppm for the aromatic quaternary carbons, which were also spotted for 
their lower intensity. The less shielded signal at 167.60 ppm belongs instead 
to the Sp2 carbon of a free carbonyl group. The remaining signals were 
attributed to the aromatic carbons. 2D NMR experiments were used to confirm 
the identity of the molecule (Figure 5.54 to 5.55), particularly the 1H-1H NOESY 
spectrum (Figure 5.56) confirmed the special configuration of the olefin.  
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Figure 5.52 1H NMR spectrum (400MHz, MeOD) of caffeic acid (10) 
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Figure 5.53 13C NMR spectrum (100MHz, MeOD) of caffeic acid (10) 
4 
2 
7 
9 
6 
8 
3 
1 5 
5
4
3
2
1
6 7
8
9
OH
O
HO
HO
 128 
Figure 5.54 1H-13C HSQC NMR spectrum (400MHz, MeOD) of caffeic acid (10) 
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Figure 5.55 1H-13C HMBC NMR spectrum (400MHz, MeOD) of caffeic acid (10) 
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Figure 5.56 1H-1H NOESY NMR spectrum (400MHz, MeOD) of caffeic acid (10) 
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5.1.4.6 Physic and spectroscopic data of daucosterol (11) 
 
 
Figure 5.57 Structure of daucosterol (11) 
 
The glycoside 11 (Figure 5.57) crystalized into the CC (needle-shaped 
crystals) when a 100% EtOAc mobile phase was reached, then it solubilized 
when 90:10 EtOAc/MeOH passed through the column. It was recovered as a 
crystalline solid washed several times with MeOH, sonicating it for 15 minutes 
each time until the solid was white. It was soluble in pyridine (Py) and partially 
soluble in hot MeOH (over 50°C). The compound did not reveal under the UV 
light, it has mp > 280°C and molecular formula of C35H60O6.  
The following spectral data of compound 11 was also confronted with 
the literature (Table 5.4). 
1H NMR (400 MHz, CDCl3) d (ppm): 0.67 (s, 3H), 0.88 (d, J=7.7 Hz, 
3H), 0. 89 (t, J=8.1 Hz, 3H), 0.90 (d, J=8.1 Hz, 3H), 0.95 (s, 3H), 1.00 (d, J=6.7 
Hz, 3H), 2.49 (brt, J=12.5 Hz, 1H), 2.75 (m, 1H), 3.96 (m, 1H), 4.02 (m, 2H), 
4.10 (brt, J=8.0 Hz, 1H), 4.32 (t, J=8.2 Hz, 1H), 4.33 (t, J=8.2 Hz, 1H), 4.45 
(dd, J=11.9, 5.1 Hz, 1H), 4.60 (brd, J=11.6 Hz, 1H), 5.01 (d, J=7.7 Hz, 1H), 
5.37 (d, J=4.7 Hz, 1H). 13C NMR (100MHz, CDCl3) d (ppm): 11.76 ppm (C-18), 
11.95 ppm (C-29), 18.80 ppm (C-21), 19.00 ppm (C-19), 19.21 (C-26), 19.77 
ppm (C-27), 21.07 (C-11), 23.18 (C-28), 24.30 (C-15), 26.17 (C-23), 28.33 (C-
16), 29.21 (C-25), 30.04 (C-2), 31.84 (C-8), 31.96 (C-7), 33.99 (C-22), 36.18 
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(C-20), 36.71 (C-10), 37.26 (C-1), 39.73 (C-12), 39.12 (C-4), 42.26 (C-13), 
45.82 (C-24), 50.12 (C-9), 56.02 (C-17), 56.61 (C-14), 62.62 (C-6’), 71.47 (C-
4’), 75.13 (C-2’), 77.86 (C-3), 78.28 (C-5’), 78.40 (C-3’), 102.36 (C-1’), 121.70 
(C-6), 140.68 (C-5). 
 
5.1.4.6.1 Structural elucidation of daucosterol (11) 
The 1H NMR spectrum (Figure 5.58) showed signals typical of a steroid, 
with signals in the upfield region. They are given for the protons of the aliphatic 
hydrogens of the four rings of the molecule. The most important and easy to 
recognize are the signals of the CH3, which were very intense: the singlet at 
0.67 ppm (3H, Me-18), the doublet at 0.88 ppm (J=7.7 Hz, 3H, Me-27), the 
doublet at 0.90 ppm (J=8.1 Hz, 3H, Me-26), the triplet at 0.89 (J=8.1 Hz, 3H, 
Me-29), the doublet of 1.00 ppm (J=6.7 Hz, 3H, Me-21) and the singlet at 0.95 
ppm (3H, Me-19). Other signals of the sterol were found at downfield: the 
broad triplet at 2.49 ppm (J=12.5 Hz, 1H, H-4a), a multiplet at 2.75 ppm that 
integer for one proton (H-4b). The molecule also presented protons relative to 
a sugar molecule which correspond to glucose according to the values of the 
J-coupling between the hydrogens of the sugar. These signals were a multiplet 
at 4.08 ppm (H-5’), and a broad triplet at 4.10 ppm (J=8.0 Hz, 1H, H-2’), then 
was observed a complex signal composed by two different triplets falling very 
close to each other at 4.32 ppm (J=8.2 Hz, 1H, H-3’) and 4.33 ppm (J=8.2 Hz, 
1H, H-4’) respectively. These signals were followed by a doublet of doublet at 
4.45 ppm (dd, J=11.9, 5.1 HZ, 1H, H-6b’), a doublet at 4.60 ppm (J=11.6 HZ, 
1H, H-6a’) and broad doublet relative to the anomeric proton at 5.01 ppm 
(J=7.7 Hz, 1H, H-1’). It was also observed a broad signal of low intensity at 
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6.53 ppm that was assigned to one hydroxyl group of the sugar. Then follow 
another multiplet that integer for another proton at 3.96 ppm (H-3), which was 
relative to the proton germinal to the hydroxyl group of the aglycone, and the 
most shielded signal of the vinylic hydrogen at 5.37 ppm (d, J=4.7 Hz, 1H, H-
6).  
The 13C NMR spectrum (Figure 5.59) also showed a glycosilated 
steroid pattern: a quaternary carbon at 140.68 ppm (C-5) and a vinylic carbon 
at 121.70 ppm (C-6) correspond to the presence of the double bond and its 
position in the molecule was confirmed by the HMBC correlations between H-
3 and C-5). Also, it was observed a carbon at 102.36 ppm (C-1’), characteristic 
of anomeric carbons in hexose sugars. The position of the glycosylation in the 
molecule was confirmed by the HMBC correlations between H-3 and C-1’ and 
vice versa between H-1’ and C-3. Then there is the carbon directly attached 
to the hydroxyl group at 77.86 ppm (C-3), which also was important to confirm 
the presence of a hydroxyl group. This signal was surrounded by the others 
signals relative to the carbon skeleton of the sugar: 78.40 ppm (C-3’), 78.28 
ppm (C-5’), 75.13 ppm (C-2’), 71.47 ppm (C-4’) and 62.62 ppm (C-6’). In the 
downfield region, there were the signals of the steroid rings and lateral chain 
(Figure 5.60) particularly the methyl carbons at 11.76 ppm (C-18), 11.95 ppm 
(C-29), 18.80 ppm (C-21), 19.00 (C-18) 19.21 ppm (C-26) and 19.77 ppm (C-
27). The 1D DEPT135 spectrum (Figure 5.61) was useful to discriminate 
between the carbons of the aglycone and the sugar. The assigned signals 
were confirmed with the literature (96). 
The molecule was also analyzed using 2D NMR experiments: 1H-
1HCOSY, 1H-13C HSQC, 1H-13C HMBC (Figure 5.62) and 1H-1H NOESY 
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(Figure 5.63). 2DNMR spectra confirmed the structure of the molecule and the 
stereocenters configuration (NOESY). Particularly, COSY and HSQC 
experiments were important for determination of correlations between 
hydrogens and their positions in the molecule skeleton, as well as to assign all 
the carbons of the compound. The position of the double bond was deduced 
by confronting the 13C NMR spectral assignation obtained experimentally from 
the HMBC and 13C DEPT experiments with those of literature. The assignation 
of C-6 was reported to be at 121.70 ppm, this carbon is farther from the OH 
than C-4. Therefore, if the double bond was between this carbon and C-5 its 
shift would have been at higher frequencies (at least of 10 ppm) then the 122.0 
ppm given experimentally. Instead carbon C-5 is certain to be the part of the 
double bond, since its shift was found at 141.0 ppm which is characteristic of 
tetrasubstituted Sp2 carbons. Also, no proton attached to this carbon is found 
in the 1H NMR spectrum, this signal if present is easily spotted for its high 
multiplicity and shift.  
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Table 5.4 Spectroscopic data of daucosterol (11) 
n 
1H NMR (400 
MHz, Py) d 
(ppm), (96) 
1H NMR (400 MHz, Py) d 
(ppm), 11 
13C NMR 
(100MHz, 
Py) d (ppm), 
(96) 
13C NMR 
(100MHz, Py) d 
(ppm), 11 
1 - - 37.6 37.26 
2 - - 30.3 30.04 
3 3.97 m 3.96 m 78.3 77.86 
4a 2.38 m 2.49 (brt, J=12.5 Hz, 1H) 
39.4 39.12 
4b 2.63 m 2.75 m 
5 - - 141.0 140.68 
6 - 5.37 (psd, J=4.7 Hz, 1H) 122.0 121.70 
7 - - 32.2 31.96 
8 - - 32.1 31.84 
9 - - 50.4 50.12 
10 - - 37.0 36.71 
11 - - 21.4 21.07 
12 - - 40.0 39.73 
13 - - 42.6 42.26 
14 - - 57.0 56.61 
15 - - 24.6 24.30 
16 - - 28.7 28.33 
17 - - 56.3 56.02 
18 0.66 s 0.67 s 12.0 11.76 
19 0.94 s 0.95 s 19.3 19.00 
20 - - 36.5 36.18 
21 0.99 d 1.00 (d, J=6.7 Hz, 3H) 19.1 18.80 
22 - - 34.3 33.99 
23 - - 26.4 26.17 
24 - - 46.1 45.82 
25 - - 29.5 29.21 
26 0.90 d 0.90 (d, J=8.1 Hz, 3H) 19.5 19.21 
27 0.87 d 0.88 (d, J=7.7 Hz, 3H) 20.1 19.77 
28 - - 23.4 23.18 
29 0.89 t 0.89 (t, J=8.1 Hz, 3H) 12.2 11.95 
1’ 4.95 d 5.01 (d, J=7.7 Hz, 1H) 102.6 102.36 
2’ 4.08 t 4.10 (bt, J=8.0 Hz, 1H) 75.4 75.13 
3’ 4.28 t 4.32 (t, J=8.2 Hz, 1H) 78.7 78.40 
4’ 4.31 t 4.33 (t, J=8.2 Hz, 1H) 71.7 71.47 
5’ 4.03 m 4.02 m 78.5 78.28 
6’a 4.59 dd 4.60 (bd, J=11.6 HZ, 1H) 
62.9 62.62 
6’b 4.42 dd 4.45 (dd, J=11.9, 5.1 HZ, 1H) 
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Figure 5.58 1H NMR spectrum (400MHz, Py-5d) of daucosterol (11) 
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Figure 5.59 13C NMR spectrum (100MHz, Py-5d) of daucosterol (11) 
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Figure 5.60 13C NMR spectrum (100MHz, Py-5d) of daucosterol (11) - expansion 
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Figure 5.61 1D DEPT135 spectrum (100MHz, Py-5d) of daucosterol (11) 
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Figure 5.62 1H-13C HMBC spectrum (400MHz, Py-5d) of daucosterol (11) 
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Figure 5.63 1H-1H NOESY spectrum (400MHz, Py-5d) of daucosterol (11) 
6 
1' 
6b' 
6a' 
4', 3' 
2' 
5' 3 4b 4a 
18 
21 
19 
6 
1' 
6b' 
6a' 
4', 3' 
5' 
3 
4b 
4a 
2' 
 142 
5.1.4.7 Physic and spectroscopic data of daucosteryl tetracetate (11a) 
 
 
Figure 5.64 Structure of daucosteryl tetracetate (11a) 
 
Compound 11a (Figure 5.64) is a white crystalline solid which crystalize 
in CHCl3 into needle shaped crystals. It was soluble in CHCl3, and insoluble in 
polar solvents, unlike the natural product (11) which was only soluble in 
pyridine, from which it was derived, and it does not reveal under the UV light. 
It has mp of 166-168 °C and molecular formula of C43H68O10. The following 
spectral data of compound 11a was also confronted with the literature (Table 
5.5).  
1H NMR (400 MHz, CDCl3) d (ppm): 0.69 (s, 3H), 0.83 (d, J=6.0 Hz, 
3H), 0.85 (d, J=8.2 Hz, 3H), 0.86 (t, J=7.5 Hz, 3H), 0.94 (d, J=6.3 Hz, 3H), 
1.01 (s, 3H), 2.03 (s, 3H), 2.04 (s, 3H), 2.07 (s, 3H), 2.10 (s, 3H), 3.51 (dq, 
J=11.2, 5.9 Hz, 1H), 3.70 (ddd, J=10.6, 4.8, 2.5 Hz, 1H), 4.13 (dd, J=12.3, 2.5 
Hz, 1H), 4.28 (dd, J=12.3, 4.7 Hz, 1H), 4.61 (d, J=8.0 Hz, 1H), 4.98 (t, J=8.8 
Hz, 1H), 5.10 (t, J=9.7 Hz, 1H), 5.23 (t, J=9.6 Hz, 1H), 5.38 (psd, J=4.9 Hz, 
1H). 13C NMR (100MHz, CDCl3) d (ppm): 11.86 ppm (C-18), 11.99 ppm (C-
29), 18.79 ppm (C-21), 19.04 ppm (C-27), 19.37 ppm (C-19), 19.83 (C-26), 
20.63 (Me-6’), 20.66 (Me-4’), 20.74 (Me-3’), 20.78 (Me-2’), 21.05 (C-11), 23.07 
(C-28), 24.30 (C-15), 26.06 (C-23), 28.25 (C-16), 29.15 (C-25), 29.45 (C-2), 
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31.87 (C-8), 31.91 (C-7), 33.94 (C-22), 36.14 (C-20), 36.72 (C-10), 37.20 (C-
1), 38.92 (C-12), 39.74 (C-4), 42.33 (C-13), 45.84 (C-24), 50.17 (C-9), 56.05 
(C-17), 56.76 (C-14), 62.11 (C-6’), 68.54 (C-4’), 71.49 (C-2’), 71.69 (C-5’), 
72.92 (C-3’), 80.09 (C-3), 99.64 (C-1’), 122.17 (C-6), 140.35 (C-5), 169.31 
(CO-6’), 169.41 (CO-4’), 170.36 (CO-3’), 170.71 (CO-2’). 
 
5.1.4.7.1 Structural elucidation of daucosteryl tetracetate (11a) 
The 1H NMR spectrum (Figure 5.65) showed signals typical of a steroid, 
with a lot of signals in the upfield region. The first signals are the CH3 of the 
aglycone: the singlet at 0.68 ppm (3H, Me-19), the doublet at 0.81 ppm (J=6.9 
Hz, 3H, Me-27), the doublet at 0.83 ppm (J=7.4 Hz, 3H, Me-26), the triplet at 
0.84 (J=7.4 Hz, 3H, Me-29), the doublet of 0.92 ppm (J=6.6 Hz, 3H, Me-21) 
and the singlet at 1.01 ppm (3H, Me-18). The spectra showed also four signals 
relative to the methyl groups of the acetylated sugar: 2.03 ppm (s, 3H, Me-6’), 
2.04 ppm (s, 3H, Me-4’), 2.07 ppm (s, 1H, Me-3’) and 2.10 ppm (s, 3H, Me-2’). 
Other signals in the downfield region are the double quartet at 3.51 ppm 
(J=11.2, 5.9 Hz, 1H, H3), which corresponds to the proton germinal to the 
glucosyl group. Followed by the signals relative to the hydrogens of the 
glucose: 3.70 ppm (ddd, J=10.6, 4.8, 2.5 Hz, 1H, H-5’), 4.13 ppm (dd, J=12.3, 
2.5 Hz, 1H, H-6a’), 4.28 ppm (dd, J=12.3, 4.7 Hz, 1H, H-6b’), 4.61 ppm (d, 
J=8.0 Hz, 1H, H-1’), 4.96 ppm (t, J=8.8 Hz, 1H, H-2’), 5.08 ppm (t, J=9.7 Hz, 
1H, H-4’) and 5.21 ppm (t, J=9.6 Hz, 1H, H-3’). The most shielded signal of 
the spectrum is the one relative to the vinylic hydrogen at 5.35 ppm (pd, J=5.5, 
1.9 Hz, 1H, H-6). The 13C NMR spectrum (Figure 5.66) also showed a steroid 
pattern with very few signals in the downfield region: first the carbonyl groups 
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of the four acetyl groups at 170.71 ppm (CO-2’), 170.36 ppm (CO-3’), 169.41 
ppm (CO-4’) and at 169.31 ppm (CO-6’), these signals confirmed the 
acetylation of the molecule. A quaternary carbon at 140.35 ppm (C-5), and the 
vinylic carbon at 122.17 ppm (C-6). The following signals were those related 
to the carbons of the sugar and the carbon of aglycone directly attached to the 
hydroxyl group: 99.64 ppm (C-1’), 80.09 (C-3), 72.92 ppm (C-3’), 71.69 ppm 
(C-5’), 71.49 ppm (C-2’), 68.54 ppm (C-4’) and 62.11 ppm (C-6’). In contrast, 
in the upfield region, there were a lot of signals which were all relative to the 
protons of the steroid rings and lateral chain. Especially simple to recognize 
were the methyl carbons at 11.86 ppm (C-18), 11.99 ppm (C-29), 18.79 ppm 
(C-21), 19.04 ppm (C-27), 19.37 ppm (C-19) and 19.83 ppm (C-26). These 
signals are the most shielded of the spectrum and are characteristic of steroid 
molecules (Figure 5.67). It was also taken a 1D DEPT135 spectrum (Figure 
5.68) which was useful to discriminate the CH2 from the CH and CH3. The 
assigned signals were also confirmed from the literature (96). The molecule 
was also analyzed using 2D NMR experiments: 1H-1H COSY, 1H-13C HSQC, 
1H-13C HMBC and 1H-1H NOESY.   
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Table 5.5 Spectroscopic data of daucosteryl tetracetate (11a) 
n 
1H NMR (400 
MHz, Py) d 
(ppm), (96) 
1H NMR (400 MHz, Py) d 
(ppm), 11a 
13C NMR 
(100MHz, Py) d 
(ppm), (96) 
13C NMR 
(100MHz, Py) d 
(ppm), 11a 
1 - - 37.2 37.20 
2 - - 29.4 29.45 
3 3.49 m 
3.51 (dq, dq, J=11.2, 5.9 
Hz, 1H) 
80.1 80.09 
4 - - 38.1 38.92 
5 - - 140.3 140.35 
6 5.37 m 5.38 (psd, J=4.9 Hz, 1H) 122.2 122.17 
7 - - 31.8 31.87 
8 - - 31.9 31.91 
9 - - 50.01 50.17 
10 - - 36.57 36.72 
11 - - 21.0 21.05 
12 - - 39.7 39.74 
13 - - 42.3 42.33 
14 - - 56.7 56.76 
15 - - 24.3 24.30 
16 - - 28.2 28.25 
17 - - 56.0 56.05 
18 0.67 s 0.69 s 11.8 11.86 
19 0.99 s 1.01 s 19.4 19.37 
20 - - 36.1 36.14 
21 0.93 d 0.94 (d, J=6.3 Hz, 3H) 18.8 18.79 
22 - - 33.9 33.94 
23 - - 26.0 26.06 
24 - - 45.8 45.84 
25 - - 29.1 29.15 
26 0.84 d 0.85 (d, J=8.2 Hz, 3H) 19.8 19.83 
27 0.82 d 0.83 (d, J=6.0 Hz, 3H) 19.0 19.04 
28 - - 23.1 23.07 
29 0.85 t 0.86 (t, J=7.5 Hz, 3H) 12.0 11.99 
1’ 4.59 d 4.61 (d, J=8.0 Hz, 1H) 99.7 99.64 
2’ 4.96 t 4.98 (t, J=8.8 Hz, 1H) 71.5 71.49 
3’ 5.21 t 5.23 (t, J=9.6 Hz, 1H) 72.9 72.92 
4’ 5.08 t 5.10 (t, J=9.7 Hz, 1H) 68.5 68.54 
5’ 3.69 ddd 
3.70 (ddd, J=10.6, 4.8, 2.5 
Hz, 1H) 
71.7 71.69 
6’a 4.13 dd 
4.13 (dd, J=12.3, 2.5 Hz, 
1H) 
62.1 62.11 
6’b 4.26 dd 
4.28 (dd, J=12.3, 4.7 Hz, 
1H) 
CO2’ - - 170.7 170.71 
CO3’ - - 170.4 170.36 
CO4’ - - 169.4 169.41 
CO6’ - - 169.3 169.31 
Me2’ 2.09s 2.10 s 20.8 20.78 
Me3’ 2.05 s 2.07 s 20.7 20.74 
Me4’ 2.03 s 2.04 s 20.6 20.66 
Me6’ 2.01 s 2.03 s 20.6 20.63 
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5.1.4.8 Isolation and purification of KCl (12) 
This inorganic compound was partially soluble in H2O and needed to 
be heated in order to achieve complete solubilization. On the other hand, it 
resulted to be completely insoluble in any organic solvent and it had mp higher 
than 300°C and its molecular formula is KCl. Also its high concentration in the 
leaves tissues is probably evidence of the halophilic nature of the plant (99). 
Since CAM plants are not usually halophites, H. glomerata might be a rare 
example of this class of organisms (100–102). 
 
5.1.4.8.1 Structural elucidation of KCl (12) 
The IR spectrum (Figure 5.69) of the molecule showed very few signals 
in general and between 1800 and 2300 cm-1 the spectrum shows a very high 
noise. This absence of signals and the high background noise it’s due to the 
nature of the compound itself, lacking vibrating covalent bonds and being very 
crystalline.  
 
 
 
Figure 5.69 IR spectrum of KCl (12) 
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That is one of the first evidences that shown that the molecule was in 
fact an inorganic compound. Also, the 1H NMR spectrum and the 13C NMR 
spectrum didn’t show any signals related to organic molecules, so the 
compound was confirmed to be an inorganic molecule or mixture of 
compounds. The X-ray analysis of the compound shows a diffractogram of an 
ionic compound, as shown in the figure 5.70. By confrontation with the data 
base of the equipment was confirmed the identity of the molecule as KCl. 
 
 
Figure 5.70 X-ray diffractogram of KCl (12) 
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5.1.5 The aqueous macerations 
The last solvent used in the extraction of H. glomerata vegetal material 
was distilled water. The latter was first used on freshly collected aerial parts of 
the plant and secondly on the material which was already macerated with the 
organic solvents. Meanwhile the roots were extracted only dried and after 
maceration with the organic solvents. Due to the high polarity of water the 
target compounds of this process are mainly polyhydroxylated compounds. 
Some examples of target molecules are sugars, poly glycosylated flavonoids, 
free AA, and polyphenols in general. This maceration had the goal of 
extracting all the metabolites more polar than those extracted with the organic 
solvents. Also, the water extraction of the fresh material was performed in 
order to extract compounds that may be sensible of oxidation processes and 
or decomposition derived from the drying process. Some of these compounds 
might be vitamins, nucleic acids and nucleosides, AA and small peptides 
among others. 
The components of these extracts were not isolated through column 
chromatography but were identified by equipment with higher perfor-mance, 
such as UPLC-MS and HPLC-MS. The bioassay-directed fractionation of one 
of leaf aqueous extracts was carried out for the identification of antibacterial 
compounds. This fractionation was performed using a flash column 
chromatography (FC) apparatus already described in the material and 
equipment chapter. 
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5.1.6 GC-MS analysis 
5.1.6.1 Hexane extract 
 
The objective of this 
analysis was to characterize the 
major components of the extract, 
even compounds that were not 
isolated using CC, to have a 
wider view of the composition of 
the extract itself and to give a 
first justification of the use of the 
plant as antibacterial and 
anticancer ethnical medicine. In 
the figure 5.71 is reported the 
chromatogram of the hexane 
extract obtained from GC analysis. The phytochemicals found in the extract 
(Table 5.6) were mainly steroids which make the 43.56 % of the extract, in 
minor quantities were also found fatty acids, saturated (6.02%) and 
unsaturated (11.84%) and two ethyl esters of unsaturated fatty acids 
(10.15%). Were also present long chain alkanes (9.13%) a dialcohol with a 30 
carbons chain (3.94%), a diterpene (2.44%) and a ketone derivate from the 
oxidation of the phytol (3.76%). It was calculated the relative retention indices 
for all the compounds (last column of the Table 5.6), which is the retention 
time (RT) of a compound normalized to retention times of adjacently eluting n-
alkanes. Retention times vary with the individual chromatographic system 
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Figure 5.71 Chromatogram obtained 
from the GC analysis 
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(column length, film thickness, diameter, carrier gas velocity and pressure, and 
void time), the retention indices are quite independent of these parameters 
and allow comparing values measured by different analytical laboratories 
under varying conditions.  
 
Table 5.6 Results of the GC-MS analysis for the hexane extract 
tR (min) Compound Abundance (%) Retention index 
59.332 Phyton 3.758 609.00 
65.881 Palmitic acid (C16:0) 6.018 1320.35 
71.359 Heneicosane 1.704 1773.38 
71.918 Phytol 2.444 2030.54 
73.842 Linoleic acid (C18:2 ∆9,12) 11.835 890.34 
74.072 Ethyl linoleate  7.712 1005.84 
74.368 Ethyl oleate 2.434 1154.49 
89.601 Unknown 4.572 - 
95.243 Heptacosane 1.483 2175.52 
96.747 Unknown 4.595 - 
102.219 Nonacosane 5.941 2386.47 
111.573 Campesterol 7.625 2414.05 
112.512 Stigmasta-5,22-dien-3-ol 1.939 203.14 
113.157 1,30-triacontanediol 3.937 915.26 
114.601 b-sitosterol 25.470 2509.50 
118.227 Stigmast-4-en-3-one 8.532 3393.00 
 
Between the identified compounds there are some that are reported in 
the literature for their biological activity, such as: campesterol, stigmasterol, 
stigmastan-4-en-3-one, β-sitosterol, phytol, γ-linoleic acid, oleic acid and 
palmitic acid. The reported activities for these compounds effectively explain 
the use of the plant in folk medicine in the treatment of cancer and bacterial 
infections. 
From the compounds isolated through CC, the major components b-
sitosterol and nonacosane were found also in the GC-MS analysis. They have 
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concentrations, which represent together more than the 30% of the extract 
composition. The other isolated compounds were not identified in the GC-MS 
analysis due to instrumental limitation and low volatilization of isolated 
compounds. In addition, some compounds were not identified because of its 
quantity and their absence in the NIST library.  
Comparing the compounds identified by GC-MS with the literature we 
found some similitudes with the reported phytochemicals from the 
Bromeliaceae family (41). 
The more prominent sterol of the hexane extract was the β-sitosterol, 
which is reported to be present in the family and the genus (67, 68); the other 
steroids were also reported in the plant’s family. Concerning, phytol, phytone, 
the other n-alkanes, the saturated and unsaturated fatty acids and their 
derivatives as well as the di-alcohol, there are no reports in the literature of the 
presence of these molecules either the genus or family of Hechtia glomerata. 
Identified hydrocarbons, heneicosane, heptacosane and nonacosane, 
together with 1,30-triacontadienol are derivatives of the reduction of long chain 
fatty acids (LCFAs) or very long chain fatty acids (VLCFAs) (103), and they 
are involved in the plant biosynthesis of esters and waxes (104). The terpenoid 
phyton is a derivative of phytol which itself derives from the metabolism of 
chlorophyll and the mevalonate/acetate biosynthetic route. Phytosterols 
campesterol, stigmasterol and β-sitosterol can be synthesized from the same 
biosynthetic route. They are the most common phytosterols in plants (105) and 
their quantity in the plants dependent on the plant’s metabolism and vitality 
(106).  
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5.1.6.2 GC-MS analysis of some isolated compounds from CHCl3/MeOH 
extract 
Some isolated compounds such as 1-7 and semisynthetic compounds 
5a and 4m were found to contain some minor contaminats thus they were 
analized by GC-MS. Table 5.7 shows results of analysis of each sample run 
in the same conditions, therefore they were pooled into one table.  
 
Table 5.7 Results of the GC-MS analysis for the isolated and derivatized compounds 
tR (min) Compound Hexane (%) C/M* (%) 
10.580 Octanal 0.06 - 
16.144 Nonanal 0.07 - 
21.431 1-Dodecene - 0.78 
25.918 2-(E)-Decenal 0.10 - 
34.148 1-Tetradecene - 2.54 
45.946 1-Hexadecene - 1.47 
50.143 Unknown - 0.02 
56.817 12-Methyltetradecanic acid (C14:0, anteiso) 0.24 - 
58.400 Pentadecanoic acid (C15:0) 1.44 - 
58.419 Isopropyl myristate 0.02 - 
62.006 n-Nonadecane 0.11 - 
62.183 Palmitoleic acid (C16:1, ∆9) 0.45 - 
65.054 Trachylobane 0.07 - 
63.700 Palmitic acid (C16:0) 15.05 - 
66.440 5-(E)-Eicosene 0.10 - 
66.748 14-Methylpalmitic acid (C17:0, iso) 1.90 - 
66.755 n-Eicosane 0.19 - 
67.261 2-Hexyl-cyclopropaneoctanoic acid 0.55 - 
67.497 Kaur-16-ene 0.11 - 
68.036 Margaric acid (C18:0) 0.50 - 
69.632 Trans-vaccenic acid (C18:1, ∆11) 0.35 - 
71.366 n-Heneicosane 2.02 7.87 
74.374 Nonadecenoic acid (C19:1, ∆13) 1.09 - 
74.861 Oleic acid (C18:1, ∆9) 0.45 - 
75.701 n-Docosane 0.43 1.57 
79.872 Gondonic acid (C20:1, ∆11) 0.49 - 
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Table 5.7 Results of the GC-MS analysis for the isolated and derivatized compounds 
(Continued) 
tR (min) Compound Hexane (%) C/M* (%) 
80.162 n-Tricosane - 6.62 
83.689 Cyclotetracosane 0.09 - 
84.004 n-Tetracosane 0.37 1.20 
87.591 12-(Z)-Pentacosene 0.04 - 
88.005 n-Pentacosane 1.60 4.10 
89.528 Unknown - 1.78 
91.381 9-Hexacosene 0.42 2.44 
91.676 n-Hexacosane 0.42 1.37 
95.033 12-(Z)-heptacosene 0.33 - 
95.243 n-Heptacosane 2.26 7.12 
98.909 Cycloocatacosane - 13.71 
99.040 n-Octacosane - 3.22 
101.871 Nonacosanol 0.13 - 
102.055 Dotriacontenol - 0.13 
102.298 n-Nonacosane 5.33 30.72 
105.313 1-Triacontanol - 1.82 
105.497 n-Triacontane 1.63 2.75 
108.545 Hentriacontane 1.42 8.78 
110.896 Ergosterol 0.79 - 
111.573 Campesterol 13.93 - 
112.512 Stigmasterol 4.18 - 
112.867 Hentriacontanol 0.09 - 
113.175 1,30-Triacontanediol 0.09 - 
115.146 β-Sitosterol 40.74 - 
115.921 (3β,5α)-Ergostanol 0.32 - 
* C/M: CHCl3/MeOH extract 
 
A total of 51 compounds were identified from the analysis, most of 
which were part of the hexane extract, since the majority of the analyzed 
samples came from this extract. For the hexane extract the most abundant 
components were the sterols (59.96 %) even though they were just 5 different 
molecules. The second most abundant group comprehended the fatty acids 
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(FAs) with a 22.51 %. The unsaturated fatty acids (UFAs) were found in a 
lower concentration (2.84 %) than the saturated fatty acids (SAFAs; 19.67 %). 
The hydrocarbons were also abundant among these compounds (16.78 %), 
with the alkanes reaching the 15.87 % and the alkenes the 0.90 %. The other 
classes of compounds with low concentration represented less than the 1 % 
of the identified components. They include 3 long chain alcohols, 3 aldehydes, 
2 terpenoids and 1 ester of SAFA. The aldehydes, octanal, nonanal and 2-(E)-
decenal can be considered as derivatives of the reduction of the FAs or further 
oxidation of hydrocarbons. These types of metabolites are produced by the 
plants when they undergo oxidative stress derived from pollution or pests 
(107). Two terpenoid compounds identified were trachylobane and kaur-16-
ene. These trachylobane and kaurane diterpenoids are considered to be 
intermediates in the biosynthesis of plant growth hormones gibberellins (108).  
On the other hand, compounds identified from samples 6 and 7 
obtained from the CHCl3/MeOH extract were mainly hydrocarbons (70.31 %) 
composed by 65.03 % of alkanes and a 5.28 % of alkenes. The other 
components identified were two alcohols, dotriacontanol and triacontanol 
(1.95 %) as well as two unknown compounds (1.80 %). 
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5.2 Metabolomic study 
5.2.1 UPLC-QTOF-MS analysis 
 
 
Figure 5.72 Chromatograms: a) Hexane extract; b) CHCl3/MeOH extract; c) Dry 
aqueous extract; d) Fresh aqueous extract 
 
Results of UPLC separation are reported in figure 5.72 which shows 
chromatograms for the four extracts: hexane (a), CHCl3/MeOH (b), dried 
aqueous (c) and fresh aqueous (d) extracts. A total of 226 metabolites were 
identified from the analysis: 42 from the hexane extract, 117 from the 
CHCl3/MeOH extract, 115 from the dry aqueous extract and 55 from the fresh 
aqueous extract. The composition of each extract was consistent with the 
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polarity of the solvent used in the maceration. At the same time extracts shared 
some similarities. Figure 5.73 showed the percentage of metabolites shared 
among extracts and the ones that were specific for each of them.  
 
Figure 5.73 Percentage of metabolites in each extract 
 
33 compounds were identified in dry aqueous and CHCl3/MeOH 
extracts. 21 compounds were identified in the CHCl3/MeOH and both aqueous 
extracts. 17 compounds were found in both aqueous extracts. Two 
compounds in fresh aqueous and hexane extracts. Two compounds in hexane 
and aqueous extracts. Two compounds were found in all extracts. Only one 
compound was found to be part of hexane and CHCl3/MeOH extracts. One 
compound was part of both the CHCl3/MeOH and fresh aqueous extracts. A 
total of 79 shared compounds representing the 34% of the entire metabolome. 
The total metabolomic profile of H. glomerata comprises 38% flavonoids and 
stilbenes, 31% terpenes and steroids, 15% phenolic acids and derivatives, 
10% fatty acids and hydrocarbons, 6% nitrogen containing compounds (Figure 
5.74).  
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Figure 5.74 Metabolomic profile of H. glomerata Zucc. 
 
Hexane extract resulted to be mostly composed by non-polar 
metabolites as predicted by the hydrophobicity of the maceration solvent (full 
extract composition is reported in table 5.8). Its profile consisted mainly of 
terpenes and steroids (67%), and the second most abundant group consisted 
of fatty acids and hydrocarbons (26%). The two minority groups of compounds 
are nitrogen-containing compounds (5%), and flavonoids and stilbenes (2%), 
the latter with only one compound. The most abundant molecules of the 
hexane extract were phytol, β-sitosterol, campesterol, stigmasterol and 
tillandsinone (Figure 5.75a). The first compound is phytol whit the higher 
concentration among them and it is a diterpene which can take part in the 
synthesis of chlorophylls and it is also produced in their breakdown (150). Its 
high concentration is justified for the need of leaf photosynthesizing pigments. 
In fact, another product of their metabolism, pheophorbide A was found among 
the identified compounds. Figure 5.75b described the production of phytol 
from chlorophyll A (1), and its catabolism is catalyzed by the enzyme 
chlorophyllase (a). 
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Table 5.8 Metabolites identified from the Hexane exract by UPLC-QTOF-MS analysis 
tR (min) Compound MW (g/mol) Chemical Formula Class 
0.8886 Ethyl behenate 368.3654 C24H48O2 FA and Hydrocarbons 
1.4800 5Z,8Z,11Z,14Z,17Z,20Z-Tricosahexaenoic acid (C23:6, ∆5,8,11,14,17,20) 342.0951 C23H34O2 FA and Hydrocarbons 
2.2010 17,20-Hexacosadienoic acid (C26:6, ∆23,20,17,14,11,8) 392.3650 C26H48O2 FA and Hydrocarbons 
2.4490 Pristanic acid 298.5110 C19H38O2 Terpenes and Steroids 
2.5100 23-trans-p-Coumaroyloxytormentic acid 650.3840 C39H54O8 Terpenes and Steroids 
2.7630 Phytenic acid (cis-γ 3-) 310.5220 C20H38O2 Terpenes and Steroids 
2.8510 13-Hydroxyoctadecadienoic acid 309.1025 C18H15NO4 FA and Hydrocarbons 
2.8520 α-Tocopherol 430.3534 C29H50O2 Terpenes and Steroids 
2.9860 (3β,5ξ,9β)-24-Methyl-9,19-cyclolanost-25-en-3-yl formate 468.7700 C36H52O2 Terpenes and Steroids 
3.3860 Hexyl stearate 368.3650 C24H48O2 FA and Hydrocarbons 
3.4970 Rosilic acid 300.2660 C18H36O3 FA and Hydrocarbons 
3.7350 Avenasterol (δ5-) 412.2100 C29H48O Terpenes and Steroids 
3.7810 Stigmasta-5,22-dien-3-β-ol 412.2590 C29H48O1 Terpenes and Steroids 
3.9760 Phytanoic acid 312.5380 C20H40O2 Terpenes and Steroids 
4.4050 Stearic acid (C18:0) 284.0000 C18H38O2 FA and Hydrocarbons 
4.5170 Nonacosene 406.4539 C29H58 FA and Hydrocarbons 
4.7220 Cafesterol 316.0766 C20H28O3 Terpenes and Steroids 
4.7960 Tillandsinone 466.7900 C33H54O Terpenes and Steroids 
4.8750 Isopropyl Palmitate 298.5110 C19H38O2 FA and Hydrocarbons 
5.1220 Stigmasterol 3-stearate 678.6320 C47H82O2 Terpenes and Steroids 
5.1800 24-hydroxy-β-amyrin 442.7280 C20H50O2 Terpenes and Steroids 
5.3150 (5α)-Ergostane 386.7100 C28H50 Terpenes and Steroids 
5.5430 (5ξ,8ξ,9ξ,13ξ)-Pimar-15-en-19-oic acid 304.2020 C20H32O2 Terpenes and Steroids 
5.5680 Catechin 4'-methyl ether 304.0950 C16H16O6 Flavonoids and Stilbenes 
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tR (min) Compound MW (g/mol) Chemical Formula Class 
5.6440 Funtumine 317.2699 C21H35NO N-compounds 
5.7047 1,21-Heneicosanediol 328.3340 C21H44O2 FA and Hydrocarbons 
5.9100 Phytol 296.5390 C20H40O Terpenes and Steroids 
5.9630 (+)-δ-Tocopherol 402.3490 C27H46O2 Terpenes and Steroids 
5.9820 β-Sitosterol 414.1020 C29H50O Terpenes and Steroids 
6.2600 Antheraxanthin 584.8850 C40H56O3 Terpenes and Steroids 
6.4600 Stigmasterol 412.0365 C29H48O Terpenes and Steroids 
6.4740 Brassicasterol 398.3549 C28H46O Terpenes and Steroids 
6.5450 Campesterol 400.9756 C28H48O Terpenes and Steroids 
7.1270 Bixin aldehyde 348.4862 C24H28O2 Terpenes and Steroids 
7.1460 Ergosterol 396.4537 C29H44O Terpenes and Steroids 
7.3000 Protopanaxatriol 476.7420 C30H52O4 Terpenes and Steroids 
7.6180 Kahweol 314.1880 C20H26O3 Terpenes and Steroids 
7.6190 16-O-Methylcafestol 330.4680 C21H30O3 Terpenes and Steroids 
7.7760 Royleanone-4 344.1604 C20H24O5 Terpenes and Steroids 
8.7060 N-Acetyl-Phytosphingosine 359.3030 C20H41NO4 N-compounds 
9.4130 Tricin 330.1676 C17H14O7 Flavonoids and Stilbenes 
9.5230 Erythrodiol 442.3811 C30H50O2 Terpenes and Steroids 
 
 
 
Table 5.8 Metabolites identified from the Hexane exract by UPLC-QTOF-MS analysis (Continued) 
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From this enzymatic reaction is produced the chlorophyllide A (2) which 
is then metabolized by the Mg-dechetalase (b), into pheophorbide A (3). The 
whole process occurs in the chloroplast.  
 
 
Figure 5.75 Major components of the hexane extract (a); Phytol production from chlorophyll 
A degradation in the Chloroplast 
 
Production of phytol throughout the chlorophyll degradation is also 
linked to the biosynthesis of tocopherols and tocotrienols. They are part of 
height compounds known as vitamin E, which are membrane component 
essential for its integrity. These liposoluble molecules are potent antioxidants 
and radical scavenging agents produced in contrast of oxidative stress. α- and 
δ-tocopherol were identified within the metabolome of H. glomerata and their 
structure and biosynthesis are reported in figure 5.76. The synthesis of 
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tocopherols takes place inside the chloroplast and can follow straight way the 
degradation of chlorophyll. The phytol produced in the catabolism is first 
phosphorylated to phytyl monophosphate (PMP) by the phytol kinase 1 (PK1). 
The latter first is decarboxylated and the generated negative charge drives the 
attack to the phytol and the formation of the 2-methyl-6-phytyl-1,4-benzoquinol 
(MPBQ). 
 
 
Figure 5.76 Biosynthesis of α-, γ-, and δ-tocopherol from phytol 
 
This last reaction is catalyzed by the enzyme homogentisate 
phytyltransferase (HPT), and its byproducts are carbon dioxide and 
pyrophosphate (PPi). The MPBQ can either be cyclized by the tocopherol 
cyclase (TC) into δ-tocopherol or it can be methylated by a methyl transferase. 
The cosubstrate used in this reaction is S-adenosylmethionine (SAM) and the 
product is the 2,3-dimethyl-6-phytyl-1,4-benzoquinol (DMPBQ). Throughout 
the cyclization of this intermediate by TC, the γ-tocopherol is then synthesized 
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and its methylation at the position 5 produces α-tocopherol. This last 
modification is catalyzed by the enzyme γ-tocopherol methyltransferase (γ-
TMT) (151). The three sterols: β-sitosterol, campesterol, and stigmasterol are 
well known and widely spread among all plant species. Membrane of plants’ 
cells has a diversified lipid composition with these three sterols being 
predominant over all the others. The ratio between these compounds in the 
plant tissues is specific of plants species, for example the ratio between β-
sitosterol and campesterol is determined by the sterol methyltransferases 
(SMT) activities. The enzymes that catalyze the methylation at position 24 of 
side chain. Also, the regulation of the ratio and composition of sterols seems 
to be a very important element of different cellular processes. In fact, it 
determines the totality of cell’s functions and the vitality of the plant (106). 
Functions of sterols within the plant’s cells, a part of being constitutively 
essential for plant’s cellular membrane are numerous. For instance, they are 
precursors of plant hormones (brassinosteroids), which regulate plants 
development and growth. They are also part of the transmembrane signal 
transduction, throughout the formation of specific lipid rafts. These act like 
microdomains on the surface of the membrane and are used by signaling 
enzyme complexes as anchoring platforms (152, 153). Tillandsinone one the 
major components of the hexane extract is a sterol reported for the first time 
in genus Tillandsia, from T. fasciculata (154). These types of steroids with 
uncommon isopropyl side chains are usually rare in terrestrial plants. They are 
found in marine sponges such as the Aplysnia species (155). There are reports 
of this unusual steroid in the species Nervilia purpurea (Orchideaceae) and 
Viola formosana (Violaceae) (156, 157). Tillandsinone could be used as 
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biomarker between H. glomerata and its family. It is also a sign of a close 
phylogenetic correlation of H. glomerata and T. fasciculata.  
In contrast to the hexane extract, the CHCl3/MeOH extract is mainly 
composed by flavonoids and stilbenes (43%). The terpenes and steroids 
(26%) represent the second biggest group of molecules, followed by the 
phenols and their derivatives (19%). The last two minority classes of 
compounds are represented by the non-polar compounds such as fatty acids 
and hydrocarbons (8%) as well as nitrogen containing compounds (4%). The 
complete composition of this extract is reported in table 5.9. Among the most 
abundant compounds of this extract are piceatannol, spinacetin, resveratrol, 
luteolin and daucosterol (Figure 5.77). Piceatannol, is a stilbene which is 
produced by the cyclization of a polyketide (phenylpropanoid pathway) starting 
from a molecule of caffeoyl-CoA. It was also successfully synthetized by the 
hydroxylation of resveratrol molecule at the position 5, throughout an 
enzymatic reaction catalyzed by a flavin-dependent monooxygenase (HpaBC) 
(158). Piceatannol shares the same biosynthetic pathway as resveratrol, 
changing only the starting point, which in this case is p-coumaroyl-CoA 
(5.77B). The synthesis of both piceatannol and resveratrol, the coenzyme A 
has three acetyl subunits obtained from three molecules of malonyl-CoA. 
Through this elongation process the polyketide precursor to the products is 
synthesized. The enzyme involved in the synthesis of piceatannol is still not 
being elucidated, but it is believed to be the pinosylvin synthase. Instead for 
the resveratrol is well known the enzyme responsible for the cyclization of its 
precursor, which is resveratrol synthase (RS). 
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Table 5.9 Metabolites identified from the CHCl3/MeOH exract by UPLC-QTOF-MS analysis 
tR (min) Compound MW (g/mol) 
Chemical 
Formula 
Class 
3.2660 Fustin-7-rhamnoside 434.1218 C21H22O10 Flavonoids and Stilbenes 
3.4180 Epicatechin 3-O-(4-methylgallate) 456.1036 C23H20O10 Flavonoids and Stilbenes 
3.4180 Cnidimol 7-glucoside 438.0930 C21H26O10 Phenols and derivatives 
3.4180 Ursolic acid 456.1037 C30H48O3 Terpenes and Steroids 
3.5680 Salviaflaside methyl ester 536.1523 C25H28O13 Phenols and derivatives 
3.6530 (17α, 23S)-Epoxy-28, 29-dihydroxy-27-norlanost-8-ene-3, 24-dione 472.3179 C29H44O5 Terpenes and Steroids 
3.6680 6'''-O-Sinapoylsaponarin 800.2157 C38H40O19 Flavonoids and Stilbenes 
3.6880 Dulxanthone G 414.1322 C22H22O8 Phenols and derivatives 
3.8650 Heliangine 362.4170 C20H26O6 Terpenes and Steroids 
4.0880 Syringaresinol 418.4370 C22H26O8 Phenols and derivatives 
4.0960 Khellol glucoside 408.1084 C19H20O10 Phenols and derivatives 
4.1320 
Pelargonidin 3-O-[β-D-Glucopyranosyl-(1-2)-[4-hydroxycinnamoyl-(-6)]-β-D-
glucopyranoside](E-) 5-O-β-D-glucopyranoside 
903.2545 C42H47O22 Flavonoids and Stilbenes 
4.1480 
Isovitexin 2''-O-[4-hydroxy-(E)-cinnamoyl-(-6)-β-D-glucopyranosyl] 4'-O-β-D-
glucopyranoside 
902.2466 C42H46O22 Flavonoids and Stilbenes 
4.1750 (E)-Oxyresveratrol 3'-O-β-D-glucoside 406.1271 C20H22O9 Flavonoids and Stilbenes 
4.2830 (-)-Medicocarpin 432.1428 C22H24O9 Phenols and derivatives 
4.4700 γ-L-Glutamyl-S-(2-carboxy-1-propyl)cysteinylglycine 393.0000 C14H23N3O8S N-compounds 
4.4780 3, 5, 8-Trihydroxy-3', 4', 7-trimethoxyflavone 360.0854 C18H16O8 Flavonoids and Stilbenes 
4.5800 4-Methoxybenzenepropanol 1-(2-sulfoglucoside) 408.1086 C16H24O10S Phenols and derivatives 
4.7290 Glabrol 392.2000 C25H28O4 Flavonoids and Stilbenes 
4.8460 Cyanidin 3-(6''-malonyl)-laminaribiose 679.4050 C30H33O19 Flavonoids and Stilbenes 
4.9390 Phytolaccagenic acid 3-O-glucose(1''->3')arabinose 810.4400 C42H66O15 Terpenes and Steroids 
4.9620 3-O-Methylrosmarinic acid 374.1009 C19H18O8 Phenols and derivatives 
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Table 5.9 Metabolites identified from the CHCl3/MeOH exract by UPLC-QTOF-MS analysis (Continued) 
tR (min) Compound MW (g/mol) 
Chemical 
Formula 
Class 
5.0220 Hispaglabridin A 392.1120 C25H28O4 Flavonoids and Stilbenes 
5.0520 2, 4, 6-Phenanthrenetriol 2-O-β-D-glucoside 388.1167 C20H20O8 Phenols and derivatives 
5.0530 8-Hydroxy-4'-methoxypinoresinol 388.1520 C21H24O7 Flavonoids and Stilbenes 
5.0540 Kaempferol 3-O-rhamnoside 431.3700 C21H19O10 Flavonoids and Stilbenes 
5.0760 9, 10, 13-trihydroxy-11-octadecenoic acid 330.2400 C18H34O5 FA and Hydrocarbons 
5.0970 Sinapoylquinic acid 398.2430 C18H22O10 Phenols and derivatives 
5.1110 (Z)-4', 6-Dihydroxyaurone 6-glucoside 416.1112 C21H20O9 Flavonoids and Stilbenes 
5.3300 Petunidin 317.2930 C16H13O7 Flavonoids and Stilbenes 
5.4230 Hydroxymethyl glutathione 336.2285 C20H32O4 N-compounds 
5.5100 Glycyrrhizin 822.9420 C42H62O16 Terpenes and Steroids 
5.5440 Sarsasapogenin 416.3290 C27H44O3 Terpenes and Steroids 
5.5500 γ-L-Glutamyl-γ-L-glutamyl-L-methionine 407.1347 C15H25N3O8S N-compounds 
5.6190 Piceatannol 4'-glucoside 406.3870 C20H22O9 Flavonoids and Stilbenes 
5.7240 3, 8-Dihydroxy-6-methoxy-7(11)-eremophilen-12, 8-olide 296.1625 C16H24O5 Terpenes and Steroids 
5.8010 (ent-15β)-15, 19-Dihydroxy-7-trachylobanone 318.2175 C20H30O3 Terpenes and Steroids 
5.8090 (ent-6α, 7α, 16αH)-6, 7, 17-Trihydroxy-19-kauranoic acid 352.2233 C20H32O5 Terpenes and Steroids 
5.9450 6-tuliposide A 278.1519 C11H18O8 FA and Hydrocarbons 
5.9460 2-Hydroxyenterodiol 318.1444 C18H22O5 Phenols and derivatives 
5.9510 10-hydroperoxy-8E, 12Z-octadecadienoic acid 312.2289 C18H32O4 FA and Hydrocarbons 
6.0550 β-Sitostanol 416.4018 C29H52O Terpenes and Steroids 
6.0600 Pregna-5,16,20-triene-3β,20-diol diacetate 398.2431 C25H34O4 Terpenes and Steroids 
6.1500 2''-O-trans-p-Coumaroylastragalin 594.1369 C30H26O13 Flavonoids and Stilbenes 
6.1520 Daucosterol 576.8600 C35H60O6 Terpenes and Steroids 
6.3010 Quercetin 3-(6''-acetylgalactoside)-7- rhamnoside 652.1640 C29H32O17 Flavonoids and Stilbenes 
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Table 5.9 Metabolites identified from the CHCl3/MeOH exract by UPLC-QTOF-MS analysis (Continued) 
tR (min) Compound MW (g/mol) 
Chemical 
Formula 
Class 
6.3010 (15α, 20R)-Dihydroxypregn-4-en-3-one 20-[glucosyl-(1-4)-6-acetyl-glucoside] 698.3495 C35H54O14 Terpenes and Steroids 
6.3270 Cirsimaritin 314.2463 C17H14O6 Flavonoids and Stilbenes 
6.3460 Peonidin 300.1339 C18H20O4+ Flavonoids and Stilbenes 
6.3650 Gliricidin 300.0630 C16H12O6 Flavonoids and Stilbenes 
6.3770 Guanosine pentaphosphate 598.1230 C10H12N5O17P4 N-compounds 
6.4260 5-p-Coumaroylquinic acid 338.2444 C16H18O8 Phenols and derivatives 
6.4320 5-enolpyruvoyl-shikimate 3-phosphate 320.2332 C20H32O3 Phenols and derivatives 
6.4450 Herbacetin 7-(6''-quinoylglucoside) 638.1480 C28H30O17 Flavonoids and Stilbenes 
6.4610 Trihydroxycinnamoyl quinic acid 370.0900 C16H18O10 Phenols and derivatives 
6.4700 Corchorosol A 536.2981 C29H44O9 Terpenes and Steroids 
6.5620 Cyclopassifloside II 682.4273 C37H62O11 Terpenes and Steroids 
6.8030 Pelargonidin 3-rutinoside-5-(maronoyl)glucoside 827.2244 C36H43O22 Flavonoids and Stilbenes 
6.8060 1-Caffeoylquinic acid 354.2742 C16H18O9 Phenols and derivatives 
6.8820 1-Hydroxy-1-phenyl-3-octadecanone 360.3012 C24H40O2 FA and Hydrocarbons 
6.9270 Kaempferol 3-(2''-galloyl-α-L- arabinopyranoside) 570.2872 C27H22O14 Flavonoids and Stilbenes 
6.9990 Apigenin 7-O-(6''-malonyl-apiosyl-glucoside) 650.5380 C29H30O17 Flavonoids and Stilbenes 
7.0210 Malvin 655.6110 C29H35O17 Flavonoids and Stilbenes 
7.0910 Hecogenin 430.6290 C27H42O4 Terpenes and Steroids 
7.1000 Phytolaccagenic acid 3-O-hexose 678.4020 C37H58O11 Terpenes and Steroids 
7.1190 Methyl cis-dihydrojasmonate 626.2747 C13H22O3 FA and Hydrocarbons 
7.1460 Phytolaccagenic acid 3-O-glycoside 678.4000 C37H58O11 Terpenes and Steroids 
7.1850 Piceid 390.2785 C20H22O8 Flavonoids and Stilbenes 
7.2600 Tricin 330.1676 C17H14O7 Flavonoids and Stilbenes 
7.3000 Pedunculagin 782.5720 C35H26O21 Phenols and derivatives 
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Table 5.9 Metabolites identified from the CHCl3/MeOH exract by UPLC-QTOF-MS analysis (Continued) 
tR (min) Compound MW (g/mol) 
Chemical 
Formula 
Class 
7.3450 Kaempferol 3-triglucoside-7-rhamnoside-p-coumaroyl 1064.3030 C48H56O27 Flavonoids and Stilbenes 
7.3450 1,3-O-Dicaffeoylglycerol 416.1100 C21H20O9 Phenols and derivatives 
7.3470 Spinacetin 3-O-glucosyl-(1->6)-[apiosyl(1->2)]-glucoside 802.6840 C34H42O22 Flavonoids and Stilbenes 
7.3480 Hexosyl-hexosyl-soyasapogenol E 780.4702 C42H68O13 Terpenes and Steroids 
7.3480 3,7,3'-O-triglucopyranosyl-dephinidine 789.6703 C33H41O22+ Flavonoids and Stilbenes 
7.3860 Quercetin-3-Galactoside-6''-Rhamnoside-3'''-Rhamnoside 770.7220 C34H42O20 Flavonoids and Stilbenes 
7.3860 Hederagenin 3-O-hexose-pentose 766.4500 C41H66O13 Terpenes and Steroids 
7.3910 Cyanidin 3-sambubioside 743.6401 C32H39O20 Flavonoids and Stilbenes 
7.4150 Quercetin 3-O-glucosyl-rhamnosyl-glucoside 772.6620 C33H40O21 Flavonoids and Stilbenes 
7.4150 1-Sinapoyl-2-feruloylgentiobiose 724.6603 C33H40O18 Phenols and derivatives 
7.4190 Luteolin-7-rutinoside 592.5522 C28H32O14 Flavonoids and Stilbenes 
7.4270 Pheophorbide A 592.2691 C35H36N4O5 N-compounds 
7.4270 (Z)-13-Oxo-9-octadecenoic acid 296.2344 C18H32O3 FA and Hydrocarbons 
7.4490 Diosmin 608.2641 C28H32O15 Flavonoids and Stilbenes 
7.4600 (3Z)-Phycocyanobilin 586.2824 C33H38N4O6 N-compounds 
7.5100 
2-(2-Methylbutanoyl)-9-(3-methyl-2E-pentenoyl)-2β, 9α-dihydroxy-4Z, 10(14)-
oplopadien-3-one 
430.2695 C26H38O5 Terpenes and Steroids 
7.5420 Tricin 7-O-(6''-(E)-sinapoyl)-β-D-glucopyranoside 698.1800 C34H34O16 Flavonoids and Stilbenes 
7.6670 Glycyrrhetinic acid 3-O-glucuronide 646.8180 C36H54O10 Terpenes and Steroids 
7.6780 Bavachalcone 338.3193 C21H22O4 Phenols and derivatives 
7.6780 Dihexosyl luteolin sulfate 690.1101 C27H30O19S Flavonoids and Stilbenes 
7.7070 Cholic acid 408.2878 C24H40O5 Terpenes and Steroids 
7.7310 Bixin aldehyde 348.4862 C24H28O2 Terpenes and Steroids 
7.7760 Cinnamtannin B1 864.6147 C45H36O18 Flavonoids and Stilbenes 
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Table 5.9 Metabolites identified from the CHCl3/MeOH exract by UPLC-QTOF-MS analysis (Continued) 
tR (min) Compound MW (g/mol) 
Chemical 
Formula 
Class 
7.8020 Galloylquinic acid isomer 800.2203 C38H40O19 Flavonoids and Stilbenes 
7.8270 Cyanidin 3,5,3'-tri-O-glycoside 773.5953 C33H41O21+ Flavonoids and Stilbenes 
7.8380 Kaempferol 3,7,4'-O-triglucoside 772.6580 C33H40O21 Flavonoids and Stilbenes 
7.8380 Hederagenin 3-O-glucose(1''->3')galactose 796.4622 C42H68O14 Terpenes and Steroids 
7.8380 Theaflavin 3-O-gallate 716.6043 C36H28O16 Flavonoids and Stilbenes 
7.8460 α-Hederin 750.9671 C41H66O12 Terpenes and Steroids 
7.8470 Spinacetin 3-O-glucosyl-(1->6)-glucoside 670.5711 C29H34O18 Flavonoids and Stilbenes 
7.8690 Luteolin 7-O-(2-apiosyl-6-malonyl)-glucoside 666.5380 C29H30O18 Flavonoids and Stilbenes 
7.8760 Petunidin 3-O-(6-O-acetyl)-glucoside 521.5890 C24H25O13+ Flavonoids and Stilbenes 
7.9010 Piceatannol 4'-glucoside 406.3870 C20H22O9 Flavonoids and Stilbenes 
8.0220 16β-16-Hydroxy-3-oxo-1, 12-oleanadien-28-oic acid 468.3210 C30H44O4 Terpenes and Steroids 
8.1270 Rutin 610.1534 C27H30O16 Flavonoids and Stilbenes 
8.2080 Luteolin 7-(6''-malonylneohesperidoside) 680.5680 C30H32O18 Flavonoids and Stilbenes 
8.2320 Aloesol 7-glucoside 396.1759 C20H28O8 Phenols and derivatives 
8.2480 1-caffeoyl-3-ferulylglycerol 430.2700 C22H22O9 Phenols and derivatives 
8.2820 γ-Tocotrienol 411.2230 C28H42O2 Terpenes and Steroids 
8.2890 2-Deoxybrassinolide 464.3488 C28H48O5 Terpenes and Steroids 
8.4670 Epiafzelechin 3-O-gallate 426.7290 C22H18O9 Flavonoids and Stilbenes 
8.8560 3-O-glucopyranosyl-6,3',5'-trimethoxy-3,5,7,4'-tetrahydroxyflavone 538.4601 C24H26O14 Flavonoids and Stilbenes 
9.4010 Zeaxanthin 568.8811 C40H56O2 Terpenes and Steroids 
9.4010 Ananaflavoside B 536.3871 C25H28O13 Flavonoids and Stilbenes 
10.1580 Isochlorogenic acid b 514.4831 C26H26O11 Phenols and derivatives 
10.1580 Cyanidin 3,5-O-diglucoside 611.5280 C27H31O16+ Flavonoids and Stilbenes 
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Stilbenes have a wide range of functions in plants, one of them is to 
protect the plant from infection and environmental stress (159). In fact they are 
involved in the inducible and constitutive defenses of the plant against fungal 
pathogens, nematodes and herbivores (160). 
 
Figure 5.77 Biosynthetic pathway schematization of resveratrol, spinacetin and luteolin (a), 
piceatannol (b), daucosterol (c) 
 
Spinacetin and luteolin are two flavonoids and they also come from the 
phenylpropanoid pathway. In fact, both of them and resveratrol share the 
same precursors, with just few enzymatic steps of cyclization, isomerization, 
hydroxylation and methylation differences (Figure 5.77a) (161). From p-
coumaroyl-CoA, there are three enzymatic steps: the naringenin chalcone 
synthesis from the polyketide, catalyzed by the chalcone synthase (CHS), the 
cyclization of chalcone into naringenin by the chalcone isomerase (CHI), the 
oxidation of naringenin to apigenin by the enzyme flavone synthase (FNS) and 
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the hydroxylation of the apigenin into luteolin by the flavone 3’ hydroxylase 
(FN-3’H). The biosynthesis can also diverge with the modification of 
naringenin, through 5 steps of consecutive oxidation, hydroxylation and 
methylation. These modifications are operated by various enzymes, many of 
which are isoforms of the cytochrome P450 (162, 163). Among flavonoids 
functions include antioxidant and radical scavenging activity, to protect the 
plant from oxidative stress. Flavonoids are involved in process of detoxification 
since they can stimulate the seeds’ germination and can act as signaling 
molecules. Some flavonoids are antibiotics to protect the plant from infection 
(164). The last compound is the daucosterol (eleutheroside A), a 
monoglycosylic saponin derivative of β-sitosterol (Figure 5.77C). It is 
synthesized throughout the glucosylation of the sterol in position 3 by a 
glucose transferase (GT). Its high concentration is well justified by the 
aglycone which is also very abundant in the hexane extract. The glycosyl 
derivatives of sterols have shown to be crucial in seed development even 
though their function as part of the cellular membrane is still unclear (165).  
The CHCl3/MeOH extract is very similar to dry aqueous extract mainly 
for their flavonoids and stilbenes (44%). Also, terpenes and steroids are 
abundant (24%), followed by the phenols and their derivatives (18%). The less 
concentrated classes of molecules are fatty acids and hydrocarbons (7%), and 
nitrogen containing compounds (6%). The identified components of the dry 
aqueous extract are listed in table 5.10. Some of the most abundant 
compounds are the same as the previous extract, being spinacetin and 
resveratrol the highest in concentration, followed by delphinidine, daucosterol, 
oleanolic acid, ananaflavoside B and kaempferol. 
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Table 5.10 Metabolites identified from the dry aqueous exract by UPLC-QTOF-MS analysis 
tR (min) Compound MW (g/mol) 
Chemical 
Formula 
Class 
2.8660 Syringin 372.1440 C17H24O9 Phenols and derivatives 
3.1550 Caffeic acid O-glucoside 342.1000 C15H18O9 Phenols and derivatives 
3.6530 Prunin 434.1200 C21H22O10 Flavonoids and Stilbenes 
3.8130 Stigmasta-5,22-dien-3-β-ol 412.2590 C29H48O1 Terpenes and Steroids 
4.1490 Pallidol 454.2830 C28H22O6 Flavonoids and Stilbenes 
4.1600 5-Heneicosylresorcinol 404.3654 C27H48O2 Flavonoids and Stilbenes 
4.6090 1-Octen-3-yl primeveroside 422.2123 C19H34O10 FA and Hydrocarbons 
4.6560 Aloesol 7-glucoside 396.3890 C19H24O9 Phenols and derivatives 
4.7710 Delphinidin 3-sophoroside 5-glucoside 789.6700 C33H41O22+ Flavonoids and Stilbenes 
4.9390 Azukisaponin III 810.9750 C42H66O15 Terpenes and Steroids 
5.0230 Phytyl monophosphate 374.1947 C18H30O8 Terpenes and Steroids 
5.0970 Sinapoylquinic acid 398.2430 C18H22O10 Phenols and derivatives 
5.4000 S-sinapyl-L-cysteine-L-glycine 370.4200 C16H22N2O6S N-compounds 
5.5100 Glycyrrhizin 822.9420 C42H62O16 Terpenes and Steroids 
5.5440 Sarsasapogenin 416.3290 C27H44O3 Terpenes and Steroids 
5.7240 3, 8-Dihydroxy-6-methoxy-7(11)-eremophilen-12, 8-olide 296.1625 C16H24O5 Terpenes and Steroids 
5.7370 Chlorogenic acid 354.0950 C16H18O9 Phenols and derivatives 
5.9450 6-tuliposide A 278.1519 C11H18O8 FA and Hydrocarbons 
5.9460 2-Hydroxyenterodiol 318.1444 C18H22O5 Phenols and derivatives 
5.9990 Daidzin 416.3820 C21H20O9 Flavonoids and Stilbenes 
5.9990 Tylactone 394.2719 C23H38O5 FA and Hydrocarbons 
6.0230 Symphytine 381.2167 C20H31NO6 N-compounds 
6.0520 2''-O-trans-p-Coumaroylastragalin 594.1369 C30H26O13 Flavonoids and Stilbenes 
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Table 5.10 Metabolites identified from the dry aqueous exract by UPLC-QTOF-MS analysis (Continued) 
tR (min) Compound MW (g/mol) 
Chemical 
Formula 
Class 
6.1500 3-Caffeoylpelargonidin 5-glucoside 595.1427 C30H27O13+ Flavonoids and Stilbenes 
6.1500 Daucosterol 576.8600 C35H60O6 Terpenes and Steroids 
6.1520 p-Coumaroyl-feruloylglycerol 414.1300 C22H22O8 Phenols and derivatives 
6.3200 Peonidin 300.1339 C18H20O4+ Flavonoids and Stilbenes 
6.3460 Coumaric acid glucoside 326.2990 C15H18O8 Phenols and derivatives 
6.3570 Gliricidin 300.0630 C16H12O6 Flavonoids and Stilbenes 
6.3650 Digalloylglucose 483.3830 C20H20O14 Phenols and derivatives 
6.3720 Guanosine pentaphosphate 598.1230 C10H12N5O17P4 N-compounds 
6.3770 Epicatechin 3-O-gallate 442.3262 C22H18O10 Flavonoids and Stilbenes 
6.4210 Herbacetin 7-(6''-quinoylglucoside) 638.1480 C28H30O17 Flavonoids and Stilbenes 
6.4450 Tetramethylquercetin 358.3165 C19H18O7 Flavonoids and Stilbenes 
6.4740 3-O-(Glcb1-4Galb)-(25R)-12-oxo-5α-spirostan-3β-ol 770.4450 C40H66O14 Terpenes and Steroids 
6.5610 Cyclopassifloside II 682.4273 C37H62O11 Terpenes and Steroids 
6.5620 4-Glycosyloxycinnamoylcholine 412.2034 C20H30NO8 Phenols and derivatives 
6.5650 Cusparine 307.1227 C19H17NO3 N-compounds 
6.5690 Kaempferol 3-O-rutinoside 594.1590 C27H30O15 Flavonoids and Stilbenes 
6.5730 All-trans-Carophyll yellow 460.3375 C32H44O2 Terpenes and Steroids 
6.7530 Kaempferol 3-O-(6''-acetyl-galactoside) 7-O-rhamnoside 636.5550 C29H32O16 Flavonoids and Stilbenes 
6.7570 Epimedin A 838.2901 C39H50O20 Flavonoids and Stilbenes 
6.7600 Pelargonodin 3-rutinoside p-coumaric 725.2100 C36H37O16 Flavonoids and Stilbenes 
6.7600 Proanthocyanin monogallate 728.8290 C36H56O15 Flavonoids and Stilbenes 
6.7610 1, 28-Dicaffeoyloctacosanediol 750.5083 C46H70O8 Phenols and derivatives 
6.7610 1,26-Hexacosanediol diferulate 750.4604 C46H70O8 Phenols and derivatives 
6.7610 Sinapoyl choline dehydro dimer-isomer 618.3223 C40H58O5 N-compounds 
 177 
Table 5.10 Metabolites identified from the dry aqueous exract by UPLC-QTOF-MS analysis (Continued) 
tR (min) Compound MW (g/mol) 
Chemical 
Formula 
Class 
6.7660 Pelargonidin 3-rutinoside-5-(maronoyl)glucoside 827.2244 C36H43O22 Flavonoids and Stilbenes 
6.8060 1-Caffeoylquinic acid 354.2742 C16H18O9 Phenols and derivatives 
6.8820 1-Hydroxy-1-phenyl-3-octadecanone 360.3012 C24H40O2 FA and Hydrocarbons 
6.9920 3-(2-Heptenyloxy)-2-hydroxypropyl undecanoate 356.2943 C21H40O4 FA and Hydrocarbons 
6.9990 Apigenin 7-O-(6''-malonyl-apiosyl-glucoside) 650.5380 C29H30O17 Flavonoids and Stilbenes 
7.0210 Malvin 655.6110 C29H35O17 Flavonoids and Stilbenes 
7.0910 Hecogenin 430.6290 C27H42O4 Terpenes and Steroids 
7.1000 Phytolaccagenic acid 3-O-hexose 678.4020 C37H58O11 Terpenes and Steroids 
7.1270 Epicatechin 3-O-(3-O-methylgallate) 456.2491 C23H20O10 Flavonoids and Stilbenes 
7.1600 Apigetrin glycoside 622.4901 C27H26O17 Flavonoids and Stilbenes 
7.1620 Piceid 390.2785 C20H22O8 Flavonoids and Stilbenes 
7.2600 Cyanidin 3,5,3'-tri-O-glucoside 773.6700 C33H41O21+ Flavonoids and Stilbenes 
7.2750 Tricin 330.1676 C17H14O7 Flavonoids and Stilbenes 
7.3000 Kaempferol-3-Rhamnoside-4''-Rhamnoside-7-Rhamnoside 724.2210 C33H40O18 Flavonoids and Stilbenes 
7.3370 Kaempferol 3-triglucoside-7-rhamnoside-p-coumaroyl 1064.3030 C48H56O27 Flavonoids and Stilbenes 
7.3450 1,3-O-Dicaffeoylglycerol 416.1100 C21H20O9 Phenols and derivatives 
7.3470 Undecaprenyl phosphate mannose 1008.7100 C61H101O9P Terpenes and Steroids 
7.3470 Oleanolic acid 3-O-glucose(1''->3')arabinose 750.4600 C41H66O12 Terpenes and Steroids 
7.3480 Spinacetin 3-O-glucosyl-(1->6)-[apiosyl(1->2)]-glucoside 802.6840 C34H42O22 Flavonoids and Stilbenes 
7.3480 Hexosyl-hexosyl-soyasapogenol E 780.4702 C42H68O13 Terpenes and Steroids 
7.3480 Peonidin 3-sophoroside-5-glucoside 787.2301 C34H43O21 Flavonoids and Stilbenes 
7.3500 3,7,3'-O-triglucopyranosyl-dephinidine 789.6703 C33H41O22+ Flavonoids and Stilbenes 
7.3860 Hederagenin 3-O-hexose-pentose 766.4500 C41H66O13 Terpenes and Steroids 
7.3910 Prenyl caffeate 248.1049 C14H16O4 Phenols and derivatives 
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Table 5.10 Metabolites identified from the dry aqueous exract by UPLC-QTOF-MS analysis (Continued) 
tR (min) Compound MW (g/mol) 
Chemical 
Formula 
Class 
7.4150 Cyanidin 3-sambubioside 743.6401 C32H39O20 Flavonoids and Stilbenes 
7.4169 Quercetin 3-O-glucosyl-rhamnosyl-glucoside 772.6620 C33H40O21 Flavonoids and Stilbenes 
7.4190 1-Sinapoyl-2-feruloylgentiobiose 724.6603 C33H40O18 Phenols and derivatives 
7.5420 
2-(2-Methylbutanoyl)-9-(3-methyl-2E-pentenoyl)-2β, 9α-dihydroxy-4Z, 10(14)-
oplopadien-3-one 
430.2695 C26H38O5 Terpenes and Steroids 
7.6060 Qurcetin-3-(dicaffeoyl)sophorotrioside-7-glucoside 1274.3220 C57H62O33 Flavonoids and Stilbenes 
7.6670 Tricin 7-O-(6''-(E)-sinapoyl)-β-D-glucopyranoside 698.1800 C34H34O16 Flavonoids and Stilbenes 
7.6780 Bavachalcone 338.3193 C21H22O4 Phenols and derivatives 
7.7310 Cholic acid 408.2878 C24H40O5 Terpenes and Steroids 
7.7760 Bixin aldehyde 348.4862 C24H28O2 Terpenes and Steroids 
7.7950 Dimer proanthocyanin monogallate 729.1511 C37H29O16 Flavonoids and Stilbenes 
7.8010 Trihydroxycinnamoylquinic acid 370.0910 C16H18O10 Phenols and derivatives 
7.8020 Cinnamtannin B1 864.6147 C45H36O18 Flavonoids and Stilbenes 
7.8270 Galloylquinic acid isomer 800.2203 C38H40O19 Flavonoids and Stilbenes 
7.8370 Agavoside B 754.6861 C34H42O19 Terpenes and Steroids 
7.8370 
(3β,9β,12α,16α,24E)-12,16-Trihydroxy-9,19-cyclolanost-24-en-26-oic acid-3-
diglucopyranoside 
796.9912 C42H68O14 Terpenes and Steroids 
7.8380 Cyanidin 3,5,3'-tri-O-glycoside 773.5953 C33H41O21+ Flavonoids and Stilbenes 
7.8389 Kaempferol 3,7,4'-O-triglucoside 772.6580 C33H40O21 Flavonoids and Stilbenes 
7.8400 Hederagenin 3-O-glucose(1''->3')galactose 796.4622 C42H68O14 Terpenes and Steroids 
7.8460 Theaflavin 3-O-gallate 716.6043 C36H28O16 Flavonoids and Stilbenes 
7.8470 α-Hederin 750.9671 C41H66O12 Terpenes and Steroids 
7.8690 Spinacetin 3-O-glucosyl-(1->6)-glucoside 670.5711 C29H34O18 Flavonoids and Stilbenes 
7.8740 Luteolin 7-sulfate-3'-rutinoside 674.5790 C27H30O18S Flavonoids and Stilbenes 
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Table 5.10 Metabolites identified from the dry aqueous exract by UPLC-QTOF-MS analysis (Continued) 
tR (min) Compound MW (g/mol) 
Chemical 
Formula 
Class 
7.8760 Luteolin 7-O-(2-apiosyl-6-malonyl)-glucoside 666.5380 C29H30O18 Flavonoids and Stilbenes 
7.9010 Petunidin 3-O-(6-O-acetyl)-glucoside 521.5890 C24H25O13+ Flavonoids and Stilbenes 
7.9880 Filfiline 389.3672 C26H47NO N-compounds 
8.0220 Piceatannol 4'-glucoside 406.3870 C20H22O9 Flavonoids and Stilbenes 
8.1850 Peonidin 3-rhamnoside 447.3610 C22H23O10+ Flavonoids and Stilbenes 
8.2280 Myricetin 3,3'-digalactoside 642.5190 C27H30O18 Flavonoids and Stilbenes 
8.2320 Luteolin 7-(6''-malonylneohesperidoside) 680.5680 C30H32O18 Flavonoids and Stilbenes 
8.2380 Kaempferol-3-sophoroside-Per-O-methoxy-cinnamoyl 890.2522 C41H46O22 Flavonoids and Stilbenes 
8.2460 Delphinidin 3-rutinoside-5-galactoside 773.2100 C33H41O21 Flavonoids and Stilbenes 
8.2480 Aloesol 7-glucoside 396.1759 C20H28O8 Phenols and derivatives 
8.2670 Spinasaponin A 794.9760 C42H66O14 Terpenes and Steroids 
8.2820 1-caffeoyl-3-ferulylglycerol 430.2700 C22H22O9 Phenols and derivatives 
8.3390 Luteolin 7-O-(2-apiosyldiacetyl) glucoside 664.1600 C30H32O17 Flavonoids and Stilbenes 
8.3410 Luteolin 7-O-diglucuronide 638.4850 C27H26O18 Flavonoids and Stilbenes 
8.4670 2-Deoxybrassinolide 464.3488 C28H48O5 Terpenes and Steroids 
8.8560 Epiafzelechin 3-O-gallate 426.7290 C22H18O9 Flavonoids and Stilbenes 
8.8890 Dolichyl D-xylosyl phosphates 572.3482 C30H52O8P Terpenes and Steroids 
9.4010 3-O-glucopyranosyl-6,3',5'-trimethoxy-3,5,7,4'-tetrahydroxyflavone 538.4601 C24H26O14 Flavonoids and Stilbenes 
9.4080 Zeaxanthin 568.8811 C40H56O2 Terpenes and Steroids 
9.4170 (3β, 16α, 21β, 22α)-12-Oleanene-3, 16, 21, 23, 28-pentol-22-angeloyloxy-23-al 586.3835 C35H54O7 Terpenes and Steroids 
10.1580 Ananaflavoside B 536.3871 C25H28O13 Flavonoids and Stilbenes 
10.1600 Isochlorogenic acid B 514.4831 C26H26O11 Phenols and derivatives 
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Delphinidine, ananaflavoside B and kaempferol are an anthocyanidin, 
a flavone and a flavonol, respectively. The biosynthesis of these molecules 
could follow the synthesis of luteolin, in the hierarchy of the pathway (Figure 
5.78). The ananaflavoside B could be synthetized from subsequent 
hydroxylations, methylations and glycosylation of luteolin. 
 
Figure 5.78 Biosynthetic pathway schematization of ananaflavoside B (a), kaempferol and 
delfinidine (b), and oleanolic acid (c) 
 
A hydroxylation at position 3 of naringenin by the flavonol synthase 
(FLS), result in dihydrokaempferol (DHK). Then kaempferol is synthesized by 
the kaempferol synthase (KS), throughout a double bond between the carbons 
2 and 3, the oxidation process consumes oxygen and 2-oxoglutarate (2-OG) 
and produces a proton, water, carbon dioxide and succinate (Succ.). Instead 
delphinidin biosynthesis starts from the DHK with four steps including 
oxidation and hydroxylation (164). Anthocyanidins functions are mostly 
pigmentation of plant’s tissues, as well as antioxidant and radical scavenging 
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actions. Anthocyanidins protect plants from abiotic stressors using many 
mechanisms of protection (sunscreen, antioxidant and metalchelating). 
Anthocyanins could delay senescence in plants by mineral deficency (166). 
Oleanolic acid is a pentacyclic triterpenoid metabolite related to 
betulinic acid, its biosynthesis involves the acetate-mevalonate pathway. It 
differentiates from the steroids synthesis by the special arrangement imposed 
by the enzyme β-amyrin synthase (AS1) on the squalene molecule during the 
cyclization. This terpenoid compound is often found together with one of its 
derivatives, the ursolic acid (Figure 5.79), identified also in the plant 
metabolome. Oleanolic acid and ursolic acid are mostly found in plants’ 
epicuticular waxes where they exert the activity of barrier against pathogens 
and water loss. They are also the precursor to many triterpenoid saponins 
which serve as well as defense to herbivores or pathogens and as allelopathic 
agents (167).  
 
Figure 5.79 Structure of ursolic acid 
 
Very closely to dry aqueous extract, the fresh aqueous extract is 
composed mainly by flavonoid and stilbenes, which are more than half of 
extract (58%). Terpenes and steroids (18%), phenols and their derivatives 
(13%) are also abundant in the extract. The lesser components are fatty acids 
and hydrocarbons (7%), and the nitrogen containing compounds (4%). This 
extract composition its fully represented in table 5.11. 
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Table 5.11 Metabolites identified from the fresh aqueous exract by UPLC-QTOF-MS analysis 
tR (min) Compound 
MW 
(g/mol) 
Chemical 
Formula 
Class 
1.9670 3, 8-Diglucosyldiosmetin 624.1670 C28H32O16 Flavonoids and Stilbenes 
2.9860 5,7-Dihydroxy-6-methoxyisoflavone 7-O-rhamnoside 430.1264 C22H22O9 Flavonoids and Stilbenes 
4.7710 Stigmasta-5,22-dien-3-β-ol 412.2590 C29H48O1 Terpenes and Steroids 
5.0230 Delphinidin 3-sophoroside 5-glucoside 789.6700 C33H41O22+ Flavonoids and Stilbenes 
5.5430 Phytyl monophosphate 374.1947 C18H30O8 Terpenes and Steroids 
5.9450 Catechin 4'-methyl ether 304.0950 C16H16O6 Flavonoids and Stilbenes 
6.1520 6-tuliposide A 278.1519 C11H18O8 FA and Hydrocarbons 
6.3460 Daucosterol 576.8600 C35H60O6 Terpenes and Steroids 
6.3560 Peonidin 300.1339 C18H20O4+ Flavonoids and Stilbenes 
6.3770 Glabridin 324.1300 C20H20O4 Flavonoids and Stilbenes 
6.4210 Guanosine pentaphosphate 598.1230 C10H12N5O17P4 N-compounds 
6.4420 Epicatechin 3-O-gallate 442.3262 C22H18O10 Flavonoids and Stilbenes 
6.4740 Chlorogenoquinone 352.1502 C18H24O7 Phenols and derivatives 
6.5730 Tetramethylquercetin 358.3165 C19H18O7 Flavonoids and Stilbenes 
6.6430 Kaempferol 3-O-rutinoside 594.1590 C27H30O15 Flavonoids and Stilbenes 
6.7140 Luteolin 7-(2''-apiosylglucoside) 580.1430 C26H28O15 Flavonoids and Stilbenes 
6.7610 Ergosterol endoperoxide 428.3110 C28H44O3 Terpenes and Steroids 
6.7630 Proanthocyanin monogallate 728.8290 C36H56O15 Flavonoids and Stilbenes 
6.7650 1, 28-Dicaffeoyloctacosanediol 750.5083 C46H70O8 Phenols and derivatives 
6.7660 1,26-Hexacosanediol diferulate 750.4604 C46H70O8 Phenols and derivatives 
7.1270 Epicatechin 3-O-(3-O-methylgallate) 456.2491 C23H20O10 Flavonoids and Stilbenes 
7.1600 Piceid 390.2785 C20H22O8 Flavonoids and Stilbenes 
7.2600 Cyanidin-3-O-(2''-O-β-xylopyranosyl-β-glucopyranoside)-5-O-β-glucopyranoside 743.6400 C32H39O20 Flavonoids and Stilbenes 
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Table 5.11 Metabolites identified from the fresh aqueous exract by UPLC-QTOF-MS analysis (Continued) 
tR (min) Compound 
MW 
(g/mol) 
Chemical 
Formula 
Class 
7.2740 Tricin 330.1676 C17H14O7 Flavonoids and Stilbenes 
7.3000 Kaempferol 3-triglucoside-7-rhamnoside-p-coumaroyl 1064.3030 C48H56O27 Flavonoids and Stilbenes 
7.3450 Oleanolic acid 3-O-glucose(1''->3')arabinose 750.4600 C41H66O12 Terpenes and Steroids 
7.3480 Spinacetin 3-O-glucosyl-(1->6)-[apiosyl(1->2)]-glucoside 802.6840 C34H42O22 Flavonoids and Stilbenes 
7.3491 Hexosyl-hexosyl-soyasapogenol E 780.4702 C42H68O13 Terpenes and Steroids 
7.3500  3-O-rutinosyl-3'-O-glucopyranosyl cyanidin 757.6710 C33H41O20+ Flavonoids and Stilbenes 
7.3820 Quercetin-3-Galactoside-6''-Rhamnoside-3'''-Rhamnoside 770.7220 C34H42O20 Flavonoids and Stilbenes 
7.3860 3,7,3'-O-triglucopyranosyl-dephinidine 789.6703 C33H41O22+ Flavonoids and Stilbenes 
7.3880 Hederagenin 3-O-hexose-pentose 766.4500 C41H66O13 Terpenes and Steroids 
7.3910 Prenyl caffeate 248.1049 C14H16O4 Phenols and derivatives 
7.4130 Cyanidin 3-sambubinoside-5-rhamnoside 727.2100 C32H39O19 Flavonoids and Stilbenes 
7.5550 Peonidin 3-sophoroside 625.1771 C28H33O16+ Flavonoids and Stilbenes 
7.7760 Bixin aldehyde 348.4862 C24H28O2 Terpenes and Steroids 
7.8010 Trihydroxycinnamoylquinic acid 370.0910 C16H18O10 Phenols and derivatives 
7.8020 Cinnamtannin B1 864.6147 C45H36O18 Flavonoids and Stilbenes 
7.8270 Galloylquinic acid isomer 800.2203 C38H40O19 Flavonoids and Stilbenes 
7.8370 Agavoside B 754.6861 C34H42O19 Terpenes and Steroids 
7.8740 Luteolin 7-sulfate-3'-rutinoside 674.5790 C27H30O18S Flavonoids and Stilbenes 
7.8760 Luteolin 7-O-(2-apiosyl-6-malonyl)-glucoside 666.5380 C29H30O18 Flavonoids and Stilbenes 
7.9010 Petunidin 3-O-(6-O-acetyl)-glucoside 521.5890 C24H25O13+ Flavonoids and Stilbenes 
8.0220 Piceatannol 4'-glucoside 406.3870 C20H22O9 Flavonoids and Stilbenes 
8.1850 Peonidin 3-rhamnoside 447.3610 C22H23O10+ Flavonoids and Stilbenes 
8.2280 Myricetin 3,3'-digalactoside 642.5190 C27H30O18 Flavonoids and Stilbenes 
8.2990 Aloesol 7-glucoside 396.1759 C20H28O8 Phenols and derivatives 
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Table 5.11 Metabolites identified from the fresh aqueous exract by UPLC-QTOF-MS analysis (Continued) 
tR (min) Compound 
MW 
(g/mol) 
Chemical 
Formula 
Class 
8.3020 Delphinidin 3-rutinoside 5-glucoside 773.6690 C33H41O21+ Flavonoids and Stilbenes 
8.3410 Myricitrin glucoside 464.0954 C21H20O12 Flavonoids and Stilbenes 
8.8560 Luteolin 7-O-diglucuronide 638.4850 C27H26O18 Flavonoids and Stilbenes 
9.4010 Epiafzelechin 3-O-gallate 426.7290 C22H18O9 Flavonoids and Stilbenes 
9.4100 3-O-glucopyranosyl-6,3',5'-trimethoxy-3,5,7,4'-tetrahydroxyflavone 538.4601 C24H26O14 Flavonoids and Stilbenes 
10.1580 Zeaxanthin 568.8811 C40H56O2 Terpenes and Steroids 
10.1600 Ananaflavoside B 536.3871 C25H28O13 Flavonoids and Stilbenes 
10.2100 Isochlorogenic acid b 514.4831 C26H26O11 Phenols and derivatives 
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High quantity of polyphenols and antioxidant compounds found in H. 
glomerata could due to adaptation of plant to arid environments. It is known 
that plants that use the Crassulacean Acid Metabolism (CAM) to survive water 
availability limitation are able to save H2O molecules minimizing their 
photorespiration (168). A CAM plant produced oxygen inside its tissues during 
the day, even if its production is minimized. That’s why polyphenols and 
antioxidant molecules in general might have an important role in preventing 
the oxidative stress produced by the Calvin cycle. The most constitutive 
molecules of the fresh aqueous extract are practically the same as the dry one. 
They are spinacetin, resveratrol, delphinidin, cyanidin and luteolin. With the 
only exception of cyanidin all the compounds are already present in the other 
extracts. Cyanidin is an anthocyanidin that can be produced from the same 
pathway of the flavonols, starting from DHK.  
 
 
Figure 5.80 Biosynthetic pathway schematization of cyanidin, cyanidin 3,5,3’-triglucoside 
and cyanidin 3-rutinoside-3’-glucoside from dihydrokaempferol (DHK) 
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Its synthesis is the conjunction of four enzymatic steps which 
comprehend hydroxylation, oxidation and two steps of reduction. Cyanidin was 
found to be present in various glycosylated forms in plant’s metabolome. Two 
of them: cyanidin 3,5,3'-triglucoside and cyanidin 3-rutinoside-3'-glucoside are 
known to cause scarlet coloration in some Bromeliaceae plants (169). 
Biosynthesis and glycosylated derivatives of cyanidin are reported in figure 
5.80. Among other abundant components of fresh aqueous extract are 
isoscoparin and isochlorogenic acid (Figure 5.81). The first one is a C-
glycosylflavone, which has C-C bond between a glucose molecule and the C-
6 of the flavone. This class of flavonoids are synthesized by the plant like other 
flavonoids (170). Instead the isochlorogenic acid is a phenylpropionate 
derivative of quinic and caffeic acid, in a 1:2 ratio. This molecule is an 
antioxidant that to protect the plant, and its metabolism is tress induced (171). 
All the metabolites identified by UPLC-QTOF-MS in H. glomerata extracts are 
reported in table 5.8. 
 
 
Figure 5.81 Structure of isoscoparin (left) and isochlorogenic acid B (right) 
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5.2.2 Statistical analysis 
5.2.2.1 Principal components analysis (PCA) 
The parameter used for PCA analysis was the relative abundance of 
each component in every extract. From PCA plots was possible to notice the 
difference in composition between the four extracts. The 2D plot (Figure 5.82) 
showed this difference against the principle coordinates (PC) 1 and 2, in which 
PC1 displays a higher percent of difference than the PC2 (79.1 % and 14.4 % 
respectively).  
 
 
Figure 5.82 2D plot of the PCA analysis 
 
The closest the extracts appear in the plots the similar the extracts are. 
The plots contain various components expressed in percentage, representing 
the variation of the calculated scores for each compound. The hexane extract 
was the most different, as shown by its distance in the 2D plot from the other 
three extracts. This is due to its different composition mainly of non-polar 
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compounds which were extracted by the hexane during the maceration. The 
CHCl3/MeOH and the aqueous extracts were almost aligned in PC1, having 
the dry aqueous extract in between the other two, meaning that they have a 
similar composition. In the PC2 the three extracts are instead separated, the 
aqueous extracts were slightly closer to each other because their composition 
was more similar, due to the polarity of the solvent used in the maceration. 
Similarities and differences of extracts were also visible from the 
chromatograms (Figure 5.71). In this sense it was clearly visible that hexane 
extract was the most different of the four. The same differences were also 
visible from the 3D PCA and loading plots in figure 5.83. 
 
 
 
Figure 5.83 3D plot (left) and loading plot (right) of the PCA analysis 
 
The 3D plot showed an extra coordinate the PC3 which had the lower 
percentage of difference (6.5 %). This allowed interpret the plot base on the 
phase of the vectors that go from the origin of the axes to the points that 
represent each extract. If the vectors (points) were close to each other (small 
angle) they correlate. If they were out of phase (90°) it means that they non-
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correlated and if they were at 180° it means that components were anti-
correlated. It was visible that vectors of CHCl3/MeOH and aqueous extracts 
were out of phase of 90° from the vector of the hexane extract. This underlined 
a lack of correlation among the data represented in the vectors which are the 
components of each extract and confirmed that the most difference was found 
in the hexane extract composition. The 3D loading plot showed this difference 
more in each compound, where the ones that find themselves close to each 
other correlated in the same way. If they were aligned on the same vector it 
means they are part of the same extract. If components were in between the 
vectors they shared among the extracts. 
 
5.2.2.2 Hierarchical clustering analysis 
 
Figure 5.84 Hierarchical clustering analysis: Heatmap (left) and dendrogram (right) of the 
components of the extracts of H. glomerata 
 
It was performed ANOVA and t-test test on the data collected form the 
UPLC-QTOF-MS analysis of the leaf extracts. Results are shown in heatmap 
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(Figure 5.84). The t-test shows the presence of specific component in each 
extract using hotter colors while using colder colors for its absence. It also 
showed the shared compounds which allow a graphical visualization of the 
composition and differences of the extracts. Other representation of the 
correlation between the extracts is the dendrogram. Results showed that 
hexane extract has the higher significance difference (P>0.05), followed by the 
CHCl3/MeOH which is more similar to dry aqueous and fresh aqueous 
extracts. Figure 5.85 showed classes of compounds responsible for the main 
differences between the extracts. The same module of MeboAnalyst was used 
for features and compound’s classes. 
 
 
Figure 5.85 Principle classes of compounds found in each extract 
 
Figure 5.85 shows the principle classes of compounds which are 
divided in two main groups in base of their abundance in the extracts, and this 
fits also with their polarity. Result confirms that extracts have different 
compositions based on the type of solvent used in the maceration. This is due 
to the fact that a polar solvent will extract more polar compounds than a non-
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polar one and vice versa, explaining why is more difficult to find all the 
compounds in the same type of extract. 
 
5.2.2.3 Pathway analysis 
Figure 5.86 showed that metabolic biosynthetic pathways of H. 
glomerata with the higher impact on its metabolome are flavone and flavonol 
(1.00), phenylpropanoid (0.46), steroid (0.39), flavonoid (0.34), diterpenoid 
(0.34) and fatty acids (0.27).  
 
 
Figure 5.86 Pathway analysis 
 
These principal pathways are correlated to the flavonoids, HCA 
derivatives, terpenes, steroids and FAs content of the plant. The lower impact 
pathways are mostly enhancing some specific process for some compounds, 
such as linoleic and arachidonic acid metabolism or FAs elongation in 
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mitochondria but they are mainly derived from the same principal classes of 
metabolites (See table 5.12).  
The identified pathways have been reported for some plants of the 
family of Bromeliaceae such as A. comosus, where the terpenes biosynthesis 
(diterpenes, triterpenes and carotenoids), FAs biosynthesis (esters) and 
polyphenols biosynthesis have been investigated (224). For A. comosus var. 
bracteatus where also reported a 5,825 unigenes which were mapped to a 
total of 117 pathways responsible for the biosynthesis of terpenes and 
phenylpropanoid compounds (225). 
 
Table 5.12 Results of pathway analysis of H. glomerata 
Pathway Tot Exp Hits Raw p -log (p) 
Holm 
adjust FDR Imp 
Steroid biosynthesis 28 2.64 15 2.08E-09 2.00E+01 1.73E-07 1.73E-07 0.39 
Flavonoid biosynthesis 37 3.48 16 3.11E-08 1.73E+01 2.55E-06 1.29E-06 0.34 
Fatty acid biosynthesis 47 4.42 13 2.02E-04 8.51E+00 1.64E-02 4.98E-03 0.27 
Phenylpropanoid 
biosynthesis 31 2.92 10 2.94E-04 8.13E+00 2.35E-02 4.98E-03 0.46 
Flavone and flavonol 
biosynthesis 8 0.75 5 3.00E-04 8.11E+00 2.37E-02 4.98E-03 1.00 
Linoleic acid metabolism 5 0.47 3 7.05E-03 4.96E+00 5.50E-01 9.75E-02 0.00 
Arachidonic acid 
metabolism 10 0.94 4 9.98E-03 4.61E+00 7.68E-01 1.18E-01 0.00 
Diterpenoid biosynthesis 19 1.79 5 2.68E-02 3.62E+00 1.00E+00 2.78E-01 0.34 
Stilbenoid biosynthesis 6 0.56 2 1.02E-01 2.28E+00 1.00E+00 9.45E-01 0.00 
Terpenoid backbone 
biosynthesis 24 2.26 4 1.83E-01 1.70E+00 1.00E+00 1.00E+00 0.21 
Phenylalanine 
metabolism 11 1.04 2 2.77E-01 1.28E+00 1.00E+00 1.00E+00 0.26 
Terpenoid-quinone 
biosynthesis 22 2.07 3 3.43E-01 1.07E+00 1.00E+00 1.00E+00 0.12 
Fatty acid elongation in 
mitochondria 13 1.22 1 7.25E-01 3.21E-01 1.00E+00 1.00E+00 0.00 
Porphyrin and 
chlorophyll metabolism 33 3.11 1 9.64E-01 3.72E-02 1.00E+00 1.00E+00 0.00 
Fatty acid metabolism 37 3.48 1 9.76E-01 2.46E-02 1.00E+00 1.00E+00 0.00 
Carotenoid biosynthesis 37 3.48 1 9.76E-01 2.46E-02 1.00E+00 1.00E+00 0.00 
Purine metabolism 55 5.18 1 9.96E-01 3.79E-03 1.00E+00 1.00E+00 0.03 
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Plants are stimulated to produce large amount of flavonoids when they 
are under environmental stress like excessive coldness, (the plant was 
collected during the winter) or after physical damage (226). Sun light and 
dryness can also affect flavonoids production, which accumulate in the tissues 
directly exposed solar radiation. Instead the biosynthesis of HCAs seems not 
to be affected by these environmental stresses (227). Soil salinity is another 
variable that can affect plants phenolic composition, producing the increase of 
antioxidants concentration (228).  
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5.3 Biological assays 
5.3.1 Antibacterial activity of H. glomerata Zucc. 
Table 5.13 reports the leaf extracts antibacterial activity, showing that 
the CHCl3/MeOH extract was active against the sensible strains of S. aureus 
with a MIC of 62.5 µg/mL and E. faecium with a MIC of 125 µg/mL, showing 
selectivity for the gram-positive bacteria. The other extracts resulted non-
active against all the sensible bacterial strains. Also, hexane, CHCl3/MeOH 
and aqueous root extracts were tested against the same sensitive bacterial 
strains giving null activity. 
 
Table 5.13 Activity of H. glomerata leaf extracts against sensible bacteria 
Extract 
MIC (µg/mL) 
S. aureus E. faecium P. aeruginosa E. coli K. Pneumoniae 
Hexane >500 >500 >500 >500 >500 
C/M* 125 62.5 >500 >500 >500 
Dry Aq. >500 >500 >500 >500 >500 
Fresh Aq. >500 >500 >500 >500 >500 
* C/M: CHCl3/MeOH extract. 
 
Table 5.14 showed results for leaf and root extracts of H. glomerata and 
some isolated and derivatized compounds against resistant bacteria. Leaves 
hexane and aqueous extracts (fresh and dry) were somehow active against E. 
coli producer of ESBL, and the three strains of K. pneumoniae resistant to 
oxacillins, producer of ESBL, and NDM-1 +, with MIC value of 500 µg/mL each. 
This is could be due to their complex composition, which does not allow a good 
concentration of active components.  
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Table 5.14 Activity of H. glomerata leaf and root extracts and some isolated compounds and their semi-synthetic derivatives against resistant bacteria 
Leaf extract 
MIC (µg/mL) 
MRSA* LRSE* VREF* CRAB* CRPA* ECPE* KPPN* KPPE* ORKP* 
Hexane >500 >500 >500 >500 >500 500 500 500 500 
C/M* >500 >500 >500 >500 >500 >500 >500 >500 >500 
Dry Aq. >500 >500 >500 >500 >500 500 500 500 500 
Fresh Aq. >500 >500 >500 >500 >500 500 500 500 500 
Root extract  
Hexane >500 >500 >500 >500 >500 >500 >500 >500 >500 
C/M* >500 500 >500 500 500 >500 >500 >500 >500 
Aqueous >500 >500 >500 >500 >500 >500 >500 >500 >500 
Compounds  
β-Sitosterol >200 200 200 200 200 >200 200 >200 >200 
β-Sit. Ac. >200 200 200 100 200 200 >200 200 >200 
Daucosterol >200 200 200 200 200 >200 >200 >200 >200 
Dauco. Tetr. >200 >200 200 200 200 >200 >200 >200 >200 
pCA* >200 >200 >200 >200 >200 >200 >200 >200 >200 
CA* >200 >200 >200 >200 >200 >200 >200 >200 >200 
Levofloxacin 12.5 6.25 100 12.5 0.78 25 100 0.78 >200 
* C/M: CHCl3/MeOH extract; MRSA: Methicillin resistant S. aureus; LRSE: Linezolid resistant S. epidermidis; VREF: Vancomycin resistant E. faecium; CRAB: 
Carbapenem resistant A. baumannii; CRPA: Carbapenem resistant P. aeruginosa; ECPE; E. coli producer of ESBL; KPPN: K. pneumoniae producer of NDM-
1+; KPEP: K. pneumoniae producer of ESBL; ORKP: Oxacillin resistant K. pneumoniae; pCA: p-Coumaric acid; CA: Caffeic acid. 
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Leaf CHCl3/MeOH extract showed null activity against all resistant 
strains tested. It is possible that the activity of this extract was masked or 
inhibited by other compounds present in this extract that’s why the extract did 
not show activity. Antibacterial activity of extracts against sensible and 
resistant bacteria could due to the genetic mutations that bacteria have to 
undergo in order to gain its resistance. Mutation changes have to be 
compensated by the bacteria resulting in changes in their metabolic processes 
and therefore genetic expression (229). These modifications can generate 
new metabolic pathways and alternative mechanisms of action and hence 
resistant bacteria might show activity even if sensible strains did not show any. 
Roots raw extracts like the leaves’ extracts, resulted to be generally 
non-active against the selected resistant bacterial strains. The CHCl3/MeOH 
extract was the only one which displayed low activity against S. epidermidis 
linezolid resistant, A. baumannii and P. aeruginosa both carbapenems 
resistant (Table. 5.11). Other extracts give null activity against the tested 
resistant strains. Because much like the previously tested extracts, their active 
components do not reach a useful concentration in the working solution. This 
is also in agreement with the ethnical use of H. glomerata, because the leaves 
are used in folk medicine whereas the roots are used as food source. On the 
other hand, the activity of some pure compounds (Table 5.14) against 
sensitive bacteria have been reported in the literature (230, 231). β-Sitosterol 
showed weak activity (MIC 200 µg/ml) against S. epidermidis (linezolid), E. 
faecium (vancomycin), A. baumannii (carbapenems), P. aeruginosa 
(carbapenems), and K. pneumoniae (NDM-1 +). β-Sitosterol acetate displayed 
weak activity (MIC 200 µg/ml) towards S. epidermidis (linezolid), E. faecium 
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(vancomycin), P. aeruginosa (carbapenems), E. coli (ESBL) and K. 
pneumoniae (ESBL) whereas against A. baumannii (carbapenems) had a 
moderate activity (MIC 100 µg/ml). Daucosterol gave activity (MIC 200 µg/ml) 
against S. epidermidis (linezolid), E. faecium (vancomycin), A. baumannii 
(carbapenems), and P. aeruginosa (carbapenems). Daucosterol acetylated 
had activity (MIC 200 µg/ml) towards E. faecium (vancomycin), A. baumani 
(carbapenems) and P. aeruginosa (carbapenems). Activity of 
phytocompounds and their semisynthetic derivatives towards resistant 
bacteria was weak, the most active tested compound was β-sitosterol acetate, 
with a MIC of 100 µg/mL against A. baumannii (carbapenems). In the literature 
the compound has shown to have some activity on the growth of various 
bacterial strains, such as S. aureus, E. coli and K. pneumoniae, reporting halos 
of inhibition (232). β-Sitosterol was the second most active of the compounds, 
respecting what reported in the literature and having no activity at its highest 
concentration against S. aureus, E. coli and two strains of K. pneumoniae. The 
other bacteria were susceptible at 200 µg/mL of the compound which is still 
too high concentration to consider the molecule active. Daucosterol and its 
tetraacetate derivative gave almost the same results of antibacterial activity. 
Chemical structure of these molecules is larger than their aglycones so 
physical barriers of bacteria could create difficulties of compounds to reach 
the cytoplasm and exert their effect. It is know that some of them (especially 
the gram-positive ones) produce biofilms which have the ability to stop 
undesirable compounds to reach the bacteria, and protect it. A. baumannii, it 
resulted to be sensible to the acetylated β-sitosterol but not β-sitosterol. It is 
possible that acetylated sterol crossess the cytoplasmic membrane of bacteria 
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due to its increased lipophilicity compared with its non-acetylated parent. On 
the other hand, both daucosterol and its derivative resulted inefficient in any 
of the tested bacterial strains. It is also ought to mention that the bacterial 
strains were very resistant, needing sometimes very high concentrations of 
levofloxacin which resulted above the ones reported. For example, the 
concentrations used for levofloxacine in the assays wer not enough to kill K. 
pneumoniae resistant to oxacillins, showing the high resistance of the strain. 
 
5.3.2 Antibacterial screening of dry aqueous extract fractions 
Six fractions were tested against four resistant bacterial strains that 
resulted sensible to the aqueous extracts (Table 5.11). Results of screening 
show that fractions were inactive against the bacteria at the maximum tested 
concentration (500 µg/mL). This could be explained by a probable loss of 
activity of the extract during time, even if stored at -20 °C. In addition, its 
fractionation throughout the flash chromatographer could speed up the extract 
degradation. To prove this hypothesis the fractions were reunited and tested 
again. A sample of aqueous extract that was not fractionated was tested also. 
None of the tested samples showed any activity. 
 
5.3.3 Cytotoxicity assay of H. glomerata’s raw extracts 
Cytotoxicity of organic leaf extracts resulted much higher than the 
aqueous extracts (Figure 5.87). Cytotoxic activity (IC50) of organic extracts was 
in the range of 24 to 49 µg/mL against cancer cell lines tested. Whereas the 
IC50 value for the aqueous extracts were 49 – 93 µg/mL.  
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Figure 5.87 Cytotoxic effect (IC50) of H. glomerata’s leaf extracts against Hep3B, HepG2, 
A549, HeLa, PC3, MCF7 and IHH cell lines. *Paclitaxel was used as positive control showing 
IC50 of 6.4±2.1, 7±3.4, 21.5±3.4, 8.5±1.7, 13.2±3 and 59.8±6.8 ng/mL respectively for the 
tested cell lines, with exception of MCF7 for which was not determined. The hexane (Hex), 
CHCl3/MeOH (C/M), dry aqueous (Dry Aq) and fresh aqueous (Fresh Aq) extracts were 
considered active when their IC50 was below the threshold (red line) was set to 30 µg/mL. 
 
The most cytotoxic active extract was the hexane, having IC50 values £ 
30 µg/mL against Hep3B, MCF7 and HepG2 tumor cell lines. The lower IC50 
reported for this extract were against Hep3B (24 ± 2 µg/mL), MCF7 (27 ± 2.5 
µg/mL) and HepG2 (28 ± 2 µg/mL). The second most affected cell lines were 
HeLa and A549 with IC50 40 µg/mL, showing a low activity. Instead, no activity 
was observed for PC3 cell line (IC50: 76 ± 5 µg/mL), which resulted less 
affected than the IHH cells (IC50: 43 ± 3 µg/mL). The CHCl3/MeOH extract was 
the second most active extract, with an IC50 of 25 ± 4 µg/mL against the PC3 
cell line. Lower cytotoxicity was observed against the MCF7 cell line with an 
IC50 of 32 ± 2 µg/mL. Dry aqueous extract showed low cytotoxic activity with 
IC50 values ³ 80 µg/mL for the cancer cell lines tested. The fresh aqueous 
extract had only two IC50 values £ 60 µg/mL these were with PC3 and MCF7 
cell lines, therefore it was considered inactive. 
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There is no remarkable selectivity between the cancer cell lines and 
immortalized normal hepatocytes (IHH). The higher selectivity was obtain with 
the chloroform/methanol extract were the lowest IC50 was 55 ± 3 µg/mL and 
the IHH had an IC50 is of 61 ± 7 µg/mL. 
Selectivity index (SI) of extracts was calculated (Table 5.15). Some 
degree of selectivity of organic extracts for cancerous cells is clearly visible 
from the calculations especially the CHCl3/MeOH extract resulted remarkably 
more cytotoxic for PC3 and MCF7 cancer cells. 
 
Table 5.15 SI calculated for the extracts 
Extract Hep3B HepG2 A549 HeLa PC3 MCF7 
Hexane 1.79±0.15 1.54±0.11 1.10±0.17 1.23±0.11 0.57±0.04 1.59±0.15 
C/M* 1.36±0.12 1.24±0.08 1.11±0.06 1.11±0.06 2.44±0.39 1.91±0.12 
Aq. 1* 1.11±0.09 1.12±0.05 1.01±0.10 1.09±0.12 1.15±0.04 1.31±0.06 
Aq. 2* 1.18±0.11 1.29±0.13 0.99±0.08 1.13±0.11 1.84±0.11 1.58±0.11 
* C/M: CHCl3/MeOH extract; Aq. 1: dry Aqueous extract; Aq. 2: Fresh aqueous extract. 
 
Difference in activity observed between the organic and the aqueous 
extracts could due to the size and polarity of their molecules (Rule of 5) rather 
than their qualitative nature. Some compouns from the aqueous extracts may 
contain multiple sugar molecules in order to stay in solution or multiple polar 
functional groups which could not allow them to cross the cellular membrane 
(233). If only few molecules can reach the cytoplasm, then the concentration 
they achieve will not be sufficient to cause a toxic effect on the cell. It would 
be easer for the cell to get rid of the toxic component by their deactivation or 
by pumping them to the extra cellular space (234). The identified compounds 
from the hexane extract justify its activity, in fact its active principle seems to 
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be the β-sitosterol which reaches the highest concentration among the 
extract’s components. 
The polarity of solvent mixture in CHCl3/MeOH extract allows it to have 
a broader set of compounds. This means that the components in this extract 
has a higher probability to have the correct characteristics to exert a 
pharmacological activity from a Lipinski rule point of view. Among the isolated 
compounds there are some that might be responsible or at least take part in 
the extract biological activity.  
Table 5.16 shows the results of the cytotoxicity of the root extracts of 
H. glomerata. Unfortunately, only the hexane extract showed some activity 
against PC3 cells (IC50 = 73.29 ± 6.76 µg/mL). Although an inhibition of cell 
growth is clearly present, the IC50 value is too high to consider the extract 
active (78). The low activity displayed by the root hexane extract is probably 
explainable by its high content in lipids. It is probably that saponifiable and 
non-saponifiable fats might be damaging the cellular membrane. 
 
Table 5.16 IC50 values (µg/mL) of the root extracts against the cancer cell lines 
Root 
extract 
IC50 (µg/mL) 
Hep3B HepG2 A549 HeLa PC3 MCF7 IHH 
Hexane N/A >200 N/A 129.6±11.79 73.26±6.76 >100 N/A 
C/M* N/A >200 N/A >200 >100 >100 N/A 
Aqueous N/A >200 N/A >200 >100 >100 N/A 
Control IC50 (ng/mL) 
Paclitaxel 6.4±2.1 7±3.4 21.5±3.4 8.5±1.7 13.2±3 ND 59.8±6.8 
* C/M: CHCl3/MeOH extract. 
 
 202 
5.3.4 ANOVA analysis of cytotoxicity results 
Results of cytotoxic activity of leaves extracts were also submitted to a 
single factor analysis of variance (One-Way ANOVA), the summary of the 
parameters used in the calculations is given in table 5.17. Results of ANOVA 
calculations are reported in table 5.18.  
 
Table 5.17 Parameters of the ANOVA calculation 
Groups Count Sum Average Variance 
Hexane 7 272 38.8571429 315.142857 
CHCl3/MeOH 7 322 46 172.333333 
Dry Aqueous 7 589 84.1428571 54.1428571 
Fresh Aqueous 7 513 73.2857143 251.904762 
 
Analysis of calculated values showed a significant variation among the 
considered variables. The F value (16.4795967) resulted much higher than 
the Fcrit (3.00878657) demonstrating that at least one of the extracts is part of 
a completely different population when compared to the others. Also, the P-
value (4.9964x10-6) resulted a 10-4 factor smaller than the selected α value 
(0.05), also stating the non-null hypothesis for the cytotoxicity results.  
 
Table 5.18 Result of the ANOVA calculation 
 
Variation SS df MS F P-value F crit 
Between 
Groups 
9807.7143 3 3269.2381 16.4795967 4.9964E-06 3.00878657 
Within 
Groups 
4761.1429 24 198.380952 - - - 
Total 14568.857 27 - - - - 
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The t-test results (Table 5.19) showed that the CHCl3/MeOH and the 
hexane extracts gave the most similar results in cytotoxicity.  
 
Table 5.19 Result of the t-test calculation 
Confronted extracts P(T<=t) two-tail 
Hexane vs CHCl3/MeOH 0.40879635 
Hexane vs Dry Aqueous 4.352x10-5 
Hexane vs Fresh Aqueous 0.00241639 
CHCl3/MeOH vs Dry Aqueous 2.1778x10-5 
CHCl3/MeOH vs Fresh Aqueous 0.00434225 
Dry Aqueous vs Fresh Aqueous 0.12652051 
 
Their P-value was 0.408796346 which is almost ten times greater than 
the selected α level. When confronted with the aqueous extracts cytotoxicity 
the organic extracts resulted producing a low P-value in the range of 2x10-3 – 
2x10-5. Instead the dry and fresh aqueous extracts resulted to be similar to 
each other having a P-value (0.126520506) greater than the selected α level. 
 
5.3.5 Reported biological activity of compounds identified by GC-MS in 
the CHCl3/MeOH extract  
Some of identified compounds from the tested extracts have already 
been reported in the literature as bioactive. For example it has been reported 
that phytol has activity against eight bacterial and eight fungal strains, showing 
a strong antibacterial activity with MICs between 3 and 38 µg/mL, against 
Bacillus cereus, Micrococcus luteus, Listeria monocytogenes, P. aeruginosa, 
Salmonella typhimurium, E. coli, Enterobacter cloacae and Micrococcus flavus 
(109). Phytol has also been reported to exert cytotoxic activity against various 
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types of cancer cell lines and normal immortalized cells giving variable results. 
It was found to be modestly active against MCF7, HeLa, A549, and PC3 cells, 
with IC50 ranging between 1.13 ± 0.05 µg/mL and 9.98 ± 0.25 µg/mL (110). 
Diterpenoids trachylobane and kaur-16-ene are also part of a family of 
bioactive compounds, reported as antibacterial (111), and both of them are 
also reported having cytotoxic effects (112). Regarding stigmasterol and 
campesterol there are just few reports of these sterols tested as pure 
compounds, but there are various reports of the biological activity of their 
mixture and derivatives. For example, their acetylated derivatives shown to 
have antibacterial activity against S. aureus, E. coli, P. aeruginosa and 
Klebsiella among other bacteria (113). β-Sitosterol and daucosterol which are 
very high in concentration are instead reported to have no antibacterial 
properties against E. coli, S. aureus and K. pneumoniae (MIC >500 µg/mL) 
(114). β-Sitosterol was also reported to have various activities, such as 
cytotoxicity against cancer cells like MCF7, A549, PC3, HeLa and HepG2. 
Their IC50 were 29.53 µg/mL, 78 µg/mL, 30.85 µg/mL, 170.60 µg/mL and 21.98 
µg/mL respectively, showing a moderate inhibition of the cellular growth on the 
cancer cell lines (115–118). The glycosylated derivative of β-sitosterol which 
is already been reported in the literature as biologically active, having mild 
toxic effect on PC3 cells with an IC50 of 31.9 ± 0.054 µg/mL (119). The 
glycosylated sterol is also capable of stimulate the Wnt/β-catenin signalization 
and therefore inhibit the proliferation, migration and invasion of hepatocellular 
carcinoma (HCC) cells. Against HepG2 the molecule showed a very low 
cytotoxicity with an IC50 of 251 µg/mL and against Hep3B resulted to have a 
medium inhibitory concentration higher than 20 µg/mL (120, 121). 
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Stigmasterol is reported to have cytotoxic activity against Hela and A549 cell 
lines with IC50 of 5.04 µg/mL and 4.28 µg/mL respectively (122). p-Coumaric 
acid is instead reported to have a contradictory antibacterial activity. Lou et al. 
found that the acid has an effect against Gram–positive bacteria such as S. 
aureus (MIC: 20 µg/mL) and Gram–negative bacteria like E. coli (MIC: 80 
µg/mL). It was also reported that this molecule has a double damage 
mechanism of action comprehending an increase in the membrane 
permeability and binding on the phosphate anion of the DNA of the bacteria 
(123). Instead other works the activity against S. aureus was reported lower 
(MIC: 625 µg/mL) or completely absent for both p-coumaric acid and caffeic 
acid (MIC > 1 µg/mL) against S. aureus, S. epidermidis and against E. coli 
among other bacteria (124). Caffeic acid and p-coumaric acid have also been 
reported to be active when tested against cancer cell lines. Da Silva et al. 
found that caffeic acid has a stronger effect than p-coumaric acid on HEp2 
cells, having an IC50 of 244.12 µg/mL and 561.86 µg/mL respectively (125). 
The two phenolic acids are also known to have antimutagenic activity and 
affect the viability of numerous tumor cell lines, such as A549, HepG2 and 
MCF7 among others, showing IC50 between 164.05 and 180.16 µg/mL or 
lower (124, 126). Cytotoxic activity of caffeic acid is also reported against PC3 
cells with an IC50 of 32 µg/mL (127). Other biological activities of some of the 
identified components of the plant H. glomerata are reported in table 5.20. 
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Table 5.20 Reported activity for the compounds identified from the hexane extract 
Compound Biological activity Source Reference 
Stigmasterol 
Chemopreventive effect in skin carcinoma; in vitro antioxidant activity; 
anti-osteoarthritic; antimutagenic activity; cytotoxic, antibacterial, 
antifungal, antimycobacterial 
Azadirachta indica, Clerodendrum 
inerme linn., Gleditsia sinensi, 
Talium paniculatum 
(128–132) 
Stigmasterol glycoside Antibacterial: Aspergillus niger Melochia umbellata (133) 
Stigmasteryl acetate 
Antibacterial: S. albus, S. aureus, S. uridans, E. coli, P. pyocyanea, 
Klebsiella 
A. tricolor, A. squamosal, A. alliceum (113) 
Stigmastan-4en-3-one Antimycobacterial; antiplasmodial Cenchrus setiserum, Erythrina stricta (134, 135) 
β-Sitosterol 
Antimutagenic activity; antioxidant and Anibacterial1; antiproliferative, 
induces apoptosis2; cytotoxic, antibacterial, antifungal, 
antimycobacterial 
Gleditsia sinensi, Vitex agnus, 
Talium paniculatum 
(131, 132, 
136, 137) 
β-Sitosteryl acetate 
Antibacterial: S. albus, S. aureus, S. uridans, E. coli, P. pyocyanea, 
Klebsiella 
A. tricolor, A. squamosal, A. alliceum (113) 
Campesterol 
Anti-inflamatory; antiangiogenic; cytotoxic, antibacterial, antifungal, 
antimycobacterial 
Lupezia racemose, Chrysantenum 
coronarium L., Talium paniculatum 
(132, 138, 
139)  
Phytol 
Anticancer3; antibacterial4; anticancer activity Gracilona edulis, Aster yumena (140–142) 
γ-Linoleic Antiproliferative; antimycobacterial; anibacterial: FabI, MR-S. aureus, 
H. pylori, mycobacteria 
Amischotolype hispida (143–145) 
Oleic acid  
Antimycobacterial: M. tuberculosis; anibacterial: FabI, MR-S. aureus, 
H. pylori, mycobacteria 
- (146, 147) 
Palmitic acid Antimycobacterial; promotion of melanoma cells growth Amischotolype hispida (144, 148) 
UFA, SAFA and linolenic acid Anibacterial: FabI, MR-S. aureus, H. pylori, mycobacteria - (149) 
1In Bacillus subtilis, S. aureus, S. epidermis, E. faecalis, E. coli; 2In colon, breast, prostate, liver, stomach cancer; 3In MCF-7, human colon carcinoma; 4In P. 
aeruginosa. 
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5.3.6 Reported biological activities of the major components identified 
by UPLC-QTOF-MS 
Biological activities of major components of H. glomerata were 
investigated in the literature. The biological activities of phytol, β-sitosterol, 
campesterol, stigmasterol and daucosterol were already discussed in 
paragraph 5.3.5. Instead no biological activity was found reported in the 
literature for the steroid tillandsinone. 
Oleanolic and ursolic acids are well known cytotoxic agents. It has been 
reported the mechanism of action of oleanolic acid, which is the induction of 
p53 dependent apoptosis throughout the ERK/JNK/AKT Pathway (172). 
Instead the ursolic acid, much like the daucosterol, mediates the Wnt/β-
catenin signaling, inducing apoptosis in PC3 cells (173). It is reported that the 
mixture of oleanolic and ursolic acid has moderate inhibitory activity against 
MCF7 cell line, with an IC50 of 23.97 µg/mL (174). Oleanolic acid alone was 
also found to have cytotoxic effects on HepG2, MCF7 and A549 cell lines with 
medium inhibitory concentrations of 36.87 ± 1.14 µg/mL, 26.19 ± 1.45 µg/mL 
and 19.50 ± 1.72 µg/mL respectively (175). In other reports the terpenoid acid 
was reported to have high toxicity on Hep3B and PC3 cells with IC50 lower 
than 3.65 µg/mL and of 2.97 µg/mL respectively after 48 hours of exposition 
(176). Mild effects were shown on HeLa with IC50 higher than 100 µg/mL (177). 
These triterpenoid acids have also antibacterial properties on S. mutans, S. 
sobrinus (MICs of 2 µg/mL), S. pneumoniae (MIC of 16 μg/mL), methicillin-
sensitive and methicillin-resistant S. aureus (MIC of 8 μg/mL and 64 μg/mL, 
resp.), Bacillus subtilis (MIC of 8 μg/mL), B. cereus and E. faecalis (MIC of 
6.25–8.00 μg/mL), E. faecium (MIC of 8 μg/mL), and P. aeruginosa (MIC of 
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256 μg/mL). It was found that oleanolic acid alters the synthesis of DnaK in E. 
coli, producing a heat-shock response in this species. Also, both oleanolic and 
ursolic acid inhibit peptidoglycan turnover in L. monocytogenes, affecting the 
cellular wall of bacteria (178). 
Biological activities of resveratrol include anticancer and 
chemopreventive. The pathways to exert its chemopreventive activity are 
various, such as the Fas receptor (CD95) signaling, apoptosis, NFκB, 
phosphoinositol 3-kinases/protein kinase B (PI3Ks/Akt), sirtuin 1 (SIRT1) and 
Wnt. It was found that miRNA is also a target of resveratrol blocking the 
process of translation (179). Resveratrol was tested for a minimum of 48h and 
maximum of 96h against HepG2, and Hep3B cells giving an IC50 ranges of 
32.48 ± 14.58 μg/mL and 34.57 ± 17.43 μg/mL; and 28.9 ± 17.07 μg/mL and 
51.14 ± 24.87 μg/mL respectively for the two cell lines (180). Against PC3 cells 
resveratrol is reported to be very active, with IC50 of 11.0 μg/mL (181), instead 
it produces a weaker inhibition over MCF7cells, with IC50 values of 213 μg/mL. 
The reported mechanism of action on MCF7 cells was associated with the 
modulation of phophorilated Akt and Caspase 9 (182). Resveratrol against 
HeLa cells had also a good antiproliferative activity with an IC50 of 67.8 ± 9.2 
μg/mL and a very good cytotoxic activity against A549 cells with an IC50 of 
5.82 µg/mL (183). The stilbene has potential antibacterial agent, having 
multiple interesting antibacterial properties, like the inhibition of the electron 
transport chain (ETC), cleavage of DNA molecules, inhibition of cell division 
by preventing the formation of the Z-ring, and the antibiofilm activity. 
Resveratrol was tested against different types of foodborne pathogens 
including S. aureus, B. cereus, B. subtilis, and L. monocytogenes, E. coli 
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O157:H7, Salmonella Typhimurium, Vibrio cholerae, Campylobacter jejuni, 
Campylobacter coli, Arcobacter butzleri, and Arcobacter cryaerophilus. The 
MICs range of resveratrol against the Gram-positive bacteria was between 
0.625 and 521 µg/mL, and for the Gram-negative bacteria between 16.5 and 
260 µg/mL (184). In another report, resveratrol was tested against six Gram-
positive bacteria including B. cereus (ATCC 11778), S. aureus (ATCC 25923), 
methicillin-sensible S. aureus (MSSA), methicillin-resistant S. aureus (MRSA), 
and E. faecalis (ATCC 29212); and seven Gram-negative bacteria: E. coli 
(ATCC 25922), E. coli (clinical), K. pneumoniae (ATCC 13883), K. 
pneumoniae (clinical), S. typhimurium (ATCC 13311), P. aeruginosa (ATCC 
27853), P. aeruginosa (clinical). The MICs range for the Gram-positive 
bacteria was 50-200 µg/mL with B. cereus being the most affected, instead all 
the Gram-negative bacteria resulted to have a MIC higher than 400 µg/mL 
(185). Antibacterial properties of resveratrol were also tested against three 
strains of Propionibacterium acnes giving IC50 of 73 µg/mL (186). It is clear 
that resveratrol is mainly active against Gram-positive bacteria. 
Among the biological activities of piceatannol there are anti-
inflammatory (NFκB), antimutagenic, and antiproliferative (cytotoxic, 
proapoptotic activity and hormesis) activities. The cytotoxic and proapoptotic 
activity were tested against prostate cancer cells (PC3, IC50: 25 μg/mL), liver 
cancer cells (HepG2; IC50 > 200 μg/mL) and cervix cancer cells (HeLa, IC50: 
50 μg/mL). It is reported that piceatannol has antitumor effect in animals and 
also antileishmanial, antiplasmodial, and antibacterial activities. The latter 
activity was tested against three strains P. acnes (IC50: 123 µg/mL) (186), 
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Salmonella infantis (IC92: 244.24 µg/mL), L. monocytogenes (IC84: 61.06 
µg/mL), Candida tropicalis (IC30: 61.06 µg/mL) (187). 
Spinacetin, luteolin and kaempferol are reported as a good antioxidant 
agents, with comparable activities (188). Spinacetin is also able to suppress 
mast cells activation and passive cutaneous anaphylaxis in a murine model, 
showing its anti-inflammatory and antiallergenic activity (189). This molecule 
is a promising hepatoprotective agent (190). It is reported that a glycosylated 
derivative of the flavonol (Spinacetin 3-O-gentiobioside) has cytotoxic effect 
against HepG2 cells reaching the 69% of inhibition with 3 mM treatment for 48 
hours (191). Luteolin and kaempferol and their derivatives exerted antiviral 
and antibacterial activity. The last activity was exhibited against MRSA, 
vancomycin-resistant enterococci (VRE) and Burkholderia cepacia, with MICs 
of 512 µg/mL or higher. More toxic results were obtained for luteolin against 
E. coli, K. pneumoniae and P. aeruginosa (ATCC) having MICs of 125 µg/mL 
for all strains (192). Luteolin has multiple biological effects, such as anti-
inflammation, anti-allergy and anticancer and these activities might be related 
to each other. The flavone was active against MCF7, HeLa, A549, Hep3B and 
HepG2 cell lines having, after 48 hours of treatment, IC50 of 9.41 µg/mL, 2.17 
µg/mL, 4.29 µg/mL, 4.31 µg/mL and 2.92 µg/mL, respectively (193–195). 
Luteolin was tested against PC3 cells for 24, 48 and 72 hours and the average 
IC50 obtained was of 9.0 µg/mL (196). The therapeutic cytotoxicity of the 
molecule is due to the inhibition of suppression of cell survival pathways, 
stimulation of apoptosis pathways, and also can block the angiogenesis 
process and the tumor growth in vivo (197, 198). Kaempferol was tested 
against different bacterial strains, including B. cereus, B. subtilis and S. aureus 
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having inhibition of bacteria growth (199). This flavonol has antineoplastic 
(anti-angiogenesis, antiproliferative, apoptosis) activity against HeLa and 
other cancerous cell lines with an IC50 of 42.1 ± 3.2 µg/mL (200). It was 
reported that it has antioxidant, anti-inflammatory and antitumor activity on 
HepG2 with IC50 of 30.92 ± 0.05 µg/mL (201). Kaemferol was active against 
MCF7, A549, Hep3B and PC-3 cell lines having IC50 of 90.82 ± 4.2 µg/mL, 
35.80 ± 0.4 µg/mL, 40 µg/mL and 41.98 µg/mL, respectively (202–204).  
Biological activity of ananaflavoside B is not deeply studied due to the 
scarce publications found, but in one report the flavone glycoside and its 
isomer ananaflavoside C are reported to be produced by plants used in the 
Nigerian ethnomedicine. In particular they might be involved in the 
hypoglycemic activity of their extracts and thus in the management of diabetes 
using traditional methods (205). 
Delphinidin and cyanidin, like most of the anthocyanidins and 
anthocyanins, are known to be potent antioxidant and antiradical agents as 
well as for their interaction with DNA (206). 3-O-Sabubioside derivatives have 
been found to inhibit the Angiotensin Converting Enzyme (ACE), as part of the 
aqueous extract of Hibiscus sabdariffa calyces (207). Delphinidin was tested 
for its cytotoxic activitiy against MCF7 (208), A549 (209), PC3 (210) and HeLa 
(211) cell lines showing IC50 of 120 µg/mL, >80 µg/mL, 90 µg/mL and 37.9 ± 
15.3 µg/mL, respectively. Cyanidin had a good cytotoxic activity against MCF7 
cells with an IC50 of 13.55 µg/mL after 48 hours exposition (208). Some of its 
glycosylated derivatives are also reported in the literature having a number of 
biological activities, such has cytotoxic or antiproliferative effect on different 
cell lines (212–214). Cyanidin-3-glycoside and various delphinidin derivatives 
 212 
were also isolated from antibacterial extracts of pomegranate fruit (215) and 
Chilean blackberry (216). 
No inhibitory concentration was found for isoscoparin against cell lines 
under study, but it was reported that some its glycosylated derivatives are 
active against bacterial neuramidase (217). The flavone-C-glycoside was 
found to be part of the components of the cytotoxic plant Gentiana farreri Balf. 
(218). Isochlorogenic acid B was reported to have an IC50 of 160.10 µg/mL 
against MCF7 cells (219), however no other study of cytotoxicity for this 
compound was found in the literature. Ethyl acetate extract of chicory roots 
was found to be compose by a mixture of chlorogenic and isochlorogenic acid 
and have antibacterial activity against 21 bacterial strains, being more active 
than the positive control (220). 
The IC50 found in the literature for the major compounds identified from 
the UPLC-QTOF-MS analysis of H. glomerata’s leaf extracts are reported in 
table 5.21. 
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Table 5.21 Reported IC50 (µg/mL) of the major components against the cell lines in analysis. 
Compound Class Extract* Hep3B HepG2 A549 HeLa PC3 MCF7 Ref 
Phytol Terpene Hex - - 7.30 1.99 9.98 1.13 (110) 
β-Sitosterol Steroid Hex - - 78 170.60 30.85 140 (115–117) 
Daucosterol Steroid C/M; AqD; AqF >20 251 17.46 - 31.9 - (119–121, 221) 
Stigmasterol Steroid Hex - - 4.28 5.04 - - (122) 
Campesterol Steroid Hex - - - >100 - - (222) 
Tillandsinone Steroid Hex - - - - - - - 
Oleanolic acid Steroid C/M; AqD; AqF <3.65 36.87 19.50 >100 2.97 26.19 (175–177, 223) 
Resveratrol Stilbene C/M; AqF 34.57 32.48 5.82 15.48 0.23 14.84 (180–183) 
Piceatannol Stilbene C/M - >48.85 - 12.21 6.11 - (186) 
Luteolin Flavonoid C/M; AqD; AqF 4.31 2.92 4.29 2.17 9.0 9.41 (193–196) 
Spinacetin Flavonoid C/M; AqD; AqF - - - - - - - 
Kaempferol Flavonoid C/M; AqD; AqF 40 30.92 35.80 42.1 41.98 90.82 (200–204) 
Ananaflavoside B Flavonoid C/M; AqD; AqF - - - - - - - 
Delphinidine Flavonoid AqD; AqF - - >24.26 11.49 27.29 36.39 (208–211) 
Cyanidin Flavonoid C/M; AqD; AqF - - - - - 13.55 (208) 
Isoscoparin Flavonoid C/M; AqD; AqF - - - - - - - 
Isochlorogenic acid B Polyphenol C/M; AqD; AqF -  - - - 160.10 (219) 
*Hex: hexane extract; C/M: CHCl3/MeOH (1:1) extract; AqD: dry aqueous extract; AqF: fresh aqueous extract. 
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5.3.7 Biodirected study of the CHCl3/MeOH extract pooled fractions 
5.3.7.1 Antibacterial screening of the CHCl3/MeOH extract pooled 
fractions 
Due to activity displayed by the CHCl3/MeOH extract against the 
sensible strains S. aureus and E. faecium, it was decided to perform a 
screening of antibacterial activity of macro-fractions of the extract. Results of 
the screening are reported in table 5.22, where is shown that fraction 1, 3 and 
8 the only active ones.  
 
Table 5.22 Screening of the CHCl3/MeOH extract fractions 
Fractions 
MIC (µg/mL) 
S. aureus 
ATCC 25923 
E. faecium 
ATCC 29212 
1 200 200 
2 >200 >200 
3 100 50 
4 >200 >200 
5 >200 >200 
6 >200 >200 
7 >200 >200 
8 100 100 
 
Fraction 1 resulted active against both sensible strains S. aureus and 
E. faecium at the maximum tested concentration of 200 µg/mL. Its activity is 
probably due to its high composition of hydrocarbons and lipids, since this is 
the less polar extract fraction and probably retains most of the composition of 
hexane extract. Fraction 3 was also active against both strains with MIC values 
of 100 and 50 µg/mL for S. aureus and E. faecium, respectively. The 
composition of this fraction is shown in the next paragraph and the 
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antibacterial results shows a higher sensitivity of E. faecium of fraction 
components. Fraction 8 also had activity against both strains with MICs of 100 
µg/mL, this fraction is the most polar and probably contains glycosylated 
compounds such as saponins and other polyphenols which have already been 
reported to have antimicrobial activity. Its composition could resemble that 
aqueous extracts in which various active compounds have been identified 
from the metabolomic study. 
 
5.3.7.2 Composition of pooled fraction 1 
Twelve compounds were identified in GC-MS analysis of fraction 1, 
almost all of them are long chain saturated alkanes with the exception of two 
terpenoids. The identified volatile compounds are reported in Table 5.23. 
The most abundant compound is nonacosane (44 %) which was also 
found very abundant in the GC-MS analysis of the hexane extract. Other 
abundant compounds are cerotic acid (17 %), tetratriacontane (13 %) and 
octacosane (11 %). The alkanes are common in plants and are part of their 
waxes and have a protective function over the leaves tissues (104, 235). 
These compounds are not reported as bioactive, but they could be damaging 
the cellular membrane and biofilms of the bacteria causing a lower 
proliferation. Because of this effect, in the whole extract these lipophilic 
molecules could allow a better penetration of other phytochemicals with 
antibacterial activity into the bacteria cytoplasm. The sterol or diterpene and 
the carotenoid could also have some antibacterial activity, but they are in very 
low concentration (<1 %). This could explain the mild activity of this fraction 
against both S. aureus and E. faecium. 
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These results are not exhaustive and still leave some of the 
components as unclear or unknown. 
 
Table 5.23 GC-MS analysis of pooled fraction 1 of H. glomerata leaves’ CHCl3/MeOH 
extract 
tR (min) Compound % area 
31.074 Heneicosane 1.10 
31.835 Saturated long chain alkane I 1.30 
32.075 Sterol or diterpene 0.28 
32.184 Saturated long chain alkane II 0.69 
32.510 Pentacosane 2.49 
32.825 Tetratetracontane 2.17 
33.134 Octacosane 10.60 
33.426 Cerotic acid 17.06 
33.574 Carotenoid 0.33 
33.735 Nonacosane 44.29 
34.009 Saturated long chain alkane III 6.25 
34.295 Tetratriacontane 13.44 
All the compounds were identified using the NIST 08 mass spectral database. 
 
That’s why it was decided to methylate the fraction and repeat the 
analysis to better volatilize its constituents in GC-MS analysis. Results showed 
eight compounds identified from this second analysis (table 5.24). The main 
components of fraction were methyl undecanoate (37 %) and a linoleic acid 
ester (36 %). The other components were mainly alkanes, the most abundant 
being nonacosane (15 %) being a total of 21 % of the fraction. A fatty alcohol: 
ceryl alcohol (2 %) was identified. As already mention lipids such as alkanes 
and FAs could take part in the activity of the fraction against the sensible 
bacteria through the debilitation of the plasmatic membrane. Linoleic acid like 
other UFAs and their derivatives are reported to have antibacterial activity 
(236). 
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Table 5.24 GC-MS analysis of the methylated pooled fraction 1 of H. glomerata leaves’ 
CHCl3/MeOH extract 
tR (min) Compound % area 
35.265 Methyl undecanoate  36.717 
88.287 Bis(2-hethylhexyl) phthalate 2.605 
93.962 Heptacosane 2.065 
97.312 Ceryl alcohol* 1.986 
97.450 Octacosane 1.072 
100.964 Nonacosane 14.946 
107.283 Hentriacontane 4.783 
132.120 Linoleic acid ester* 35.827 
The majority of the compounds were identified using the NIST 08 mass spectral 
database. *Compounds identified manually or tentatively (Lipid Maps). 
 
To complete analysis of fraction 1 it was also analyzed by HPLC-QTOF-
MS (Table 5.25). A total of 105 compounds were identified from the analysis: 
56 FAs and derivatives (50 %), 14 steroids (20 %), seven polyphenols (15 %), 
15 terpenoids (9 %), five N-compounds (2 %), and two alkenes (1 %). Six 
compounds (3 %) were not identified and are still unknown.  
FAs and derivatives were the most abundant class of metabolites which 
is in agreement with the low polarity of the fraction and extract. They are thirty-
one FAs (29 %), seven esters (7 %), eight oxidation products (5 %), one 
aldehyde (4%), four ketones (3 %), three alcohols (1 %), and two diacids (1 
%). From identified FAs twenty-three were UFAs (28 %) while eight were 
SAFAs (14 %), these last ones were mostly VLCFAs. As mentioned before 
FAs and especially UFAs such as linoleic acid are reported to have 
antibacterial activity against Gram-positive bacteria (149), which could partially 
justify the activity of the fraction against the two sensitive bacteria.  
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Table 5.25 HPLC-QTOF-MS analysis of pooled fraction 1 of the CHCl3/MeOH extract of H. glomerata 
tR 
(min) 
Compound 
Molecular 
formula 
m/z 
Experimental 
mass 
Calculated 
mass 
Error 
(ppm) 
Area 
% 
Ref 
0.290 Dodecadienyl acetate C14H24O2 225.1379 - 224.1776 - 1.52 a 
0.301 Betaine aldehyde C5H12NO 102.0915 102.0921 102.0919 1.76 0.66 b 
0.301 Pentanamide C5H11NO 102.0915 101.0842 101.0841 1.79 0.66 b 
0.301 2-Methyl-2-butenal C5H8O 102.0916 84.0575 - - 3.69 c 
0.378 Unknown - 107.0129 - - - 0.83 - 
0.389 2,3,4-Trimethoxybenzoic acid C10H12O5 213.0782 - 212.0685 - 0.33 c 
0.389 Benzyl nicotinate C13H11NO2 213.0782 213.0789 213.0790 -0.56 0.40 b 
0.411 16-Hydroxy hexadecanoic acid C16H32O3 272.2324 272.2328 272.2351 -8.50 0.77 b 
0.411 16-Oxo-palmitate C16H30O3 270.2164 270.2168 270.2195 -9.84 0.67 b 
0.422 N1,N8-Diacetylspermidine C11H23N3O2 252.1674 229.1770 229.1790 -9.00 0.33 b 
0.422 Unknown - 233.1023 - - - 0.35 - 
0.422 12-(2,3-Dihydroxycyclopentyl)-2-dodecanone C17H32O3 284.2334 284.2338 284.2351 -4.67 0.67 b 
0.433 Sterebin D C18H30O3 294.2184 294.2189 294.2195 -1.85 0.36 b 
0.433 
6-Oxabicyclo[3.1.0]hexane-2-undecanoic acid 
methyl ester 
C17H30O3 282.2174 282.2178 282.2195 -5.98 0.48 b 
0.433 Miyristic acid (C14:0) C14H22N2O2 268.2004 - 250.1908 - 0.52 c 
0.433 2-Methoxy-hexadecanoic acid C17H34O3 286.2494 286.2498 286.2508 -3.64 0.87 b 
0.444 Phytyl acetate C22H42O2 339.1528 - 338.3185 - 0.45 c 
0.444 Dimorphecolic acid C18H32O3 296.2343 296.2346 296.2351 -1.77 0.36 b 
0.444 Catelaidic acid (C22:1, ∆11) C16H22N2O6 339.1528 - 338.3185 - 0.45 c 
0.444 Oleic acid (C18:1, ∆9) C18H34O2 283.2200 - 282.2559 - 0.51 a 
0.444 18-Hydroxyoleate C18H33O3 298.2503 - 297.2435 - 0.73 a 
0.444 Linoleic acid (C18:2, ∆9,12) C18H32O2 281.1917 280.2402 262.1681 -2.57 0.48 a 
0.444 Oxo-oleate C18H31O3 296.2343 - 295.2279 - 0.39 c 
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Table 5.25 HPLC-QTOF-MS analysis of pooled fraction 1 of the CHCl3/MeOH extract of H. glomerata (Continued) 
tR 
(min) 
Compound 
Molecular 
formula 
m/z 
Experimental 
mass 
Calculated 
mass 
Error 
(ppm) 
Area 
% 
Ref 
0.444 Erucic acid (C22:1, ∆13) C16 H19 N O6 339.1528 - 338.3185 - 0.45 c 
0.444 12R-hydroxy-9Z-octadecenoic acid C18H34O3 298.2503 298.2508 298.2508 -0.11 0.73 b 
0.477 Hexadecene C16H32 288.2668 - 224.2504 - 0.40 b 
0.488 (R)-10-Hydroxystearic acid C18H36O3 300.2661 300.2671 300.2664 2.12 0.64 b 
0.565 2-Oxophytanic acid C20H38O3 326.2833 326.2838 326.2821 5.09 0.30 b 
0.576 Methylsuberic acid C9H16O4 189.1100 - 188.1050 - 0.70 a 
0.598 Unknown - 233.1020 - - - 0.38 - 
0.598 Unknown - 233.1018 - - - 0.48 - 
0.609 Hexadecenoic acid (C16:1, ∆2) C16H30O2 255.1313 - 254.2246 - 0.19 c 
0.653 Geranate derivative I - 167.9716 - - - 0.53 c 
0.653 Geranate derivative II - 167.9716 - - - 0.56 c 
0.675 Gadoleic acid (C20:1, ∆9) C20H38O2 328.2990 - 310.2872 - 0.36 c 
0.731 Undecanedioic acid C11H20O4 217.1467 - 216.1362 - 0.61 c 
0.819 Heptadecenoic acid (C17:1, ∆10) C17H32O2 345.1592 - 268.2402 - 0.58 c 
0.819 Heptadecanedione C17H32O2 345.1592 - 268.2402 - 0.71 c 
0.819 Heptadecenoic acid isomer C17H32O3 345.1592 - 268.2402 - 0.64 c 
0.830 Margaroleic acid (C17:1 ∆9) C17H32O2 269.1885 - 268.2402 - 0.60 a 
0.885 Anethole C10H12O 148.9966 - 148.0888 - 4.47 d 
0.973 Pentacosanoic acid (C25:0) C25H50O2 383.2803 - 382.3811 - 0.17 c 
1.105 Methyl cinnamate C10H10O2 163.0159 162.0088 162.0681 - 4.24 c 
1.105 Chavicol C9H10O 135.0130 - 134.0732 - 0.95 c 
1.105 3-(4-Methoxyphenyl)-2-propenal C10H10O2 163.0159 - 162.0681 - 4.24 c 
1.150 Unknown - 326.1027 - - - 0.61 - 
1.150 Hydroxycinnamate derivative C15H18O8 326.1027 326.1026 326.1002 7.58 0.61 b 
 220 
Table 5.25 HPLC-QTOF-MS analysis of pooled fraction 1 of the CHCl3/MeOH extract of H. glomerata (Continued) 
tR 
(min) 
Compound 
Molecular 
formula 
m/z 
Experimental 
mass 
Calculated 
mass 
Error 
(ppm) 
Area 
% 
Ref 
1.150 Unknown - 326.1027 - - - 0.61 - 
1.172 Lignoceryl alcohol C24H50O 355.0748 - 354.3862 - 0.55 c 
1.172 Ucriol C20H32O3 321.1354 - 320.2351 - 0.03 c 
1.172 Gallic acid derivative C13H16O10 350.1055 332.0751 332.0743 2.23 trace b 
1.172 Kaurene isomer C20H28O4 333.0953 - 332.1988 - 0.55 c 
1.194 Tangeraxanthin C34H44O2 485.3489 - 484.3341 - 0.26 c 
1.502 Farnesal C15H24O 468.3912 - 220.1827 - 0.57 c 
1.569 Nonacosene C29H58 407.3388 - 406.4539 - 0.65 a 
1.646 Tetracosatrienoic acid (C24:3, ∆15,18,21) C24H42O2 363.3119 - 362.3185 - 1.63 a 
1.646 Tetracosatrienoic acid isomer C24H42O3 363.3119 - 362.3185 - 1.63 a 
1.646 kaurenoic acid derivative C20H30O2 385.2942 - 302.2246 - 0.51 c 
1.899 24-Methylcycloart-23-en-3β-yl acetate C33H54O2 482.4072 482.4076 482.4124 -9.93 0.64 b 
2.065 Montanic acid (C28:0) C28H56O2 425.2894 - 424.4280 - 0.31 c 
2.087 Nonacosanol C29H60O 425.2894 - 424.4644 - 0.31 c 
2.087 Citronellic acid C10H18O2 171.1165 - 170.1307 - 0.43 a 
2.098 5β-Cholestane-3α,7α,12α,26-tetrol C27H48O4 459.3421 436.3585 436.3553 7.42 trace b 
2.175 Eicosanediol C20H42O2 378.3310 - 314.3185 - 0.52 b 
2.175 Cholest-5-ene C27H46 388.3947 370.3609 370.3600 2.53 0.01 b 
2.285 Docosatetraenoic acid (C22:4, ∆4,7,10,13) C22H36O2 333.2999 - 332.2715 - 1.26 a 
2.285 Methyl acetyl ricinoleate C21H38O4 355.2828 354.2755 354.2770 -4.31 0.57 b 
2.285 Hexadecanone derivative C22H36O2 333.2999 - 332.2715 - 1.26 c 
3.013 Triacontapentaenoic acid (C30:5) C30H50O2 443.2586 - 442.3811 - 0.08 a 
3.697 Ethyl oleate C20H38O2 310.3091 - 310.2872 - 2.58 c 
4.083 (9E)-Valenciaxanthin C27H40O3 413.3068 412.2996 412.2977 4.39 0.68 b 
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Table 5.25 HPLC-QTOF-MS analysis of pooled fraction 1 of the CHCl3/MeOH extract of H. glomerata (Continued) 
tR 
(min) 
Compound 
Molecular 
formula 
m/z 
Experimental 
mass 
Calculated 
mass 
Error 
(ppm) 
Area 
% 
Ref 
4.259 Boviquinone 4 C26H36O4 413.2688 412.2615 412.2614 0.25 1.27 b 
4.336 Nutriacholic acid C24H38O4 413.2689 390.2794 390.2770 6.21 1.98 b 
4.336 Caleic acid (C18:3, ∆3,9,12) C18H30O2 279.1553 - 278.2246 - 1.84 a 
4.336 Octadecatrienoic acid isomer I C18H30O2 279.1553 - 278.2246 - 1.84 a 
4.336 Octadecatrienoic acid isomer II C18H30O3 279.1553 - 278.2246 - 1.84 a 
4.336 Decatrienoic acid (C10:3, ∆2,4,6) C10H14O2 167.0120 - 166.0994 - 2.76 a 
4.336 Octadecatrienoic acid isomer III C18H30O3 279.1553 - 278.2246 - 1.84 a 
4.347 7α,12β-Dihydroxy-5β-cholan-24-oic Acid C24H40O4 392.2901 392.2904 392.2927 -5.86 1.40 b 
4.358 But-3-en-2-one C4H6O 71.0498 - 70.0419 - 0.78 c 
4.369 Linolenyl myristate C32H58O2 475.2390 - 474.4437 - 0.37 a 
4.369 Myristyl linolenate C32H58O3 475.2390 - 474.4437 - 0.37 a 
4.446 Oleic acid derivative C24H44O6 429.2427 - 428.3138 - 0.80 a 
4.446 Stigmasterol derivative I C29H48O2 429.2427 - 428.3654 - 0.73 a 
4.446 Stigmasterol derivative II C29H48O3 429.2427 - 428.2311 - 0.69 a 
4.579 7α,12β-Dihydroxy-5β-cholan-24-oic Acid C24H40O4 393.2993 392.2921 392.2927 -1.55 0.33 b 
4.590 24-methyl-5Z,9Z-pentacosadienoic acid C26H48O2 393.2992 - 392.3654 - 0.31 a 
5.064 Phytal C20H38O 312.3250 294.2912 294.2923 -3.66 2.13 b 
5.715 Pentadecylic acid (C15:0) C15H30O2 243.1874 - 242.2246 - 0.98 a 
5.715 Isopentadecylic acid (C15:0, iso) C15H30O3 243.1874 - 242.2246 - 0.98 a 
5.748 Carboceric acid (C27:0) C27H54O2 411.3495 - 410.4124 - 2.18 a 
5.748 25-Azacholesterol C26H45NO 388.3574 387.3495 387.3501 -1.51 0.01 b 
5.957 Hexacosatrienoic acid (C26:3) C26H46O2 390.3739 - 390.3498 - 0.01 a 
5.957 Hexacosatrienoic acid derivative C26H52O3 412.3530 - 412.3916 - 2.16 a 
8.019 9,9-Dimethoxy-nonanoic acid C11H22O4 219.1626 - 218.1518 - 0.37 b 
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Table 5.25 HPLC-QTOF-MS analysis of pooled fraction 1 of the CHCl3/MeOH extract of H. glomerata (Continued) 
tR 
(min) 
Compound 
Molecular 
formula 
m/z 
Experimental 
mass 
Calculated 
mass 
Error 
(ppm) 
Area 
% 
Ref 
11.691 4α-Methylfecosterol C29H48O 412.3674 412.3682 412.3705 -5.70 0.39 b 
11.702 (3β,22E,24R)-23-Methylergosta-5,7,22-trien-3-ol C29H46O 411.3642 410.3569 410.3549 4.89 1.33 b 
13.477 Campesterol derivative C28H44O2 412.3527 - 412.3341 - 4.96 c 
13.477 (24R)-Ergost-4-ene-3,6-dione C28H44O2 435.3249 412.3343 412.3341 0.52 trace b 
13.477 Ergostanol derivative C29H46O 411.3492 - 410.3549 - 6.19 c 
13.477 Glycerol triundecanoate C36H68O6 619.4907 596.5022 596.5016 1.03 0.62 b 
13.488 
(3S,3'S,5R,5'R,6R)-3,6-Epoxy-5,6-dihydro-3',5,8'-
trihydroxy-β,κ-caroten-6'-one 
C40H56O5 616.4080 616.4152 616.4128 3.96 trace b 
13.488 Phthioceranic acid (C37:0) C43H86O2 635.4649 - 634.6628 - 1.15 a 
13.488 Linoleic acid derivative C20H33O2 652.5182 - - - trace c 
13.488 Episteryl palmitoleate C44H74O2 635.4649 - 634.5689 - 1.15 a 
aLipidmaps; bMETLIN; cFooDB; dPhytoHub. 
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Some FAs have been reported to have antibacterial activities against 
different strains of bacteria and mycobacteria. The mechanism of action 
involved in their bacteria toxicity has been shown to involve the inhibition of 
the bacterial enzyme enoyl-acyl carrier protein reductase (FabI) (236). 
Identified steroids were derivative of cycloartenol, cholestanol, 
stigmasterol, campesterol, fecosterol, episterol and ergosterol. These sterols 
are part of the leaf cuticle, and/or derivatives of the metabolism of more 
abundant steroids, like cholestanol which is a derivative of the metabolism of 
campesterol (237). Some of them could also be a sign of infection, such as 
fecosterol and episterol (238). Some of them, like cycloartenol, stigmasterol, 
campesterol and ergosterol derivatives have already been reported as 
bioactive against bacteria (113, 132, 138, 139, 239, 240). Among the 
polyphenols five were phenyl propene derivatives and two were benzoic acid 
derivatives. From the first category of phytocompounds anethole, methyl 
cinnamate and 3-(4-Methoxyphenyl)-2-propenal are the most abundant. They 
are mainly found in plants’ essential oils, and have demonstrated antibacterial 
and antimicrobial activity (241). The terpenoids were also abundant but only 
few reached a concentration higher than 1 % of the fraction 1. In general, 
various kauranes, xanthins and phytol derivatives have been identified, the 
last one being the most abundant and active. The identified terpenoids such 
as monoterpenes, sesquiterpenes, diterpenes, and triterpenes are employed 
by plants for a variety of functions. They regulate plant growth and 
development, and are used for specialized chemical interactions and 
protection with the abiotic and biotic environment (242). The most abundant of 
identified terpenoids is phytal (2 %) which is been reported as a drug 
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resistance reversal agent derivative of phytol, showing reduction of resistance 
on E. coli strains (243). Other identified compounds were the nitrogenated 
compounds from which the most interesting is a betalain aldehyde already 
reported in the family of Bromeliads (41). Only two alkenes: hexadecene and 
nonacosene were identified despite the non-polar nature of the fraction. This 
can be explained by the sample treatment needed for the HPLC technique, 
which does not allow the solubilization and therefore the analyzation of non-
polar compounds. Composition of this fraction partially explains its activity 
against the two Gram-positive sensitive bacteria. 
 
5.3.7.3 Composition of pooled fraction 3  
Pooled fraction 3 was analyzed by HPLC-QTOF-MS in both positive 
and negative modes, identifying 28 components reported in table 5.26. The 
major identified components were phenolic acids (PAs) derivatives (57 %), 
including: hydroxycinnamic acids (HCAs) derivatives (46 %), coumarins (10 
%) and benzoic acid derivatives (1 %). Other components were flavonoids (31 
%) a pigment (6 %) and two unknown compounds (6 %). The antibacterial 
activity of this fraction is partially justified from its composition. Some of the 
compounds are reported as bioactive or are similar in structure to other 
antibacterial compounds. Among the HCAs derivatives are the two 
phenylpropyl coumarates: 3-(4-hydroxyphenyl) propyl coumarate and 3-(4-
hydroxyphenyl-5-methoxy) propyl coumarate.  
Their structure is very similar to the caffeic acid phenethyl ester 
(CAPE), a propolis component which, along with its derivatives, is already 
reported to have antibacterial activity.  
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Table 5.26 HPLC-QTOF-MS analysis of pooled fraction 3 of the CHCl3/MeOH extract of H. glomerata 
tR 
(min) 
Compound 
Calculated 
formula 
Negative 
(m/z) 
Positive 
(m/z) 
Fragments Error (ppm) 
Area 
(%) 
Ref. 
1.001 Protocatechuic acid C7H6O4 153.0189 - [M-H]-: 109 -2.61 0.69 (244) 
1.732 Salicylic acid C7H6O3 137.0239 - [M-H]-: 93 -3.65 0.60 a, b 
3.129 Caffeic acid C9H8O4 179.0342 - [M-H]-: 135 -4.47 0.18 a 
4.416 2-O-p-coumaroylglycerol C12H14O5 237.0768 239.0917 [M-H]-: 119, 145, 163; [M+H]+: 147, 119 5.48; 1.25 3.92 (244) 
4.737 p-Coumaric acid C9H8O3 163.04 - [M-H]-: 119 -0.61 3.79 (245) 
4.990 1-O-p-coumaroylglycerol C12H14O5 237.0767 - [M-H]-: 119, 145, 163 -0.42 10.52 c 
6.000 Prunin C21H22O10 433.1141 - ND 0.23 0.02 m 
6.741 Dicaffeoyl glycerol C21H20O9 415.1044 417.1176 
[M-H]-: 253, 161, 179, 135, 237  
[M+H]+: 163, 145, 164, 237 
-0.96; 2.17 11.11 (43) 
7.063 Caffeoyl coumaroyl glycerol C21H20O8 399.1102 401.1221 
[M-H]-: 163, 253, 119, 145, 135, 235, 
179; [M+H]+: 147, 163, 145, 119 
-2.49; 4.26 2.64 m 
7.158 
Feruloyl coumaroyl glycerol 
isomer 
C22H20O8 - 413.1222 [M+H]+: 163, 177, 145, 320 -2.18 0.28 (43) 
7.363 
Feruloyl caffeoyl glycerol 
isomer 
C22H22O9 429.1199 431.1322 
[M-H]-: 134, 193, 253, 235  
[M+H]+: 177, 145, 163 
-3.48; 1.86 1.78 m 
7.378 Naringenin C15H12O5 271.0615 - [M-H]-: 151, 119 1.11 0.36 a, c 
7.514 Naringenin derivative C24H20O8  - 437.1215 [M+H]+: 437, 177, 251, 147, 243, 221 -3.66 1.81 e 
7.572 Synapoyl derivative C18H18O8 - 363.1077 [M+H]+: 183, 207, 175, 168 0.83 2.77 e 
7.608 Homoeriodictyol C16H14O6 301.0715 - [M-H]-: 151 -1.33 0.43 b 
7.767 Unknown C26H46O6 - 455.3339 [M+H]+: 239 -6.15 3.01 - 
7.772 Diosmetin or chrysoeriol C16H12O6 299.0568 - [M-H]-: 284 2.34 0.83 b 
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Table 5.26 HPLC-QTOF-MS analysis of pooled fraction 3 of the CHCl3/MeOH extract of H. glomerata (Continued) 
tR 
(min) 
Compound 
Calculated 
formula 
Negative 
(m/z) 
Positive 
(m/z) 
Fragments Error (ppm) 
Area 
(%) 
Ref. 
7.837 Chlorophyll derivative NA - 843.2336 [M+H]+: 843, 555, 844, 597, 556 ND 6.29 e 
8.088 Unknown C21H18O5 - - [M+H]+: 349, 351, 207, 193 - 3.46 - 
8.014 Coumarin isomer C9H6O2 - 147.0438 [M+H]+: 91, 119, 147, 65 -2.04 2.57 m 
8.168 Coumarin derivative C20H22O6 - 359.1488 [M+H]+: 147, 119 -0.28 7.18 m 
8.215 
3-(4-Hydroxyphenyl) propyl 
coumarate 
C18H18O4 297.1151 - 
[M-H]-: 119, 145, 163 [M+H]+: 107, 147, 
135 
6.39; 1.34 6.08 m 
8.297 
3-(4-Hydroxyphenyl-3-
methoxy) propyl coumarate 
C19H20O5 327.1255 - 
[M-H]-: 163, 119, 145, 177, 133, 312, 
299 
5.20 2.46 m 
8.370 
Kaempferol or cyanidin 
derivative 
C18H16O7 - 345.097 [M+H]+: 345, 312, 329, 330, 287 0.29 2.30 
e 
8.508 Isorhamnetin derivative C19H18O8 - 375.1076 [M+H]+: 375, 342, 245, 317, 360 0.53 13.48 e 
9.156 Demethylnobiletin C20H20O8 - 389.1227 [M+H]+: 389, 356, 331, 373, 359, 374 -1.03 4.90 d 
9.342 Tetramethylquercetin C19H18O7 - 359.1127 [M+H]+: 359, 326, 343, 360, 344, 301 0.56 1.54 m 
9.992 
Keampferol or quercetin 
derivative 
C24H38O4 - 391.2843 [M+H]+: 149, 57, 71 0.00 4.97 e 
aMETLIN; bMassBank; cIn-house database; dFooDB; eReSpect; mManual 
 227 
The bacteril strains reported to be sensitive to CAPE are S. aureus, 
Bacillus subtilis, and P. aeruginosa (MICs: 62.5-125 µg/mL, 125-250 µg/mL, 
and 125-250 µg/mL, respectively) (246). The flavonoid quercetin and its 
derivatives are also reported to have antibacterial activity. For example its 
methylated derivative showed inhibition against MRSA (247). Inhibition of bio-
film formation and growth of E.coli was also observed after incubation with 
extracts rich in quercetin derivatives or with the extracted pure molecules 
(248).  
Some derivatives of kaempferol are also reported to have activity 
against both Gram-positive and Gram-negative bacteria. Reporting MICs in 
the range of 32-256 µg/mL for S. aureus and P. aeruginosa (249). Other 
flavonoids like cyanidin, isorhamnetin and diosmetin could also take part in the 
whole antibacterial activity (250). 
 
5.3.7.4 Composition of pooled fraction 8  
Data obtained from the analysis of pooled fraction 8 are showed in table 
5.27. The dentified components were 16 including: eight HCAs (71 %), three 
flavonoids (7 %), three sugar derivatives (12 %) and two benzoic acid 
derivatives (10 %). The majority of the compounds were shared with fraction 
3 which in part explains the antibacterial activity of this fraction. The 
components responsible for this fraction activity are probably the glycerol 
derivatives of caffeic acid, which represent the most abundant metabolites. 
Glycerol derivatives of caffeic acid comprise caffeoyl glycerol, 1-O-p-
coumaroyl glycerol, 2-O-p-coumaroyl glycerol, dicaffeoyl glycerol, caffeoyl 
coumaroyl glycerol and feruloyl caffeoyl glycerol. 
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Table 5.27 HPLC-QTOF-MS analysis of pooled fraction 8 of H. glomerata CHCl3/MeOH extract 
tR 
(min) 
Compound 
Calculated 
formula 
Negative 
(m/z) 
Fragments 
Error 
(ppm) 
Area 
(%) 
Ref. 
0.516 Sucrose C12H22O11 341.1081 179, 89, 119, 101, 161 -2.35 8.83 (251) 
0.517 Quinic acid C7H12O6 191.0555 191, 85 -3.14 0.81 a 
0.517 Trihydroxybutanoic acid C4H8O5 135.0293 75, 71, 115, 59, 135, 57, 45 -4.44 0.50 b 
0.519 Tetrahydroxypentanoic acid C5H10O6 165.0395 75, 59 -6.06 1.05 b 
0.977 Protocatechuic acid C7H6O4 153.0185 109 -5.23 5.12 (244), c 
3.839 Caffeoyl glycerol C12H14O6 253.0705 161, 135, 253, 179 -5.14 14.22 (43) 
4.309 2-O-p-coumaroyl glycerol C12H14O5 237.0765 145, 119, 163 -1.27 0.96 (244) 
4.768 p-Coumaric acid C9H8O3 163.0398 119 -1.84 10.23 a 
4.883 1-O-p-coumaroyl glycerol C12H14O5 237.0758 145, 119, 163 -4.22 6.24 a 
5.802 Prunin C21H22O10 433.1127 161, 135, 253 -3.00 0.25 a, d  
5.917 Quercetin-3-O-rutinoside C27H30O16 609.1434 300, 609 -4.43 0.23 a, d  
6.064 Ferulic acid C10H10O4 193.0496 161, 134, 135 -5.18 1.41 a 
6.836 Dicaffeoyl glycerol C21H20O9 415.1016 253, 161, 179, 135, 237 -4.58 37.82 (43) 
7.065 Kaempferol C15H10O6 285.0395 NA -3.51 0.03 a 
7.295 Caffeoyl coumaroyl glycerol isomer C21H20O8 399.1072 163, 253, 119, 145, 135, 235, 179 -3.26 9.64 m 
7.410 Feruloyl caffeoyl glycerol C22H22O9 429.1178 134, 193, 253, 235 -3.03 2.66 m 
aIn-house database; bFooDB; cMETLIN; dMassBank; mManual
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p-Coumaric acid and protocatechuic acid are reported in good 
concentrations, and they might also take part in the antibacterial activity of this 
fraction. The identified flavonoids: quercetin and kaempferol, are reported to 
have antibacterial or antimicrobial effects. On the other hand, the presence of 
sugar derivatives might be affecting the growth of the bacteria enhancing their 
proliferation and therefore lowering the whole antibacterial effect. 
 
5.3.7.5 Cytotoxicity screening of the CHCl3/MeOH extract pooled 
fractions 
Since the CHCl3/MeOH extract resulted to have a good activity against 
PC3 and MCF7 cell lines, and because of its wider composition it was decided 
to test its fractions. They were screened against both cell lines in order to find 
out which fraction was the most active and, in this way, perform a biodirected 
study for the identification of cytotoxic compounds. The results of the 
screening are reported in figure 5.88.  
MCF7 cells resulted to be sensible to both pooled fractions 3 and 4, at 
concentrations of 100 µg/mL (47.4 ± 3.9 % and 12.7 ± 1.9 %, viability 
percentage, respectively) and pooled fraction 4 at 50 µg/mL (33.5 ± 7.9 %, 
viability percentage) (Figure 5.88A). PC3 cells was sensible to pooled fraction 
2, 3 and 4 at 100 µg/mL (33.8 ± 3.5 %, 25.4 ± 1.7 % and 15.8 ± 1.9 %, viability 
percentage respectively), while pooled fraction 4 at 50 µg/mL (48.8 ± 7.2 %, 
viability percentage) (Figure 5.88B).  
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Figure 5.88 Viability for PC3 (A) and MCF7 (B) cells after 48h treatment with 100, 50 and 25 
µg/mL of the macro-fractions of the CHCl3/MeOH extract. 
 
Results showed selectivity of pooled fractions 3 and 4 for both prostate 
and breast cancer cells pointing out their bioactive composition. Their 
contiguity also suggest that the active compounds must be shared among 
these two fractions and therefore implying a possible similitude in structure 
and properties of their components.  
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5.3.7.6 Composition of pooled fraction 4 
Pooled fraction 4 was analyzed by UPLC-QTOF-MS, in both positive 
and negative mode identifying 22 compounds (Table 5.28), 16 compounds are 
shared with pooled fraction 3. The majority of them were PAs derivatives (56 
%), including HCAs derivatives (45 %), coumarins (6 %), and benzoic acid 
derivatives (2 %) and a lignan: syringaresinol (3 %). It was also identified four 
flavonoids (27 %), a pigment (4 %) and a FA: palmitoleic acid (3 %) while two 
compounds is still unknown (10 %).  
From identified compounds the cytotoxic activity of the fraction is 
partially explained. Phenolic compounds of extract are known to have the 
ability to form reactive oxygen species (ROs) in the culture medium, such as 
H2O2 that take part in the fraction toxicity (252). As already mentioned, caffeic 
acid and its derivatives are already been reported as part of the extract of other 
plants of family of Bromeliads taxonomically related to the genus Hechtia and 
to have cytotoxic activity on cancer cells. The same is reported for the CAPE 
to exert a potent and specific inhibition of nuclear transcription factor NF-kappa 
B (253). CAPE also inhibit the PI3K/Akt signaling pathway lowering cell 
survival (254). The majority of identified flavonoids in this fraction were already 
reported in the metabolomic profile of the plant (Section 5.2). Their biological 
activity was also investigated in the literature and already reported in the same 
section. The only new molecule is the demethylnobiletin, but its activity against 
cancer is still unknown. 
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Table 5.28 HPLC-QTOF-MS analysis of pooled fraction 4 of the CHCl3/MeOH extract of H. glomerata 
tR(min) Compound 
Calculated 
formula 
Negative 
(m/z) 
Positive 
(m/z) 
Fragments 
Error 
(ppm) 
Area 
(%) 
Ref. 
1.001 Protocatechuic acid C7H6O4 153.0189 - [M-H]-: 109 -2.61 0.89 (244) 
1.732 Salicylic acid C7H6O3 137.0239 - [M-H]-: 93 -3.65 0.86 a, b 
3.129 Caffeic acid C9H8O4 179.0342 - [M-H]-: 135 -4.47 0.24 a 
4.416 2-O-p-coumaroylglycerol C12H14O5 237.0768 239.0917 [M-H]-: 119, 145, 163; [M+H]+: 147, 119 5.48; 1.25 7.22 (244) 
4.737 p-Coumaric acid C9H8O3 163.04 - [M-H]-: 119 -0.61 6.05 (245) 
4.990 1-O-p-coumaroylglycerol C12H14O5 237.0767 - [M-H]-: 119, 145, 163 -0.42 12.18 c 
5.384 Unknown NA - 275.1307 [M+H]+: 79, 197, 179, 135 ND 3.84 m 
6.561 Dicaffeoyl glycerol isomer C21H20O9 - 417.117 [M+H]+: 163, 145, 237 -2.40 3.50 c 
6.741 Dicaffeoyl glycerol C21H20O9 415.1044 417.1176 
[M-H]-: 253, 161, 179, 135, 237  
[M+H]+: 163, 145, 164, 237 
-0.96; 2.17 14.53 (43) 
7.063 Caffeoyl coumaroyl glycerol C21H20O8 399.1102 401.1221 
[M-H]-: 163, 253, 119, 145, 135, 235, 179  
[M+H]+: 147, 163, 145, 119 
-2.49; 4.26 3.66 m 
7.514 Naringenin derivative C24H20O8   437.1215 [M+H]+: 437, 177, 251, 147, 243, 221 -3.66 2.22 e 
7.569 Malvidin C17H14O7 - 331.0805 [M+H]+: 331, 315, 298, 273, 281 -2.11 3.83 e 
7.837 Chlorophyll derivative NA - 843.2336 [M+H]+: 843, 555, 844, 597, 556 ND 10.32 m 
8.013 Unknown C19H18O9 - 391.1019 [M+H]+: 391, 361, 389, 375, 358 -1.28 2.70 m 
8.014 Coumarin isomer C9H6O2 - 147.0438 [M+H]+: 91, 119, 147, 65 -2.04 1.84 m 
8.168 Coumarin derivative C20H22O6 - 359.1488 [M+H]+: 147, 119 -0.28 5.32 m 
8.215 
3-(4-Hydroxyphenyl) propyl 
coumarate 
C18H18O4 297.1151 - 
[M-H]-: 119, 145, 163  
[M+H]+: 107, 147, 135 
6.39; 1.34 4.33 m 
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Table 5.28 HPLC-QTOF-MS analysis of pooled fraction 4 of the CHCl3/MeOH extract of H. glomerata (Continued) 
tR(min) Compound 
Calculated 
formula 
Negative 
(m/z) 
Positive 
(m/z) 
Fragments 
Error 
(ppm) 
Area 
(%) 
Ref. 
8.297 
3-(4-Hydroxyphenyl-3-
methoxy) propyl coumarate 
C19H20O5 327.1255 - [M-H]-: 163, 119, 145, 177, 133, 312, 299 5.20 3.02 m 
8.370 
Kaempferol or cyanidin 
derivative 
C18H16O7 - 345.097 [M+H]+: 345, 312, 329, 330, 287 0.29 3.37 e 
8.784 Palmitoleic acid C16H30O2 - 255.2318 
[M+H]+: 69, 67, 83, 55, 81, 97, 95, 71, 43, 135, 
93, 121, 107, 97, 149, 67, 109 
-0.39 1.71 m 
9.156 Demethylnobiletin C20H20O8 - 389.1227 [M+H]+: 389, 356, 331, 373, 359, 374 -1.03 5.74 d 
9.453 Syringaresinol C21H22O9 - 419.1342 [M+H]+: 419, 389, 371, 420, 390 1.19 2.63 m 
aMETLIN; bMassBank; cIn-house database; dFoodb; eReSpect; mManual. 
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5.3.7.7 Cytotoxicity of p-coumaric acid and caffeic acid 
Since p-Coumaric and caffeic acid were isolated from the active 
fractions of the CHCl3/MeOH extract they were tested for their cytotoxic activity 
against MCF7 and PC3 cell (Table 5.29). Caffeic acid was the most active 
showing IC50 of 68.8 ± 12.2 and 91.5 ± 5.3 µg/mL against PC3 and MCF7 
respectively. Instead p-coumaric acid showed an IC50 of 179.9 ± 31.6 µg/mL 
for PC3 cells, but no activity was shown towards MCF7.  
Caffeic acid resulted extremely sensible to the ambience conditions 
once dissolved in the culture medium change the colour of the medium 
signalling of its decomposition. This kind of behaviour was already described 
for the molecule as the formation of reactive oxygen species (ROs) (255). 
 
Table 5.29 Cytotoxic activity of p-coumaric and caffeic acid 
Compound 
IC50 (µg/mL) 
MCF7 PC3 
p-Coumaric acid >100 179.9 ± 31.6 
Caffeic acid 91.5 ± 5.3 68.8 ± 12.2 
 
It is important to point out that the high standard deviation obtained in 
some cases from the assays is probably due to random fluctuation in the 
cellular growth. This caused some of the experiments to be inconsistent and 
to somehow affect results of experiments.  
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5.4 Microarray analysis 
5.4.1 Genetic expression of PC3 cells treated with p-coumaric acid 
Genes (35,764) were monitored during the microarray analysis of 
PC3’s RNA, and a total of 25,606 genes gave a variation of Zscore. Figure 
5.89 showes the fluorescence observed from the chip after hybridization. 
Green fluorescence is given by the genes expressed for the treated cells, red 
fluorescence comes from the genes expressed for the control, and the yellow 
fluorescence is given by both treated and untreated cells.  
 
 
Figure 5.89 Fluorescence emitted by the hybridized H35K chip: treated cells (green), 
untreated cells (reed) and both (yellow) 
 
The up or down-regulated genes represent the response of PC3 cells 
to the pCA treatment. From the observed genes 16,936 had a Zscore < +1 
and > -1, while 2751 had a Zscore ≤ +1.5 and ≥ +1, and finally 1524 and 424 
had a Zscore ≥ +1.5 and ≥ +2 respectively. Instead 2706 had a Zscore ≥ -1.5 
and ≤ -1, while 1689 and 394 had a Zscore ≤ -1.5 and ≤ -2 respectively. The 
dispersion plot of the obtained genes is reported in figure 5.90. These results 
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were submitted to a statistical evaluation in order to assess their divergence 
from the house-keeping genes (Zscore = 0). 
 
 
Figure 5.90 A) Dispersion plot of all monitored genes: -1< Zscore <+1 (green crosses); +1≤ 
Zscore ≥+1.5 and -1.5≤ Zscore ≤-1 (blue crosses); Zscore ≥ +1.5 and ≤ -1.5 (light blue 
crosses); Zscore ≥ +2 and ≤ -2 (white crosses). B) Dispersion plot of genes with Zscore ≥ +2 
and ≤ -2 
 
Since the genes with Zscore ≥ +2 and ≤ -2 (white crosses) are the most 
different (P>0.05) from the data mainstream, they represent the most relevant 
change in the cellular genetic expression. For this reason and for simplicity, 
only these genes will be considered in the data analysis. The dispersion plot 
obtained from the statistical analysis of all genes based on their Zscore is 
showed in figure 7.88. See appendix for the full lists of genes with Zscore ≥ +2 
and ≤ -2.  
 
5.4.2 Bioinformatics analysis 
Selected lists of genes were submitted to DAVID bioinformatics web 
database. This recognized 230 up-regulated genes and 201 down-regulated 
genes. The functional annotation results of the up-regulated and down-
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regulated genes were grouped in clusters based on the class of proteins they 
encoded. This way the principal characteristics of the identified genes and the 
pathways they affected were highlighted. 
 
5.4.2.1 Up-regulated genes 
The principal identified up-regulated genes are involved in the 
regulation of transcription, protein activation, DNA-binding. Most of these 
genes encode for Zn-fingers or for protein kinases and are found in the 
nucleus. Other genes regulate angiogenesis, ubiquitination, protein 
conjugation, and cell adhesion. Certain genes also regulate cellular stress-
related processes, such as stress and inflammation responses, DNA repair, 
cell survival and also cellular proliferation. Some of the most interesting 
clusters of genes are reported in figure 5.91.  
 
Figure 5.91 Most interesting up-regulated genes clusters (Enrichment Score > 1) 
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From the project point of view, the most important genes of these 
clusters are the inhibitor of nuclear factor κ B kinase regulatory subunit γ 
(IKBKG/NEMO), the mitogen activated protein kinase 8 (MAPK8/JNK1), the 
mitogen activated protein 3 kinase 1 (MAP3K1/MEKK1), the proto oncogene 
MDM2, the angioproteins 2 and 4 (ANGPT2/4), the Ras GTPase-activating 
protein 4 (RASA4), Ser/Thr kinase 3 (STK3), cyclin E2 (CCNE2), voltage-
dependent T-type Ca channel subunit α-1G (CACNA1G), G protein subunit γ 
11 (GNG11), ephrin-A5 (EFNA5), myocyte enhancer factor 2C (MEF2C), MAP 
kinase-interacting Ser/Thr-protein kinase 2 (MKNK2) and Ser/Thr-protein 
phosphatase 2A regulatory subunit B'' subunit γ (PPP2R3C). 
IKBKG encodes a protein also known as NEMO a Zn-finger which is 
essential in the modulation of the NF-kB signalization pathway. In fact, this 
protein is the regulatory subunit of the IKK core complex and phosphorylates 
the NF-kB inhibitor deactivating it. This activates many signalization pathways 
such as inflammation, immunity, differentiation, cell growth, tumorigenesis and 
apoptosis (256). MAPK8 or JNK1 is a Ser/Thr kinase involved in various 
biological processes like cell proliferation, differentiation, migration, 
transformation and programmed cell death. It was reported that, in cancer, this 
protein pathway to cell apoptosis is stimulated by antioxidant compounds like 
flavonoids (257). MAP3K1 also known as MEKK1 is a protein kinase part of a 
transduction cascade that activates the ERK and MAPK8 pathways. It is also 
involved in the activation of the kinases of CHUK and IKBKB which are part of 
the NF-kB pathway (258, 259). MDM2 is a ubiquitin ligase that mediates the 
ubiquitination of p53 and consequently its proteasome degradation. 
Furthermore, it inhibits p53-mediated cell cycle arrest and apoptosis by 
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binding its transcriptional activation domain (260). The RING type region of 
the MDM2 protein is a Zn-finger that if mutated causes the loss of the 
ubiquitination activity of this protein (261). ANGPT2 is a glycoprotein which 
can interact with the vascular endothelial growth factor (VEGF) to facilitate 
endothelial cells migration and proliferation. This protein can induce the 
loosening of the cell-matrix contact and cause consequent apoptosis and 
vascular regression (262). ANGPT4 is also a glycoprotein and is the main 
ligand of the transmembrane receptor protein Tyr-kinase (TEK/TIE2) activator. 
It also promotes endothelial cell survival, migration and angiogenesis (263). 
RASA4 or CAPRI encodes for Ras, a Ca2+-dependent GTPase activating 
protein which regulates the Ras-MAPK pathway (264). This is also known as 
MAPK/ERK cascade, can be involved in many cellular processes based on 
the cellular context. These processes comprise cell growth, adhesion, survival 
and differentiation through the regulation of transcription, translation and 
cytoskeletal rearrangements (265). STK3/MST2 is a stress activated, pro-
apoptotic Ser/Thr-kinase. This protein may also take part in the activation of 
the oncoprotein YAP1 which in turns migrate in the nucleus and regulates the 
expression of genes important for cell proliferation, death and migration (266). 
G1/S-specific Cyclin E2 is essential for the regulation of late G1 and early S 
cellular phase. It regulates cyclin-dependent Ser/Thr kinase binding and 
activity, it is also involved in cell division and initiation of DNA replication (267). 
Another important function of this protein is telomere maintenance which 
include: maintain proper telomeric long and structure, replicate and repair the 
telomeric DNA sequences (268). CACNA1G is a low-voltage-activated (LVA) 
channel which mediates the entrance of Ca2+ ions into the cytoplasm. It is in 
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fact involved in a variety of Ca-dependent processes among which are gene 
expression, cell motility, growth, division, and death (269). Guanin nucleotide-
binding protein subunit γ is a G protein involved in several transmembrane 
signaling systems. The γ chain is required for GTPase activity and regulates 
cellular senescence (267, 270). Ephrin-A5 is glycophos-phatidylinositol (GPI) 
-bound ligand for Eph-receptors, which are Tyr-kinase crucial for cell 
migration, repulsion, adhesion (271). MEF2C is a transcription factor part of a 
family of proteins that are associated with the development of many diseases. 
It is associated with various pathways of signalization such as Ca2+ signaling, 
MAP kinase signaling, Wnt signaling, PI3K/AKT signaling among others (272). 
The Wnt pathway regulates the development in many cancer types (273), 
while the PI3K/AKT pathway components are responsible for the regulation of 
cell survival, cell cycle progression and cellular growth. These signalization 
pathways are usually altered in cancer (274). MKNK2 is Ser/Thr-kinase that 
could play a role in the response to environmental stress, and is also involved 
in the phosphorylation of the eukaryotic initiation factor 4E (eIF4E) which 
promotes tumorigenesis and prostate cancer progression (275, 276). MKNK2 
is also implicated in the pro-survival response in drug resistance (277). 
PPP2R3C is Ca2+-binding Ser/Thr-kinase regulatory subunit, and it is part of 
a phosphatase protein complex that inhibits the function of P-
glycoprotein/ABCB1. The latter is a molecule involved in cancer multidrug 
resistance (278). 
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5.4.2.1.1 Affected pathways 
The analyzed clusters reported some pathways in which the up-
regulated genes are found (Table 5.30). The majority of these affected 
pathways correspond to cancer-related biological processes. 
 
Table 5.30 Pathways affected by the selected up-regulated genes 
Term Count % Genes 
Epstein-Barr virus 
infection 
6 2.61 
PSMD14, PSMD1, IKBKG, MDM2, MAPK8, 
PSMD7 
Ras signaling pathway 8 3.48 
IKBKG, GNG11, EFNA5, MAPK8, FGF21, 
ANGPT2, ANGPT4, RASA4 
MAPK signaling pathway 8 3.48 
MEF2C, MAP3K1, IKBKG, MKNK2, 
CACNA1G, MAPK8, FGF21, STK3 
PI3K-AKT signaling 
pathway 
9 3.91 
CCNE2, IKBKG, MDM2, GNG11, EFNA5, 
FGF21, ANGPT2, ANGPT4, PPP2R3C 
Ubiquitin mediated 
proteolysis 
5 2.17 UBE2A, MAP3K1, MDM2, MID1, UBE2U 
Proteasome 3 1.30 PSMD14, PSMD1, PSMD7 
Prostate cancer 3 1.30 MDM2, CCNE2, IKBKG 
Pathways in cancer 6 2.61 
MAPK8, MDM2, CCNE2, IKBKG, GNG11, 
FGF21 
Rap1 signaling pathway 5 2.17 
FARP2, EFNA5, ANGPT2, ANGPT4, 
FGF21 
Toll-like receptors 
pathway 
3 1.30 MAPK8, IKBKG, MAP3K1 
TNF/stress related 
signaling 
3 1.30 MAPK8, IKBKG, MAP3K1 
RIG-I-like receptor 
pathway 
3 1.30 MAPK8, IKBKG, MAP3K1 
Hepatitis B 4 1.75 MAPK8, IKBKG, MAP3K1, CCNE2 
Fc-ε receptor signaling 
pathway 
7 3.05 
MAPK8, IKBKG, MAP3K1, PSMD14, 
PSMD7, PSMD1, IGLV7-43 
The pathways were identified by DAVID bioinformatics in the KEGG database. 
 
Among the most important pathways affected by the pCA treatment are 
the PI3K/AKT signaling pathway (Figure 5.92). In this pathway nine genes 
were upregulated in response to the treatment: FGF21, ANGPT2, ANGPT4, 
EFNA5, GNG11, MDM2, IKBKG, CCNE2 and PPP2R3C.  
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Figure 5.92 PI3K/AKT signalling pathway: GF) FGF21, ANGPT2, ANGPT4, EFNA5; RTK) 
FGF21; Gβγ) GNG11; MDM2) MDM2; IKK) IKBKG; Cyclin) CCNE2; PP2A) PPP2R3C. The 
up-regulated components of the pathway are marked with a red star. 
 
As already mentioned, this pathway is involved in the regulation of cell 
survival, cell cycle progression and cellular growth. Some of the reported 
genes are found upstream of the pathway like FGF21, ANGPT2/4, EFNA5, 
GNG11 and PPP2R3C. These proteins are able to control the pathway in a 
general way, affecting a wider variety of components and processes. The 
effect of their up regulation could be reflected in any of the signalization 
outcome, form cell metabolism and nutrients uptake to cell survival and 
proliferation. Instead other genes like MDM2, IKBKG and CCNE2 are found 
more downstream of the pathway. MDM2 is involved in the p53 signaling 
pathway, while IKBKG regulates the NF-kB signaling pathway and therefore 
in cell survival. Finally, CCNE2 affects the cell cycle progression. 
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Another identified pathway is the MAPK signaling pathway, which 
contains eight up-regulated genes: FGF21, CACNA1G, MKNK2, IKBKG, 
MAP3K1, STK3, MAPK8 and MEF2C (Figure 5.93). 
 
 
Figure 5.93 MAPK signalling pathway: GF, RTK) FGF21; CACN) CACNA1G; MNK1/2) 
MKNK2; IKK) IKBKG; MEKK1) MAP3K1; MST1/2) STK3; JNK) MAPK8; MEF2C) MEF2C. 
The up-regulated components of the pathway are marked with a red star. 
 
The affected genes found most upstream in this pathway are FGF21 
and CACNA1G. In this signalization route these genes seem to be associated 
with cell proliferation, differentiation and inflammation. But these might also 
activate other pathways like the phosphatidylinositol signaling system and the 
Ras signaling pathway. Meanwhile STK3, MAP3K1, MAPK8, IKK and MKNK2 
are kinases involved in the in the phosphorylation and therefore 
activation/inactivation of other components of the pathway. Of these proteins 
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the ones reported more downstream can also interact with both kinases and 
transcription factors. For example, IKBKG can activate NF-κB and MKNK2 
activates CREB which regulate cell proliferation, differentiation, inflammation 
and anti-apoptotic processes. Instead MEF2C is a transcription factor which 
may be activated indirectly by MAPK8, MAP3K1 and all the peripheral 
membrane proteins. This protein directly interacts with DNA and regulates 
apoptosis and cell cycle. The same outcome can be obtained by MAPK8. The 
Ras signaling pathway is also among the treatment affected pathways, 
comprising eight up-regulated genes: FGF21, ANGPT2, ANGPT4, EFNA5, 
GNG11, RASA4, IKBKG and MAPK8 (Figure 5.94).  
 
 
Figure 5.94 Ras signalling pathway: GF) FGF21, ANGPT2, ANGPT4, EFNA5; RTK) FGF21; 
Gβγ) GNG11; RasGAP) RASA4; IKK) IKBKG; JNK) MAPK8. The up-regulated components 
of the pathway are marked with a red star. 
 
The same genes as the past two pathways are reported upstream of 
the actual one: FGF21, ANGPT2, ANGPT4, EFNA5. Instead GNG11 in this 
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case is implicated in the regulation of the Ras activator RasGRPs that 
activates Ras which is the central node of this pathway. Another important 
overexpressed component of the Ras pathway is RasGAP which is a protein 
that also regulates de activity of Ras. In fact, this protein is able to switch Ras 
off through the activation of GTPase which changes Ras from GTP-bound to 
GDP-bound. Meanwhile, MAPK8 is involved in the regulation of gene 
expression and IKBKG in cell survival, growth, migration, cell cycle 
progression and transcription. 
Other important pathways affected by the pCA are the pathways in 
cancer, in which six genes were found up-regulated: GNG11, MDM2, CCNE2, 
FGF21, IKBKG and MAPK8 (Figure 5.95).  
 
 
Figure 5.95 Pathways in cancer: GF) FGF21, ANGPT2, ANGPT4, EFNA5; RTK) FGF21; 
Gβγ) GNG11; RasGAP) RASA4; IKK) IKBKG; JNK) MAPK8. The up-regulated components 
of the pathway are marked with a red star. 
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Of these genes the most upstream are growth factors (GF) and GF 
receptors like FGF21. These proteins could also indirectly activate Ras which 
in turns could activate MAPK8 and lead to the cell evasion from apoptosis. 
Meanwhile In this pathway GNG11 is reported to regulate the activity of PI3K 
and consequently IKBKG and MDM2 which cause the apoptosis evasion. 
Also, the activity of MDM2 can be derived from DNA damage and reparation, 
while cyclin E2 is responsible for cellular proliferation. 
The last affected pathway that was considered interesting is the 
prostate cancer pathway. Only three genes of this path were found up-
regulated: MDM2, IKBKG and CCNE2 (Figure 5.96).  
 
 
Figure 5.96 Prostate cancer: MDM2) MDM2; CyclinE) CCNE2; IKK) IKBKG. The up-
regulated components of the pathway are marked with a red star. 
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In this route the activity of MDM2 is also correlated to the inactivation 
of the tumor suppressor p53, which causes the impaired G1 and G2 arrest, 
reduced apoptosis and genomic instability. Meanwhile IKBKG, through the 
regulation of NF-κB and indirectly of Bcl-2 regulates genetic expression and 
cell survival. Cyclin E2 is involved in the cell cycle inducing G1/S phase 
progression. 
 
5.4.2.2 Down-regulated genes 
The principal down-regulated genes are G-coupled receptors, kinases, 
transferases, protooncogenes and signal transducers. They regulate cell-cell 
adhesion, protein activation by phosphorylation, protein folding, cell survival, 
cell growth, proliferation, angiogenesis, migration and invasion, apoptosis and 
are either peripheral or transmembrane proteins. Some genes are also 
responsible for the olfactory and sensory transduction and were also found 
multiple Zn-fingers and transcription factors. The cluster more important for 
cancer is reported in figure 5.97. Among the down-regulated genes the most 
interesting are the caspase-9 (CASP9), G2/mitotic-specific cyclin-B2 
(CCNB2), Ser/Thr-protein kinase Chk1 (CHEK1), fibroblast growth factor 
receptor 2 (FGFR2), RAC-β Ser/Thr-protein kinase (AKT2), protein MDM4 
(MDM4), NT-3 growth factor receptor (NTRK3), 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase 2 (PFKFB2), ATP-dependent 6-phospho-
fructokinase, platelet type (PFKP), Solute carrier family 2, facilitated glucose 
transporter member 4 (SLC2A4) and Ser/Thr-protein kinase 11 (STK11). 
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Figure 5.97 Most interesting down-regulated genes clusters (Enrichment Score > 1) 
 
Caspase-9 is a protein involved in the activation of the caspases 
cascade that leads to the activation of apoptosis promoted by DNA damage 
(279). It has a Cys-type endopeptidase activity which regulates the apoptotic 
process and signaling. Caspase-9 is also involved in the response to drug and 
harsh environmental conditions (280). Cyclin B2 is an essential regulator for 
the G2/M transition (mitosis), which activates cyclin-dependent Ser/Thr-
protein kinases (267). By extension this protein regulates also cell division and 
growth. 
CHEK1 is a Ser/Thr-protein kinase required for cell cycle arrest and 
DNA repair caused by persistent DNA damage or lack of replication. It is 
involved in the apoptotic process, transcription maintenance, protein 
phosphorylation, and regulation of signal transduction by p53 class mediator 
(281, 282). FGFR2 is a cell surface receptor with Tyr-protein kinase activity 
essential in the regulation of cell proliferation, differentiation, migration and 
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apoptosis (283). This protein also mediates the activation of Ras, MAP kinase 
and AKT signaling pathways and is down regulated by ubiquitination. The 
fibroblast growth factor receptor malfunction is also associated with cancer 
pathologies (284). AKT2 is one of three closely related isoforms (AKT1, AKT2 
and AKT3) of Ser/Thr-protein kinases called AKT kinases. These proteins 
regulate many cellular processes such as metabolism, cell proliferation, 
survival, growth, angiogenesis and programmed death. They phosphorylate a 
wide range of downstream substrates, of these more than a 100 have been 
identified (285). MDM4 inhibits p53 and p73-mediated cell cycle arrest and 
apoptosis and it can reverse MDM2 degradation of apoptosis (286). This 
protein is activated in response to DNA damage, hypoxia and cell population 
growth, having a negative effect on apoptosis, cell cycle arrest and 
proliferation (287). NTRK3 is a single transmembrane α-helix receptor Tyr 
kinase, which activates many pathways of signalization including: AKT and 
MAPK pathways that control cell survival and differentiation (288). The protein 
also regulates cell migration and multiple nervous system-related functions 
(289). PFKFB2 is an enzyme that regulates fructose 2,6-bisphosphate 
degradation. It responds to the presence of sugar and is part of the glycolysis 
process (267). This protein is also reported to be activated and overexpressed 
in the AKT signaling pathway in prostate cancer among others (290, 291). 
PFKP is a protein which activity is the phosphorylation of D-fructose 6-
phosphate to fructose 1,6-bisphosphate using ATP as phosphate donor. This 
process consists in the first step of glycolysis and it was found that silencing 
the genes that activate the transcription of the PFKP gene promotes prostate 
cancer aggressiveness (292). In tumor hypoxia PFKP and PFKFB2 are often 
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upregulated, which seems contrary to in vitro conditions and after the pCA 
treatment. These proteins have crucial roles in the development of malignant 
tumors since they are rate-limiting enzymes in glycolysis. In addition to tumor 
growth they also participate in cancer metastasis regulating the transcription 
of oncogenes (293). SLC2A4 is insulin regulated facultative glucose 
transporter which eliminates glucose from circulation. It also responds to the 
tumor necrosis factor (TNF) and it is reported to be central in the protein-
protein interaction (PPI) network necessary for prostate cancer genesis (294). 
Last but not least STK11 is a tumor suppressor Ser/Thr-protein kinase which 
is involved in the regulation of the AMP-activated protein kinase (AMPK) 
members (295). Because of its function this protein plays a role in cell 
metabolism, cell polarity, apoptosis and DNA damage response. STK11 also 
mediates the p53-dependent apoptosis through the interaction with p53, as a 
result of this interaction it translocates into the mitochondrion during apoptosis 
to regulate the apoptotic process (296). It was reported that STK11 expression 
loss or reduction is a crucial step in prostate cancer development and 
prediction of therapeutic response (297). 
 
5.4.2.2.1 Affected pathways 
Some pathways were found to be affected by the pCA treatment and 
some of them were also found in the genes’ clusters (Table 5.31). All the 
pathways described herein are related to cancer, some of them were not found 
in the KEGG database and therefore were not included.  
 251 
The first important pathway is the PI3K/AKT signaling pathway, 
comprising seven down-regulated genes: AKT2, CASP9, FGFR2, HSP90AB1, 
IFNB1, NR4A1 and STK11 (Figure 5.98). 
 
Table 5.31 Pathways affected by the selected down-regulated genes 
Term Count % Genes 
Apoptosis 4 2.00 STK11, CASP9, FGFR2, AKT2 
Apoptotic process 4 2.00 NR4A1, CASP9, FGFR2, AKT2 
MAPK signaling pathway 4 2.00 AKT2, FGFR2, NR4A1, PPM1A 
PI3K-AKT signaling 
pathway 
7 3.50 
AKT2, CASP9, FGFR2, HSP90AB1, IFNB1, 
NR4A1, STK11 
Pathways in cancer 5 2.50 
AKT2, CASP9, FGFR2, HSP90AB1, 
PTGER3 
Central carbon 
metabolism in cancer 
4 
2.00 
AKT2, FGFR2, NTRK3, PFKP 
Prostate cancer 4 2.00 AKT2, CASP9, FGFR2, HSP90AB1 
Adipocytokine signaling 
pathway 
3 1.50 SLC2A4, STK11, AKT2 
FoxO signaling pathway 4 2.00 CCNB2, SLC2A4, STK11, AKT2 
AMPK signaling pathway 5 2.50 PFKB2, AKT2, PFKP, STK11, SLC2A4 
Cell-cell adhesion 8 4.00 
CCNB2, DDX6, HSP90AB1, CHMP5, 
LDHA, EIF4H, MKL2, PFKP 
Cadherin binding 
involved in cell adhesion 
8 4.00 
CCNB2, DDX6, HSP90AB1, CHMP5, 
LDHA, EIF4H, MKL2, PFKP 
Cell-cell adhesion 
junction 
9 4.50 
NCR3, CCNB2, DDX6, HSP90AB1, 
CHMP5, LDHA, EIF4H, MKL2, PFKP 
p53 signaling pathway 4 2.00 MDM4, CASP9, CHEK1, CCNB2 
The described pathways were identified by DAVID bioinformatics in the KEGG database. 
 
The most upstream down-regulated gene of this pathway is IFNB1, this 
gene which encodes for the interferon β which as anticancer activities (298). 
This protein interacts with cytokine receptor and may activate PI3K and 
consequently AKT. This could allow the cascade to regulate multiple 
processes, from metabolic like protein synthesis, glucose uptake and 
glycolysis, to actin reorganization. Also, the downregulation of this gene could 
affect the cellular cycle progression and apoptosis and finally it could regulate 
other pathways such as NFκB and p53 signaling pathways. Similar effects 
should be observed from the downregulation of FGFR2, which affects, 
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throughout interaction with Ras: cell proliferation, angiogenesis and DNA 
repair. Other down-regulated genes from this PI3K/AKT pathway are 
HSP90AB1 and STK11. 
 
 
Figure 5.98 PI3K/Akt signalling pathway: Cytokins) IFNB1; RTK) FGFR2; HSP90) 
HSP90AB1; AKT) AKT2; LKB1) STK11; CASP9) CASP9; NUR77) NR4A1. The down-
regulated components of the pathway are marked with a red star. 
 
The first one encodes for a heat-shock protein, which acts as a 
molecular chaperone that promotes maturation, structural maintenance and 
proper regulation of specific proteins and activates AKT (299). Instead STK11 
is a tumor suppressor part of the mTOR signaling pathway which regulates 
protein synthesis among other processes. Finally, CASP9 and NR4A1 were 
also down regulated since they are involved in cell survival and apoptosis 
signaling. 
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Another important affected pathway is the MAPK signalization pathway, 
where four genes are reported to be down regulated: AKT2, FGFR2, NR4A1 
and PPM1A (Figure 5.99).  
 
 
Figure 5.99 MAPK signalling pathway: RTK) FGFR2; AKT) AKT2; PP2CA) PPM1A; Nur77) 
NR4A1. The down-regulated components of the pathway are marked with a red star. 
 
In this pathway the most upstream of down-regulated genes is FGFR2, 
which encodes for the fibroblast growth factor receptor 2. This protein kinase 
has the ability to regulate other downstream processes such as the activation 
of the Ras cascade, which in turn regulates the proliferation and differentiation 
of the cell. This cascade can also activate some protein kinases (MEKKKK) 
like MAP3K1 which can produce the activation of other protein kinases 
(MAPK). The latter can regulate gene expression throughout the 
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activation/inactivation of transcription factors that are involved with the 
activation of tumor suppressors, like p53. Also, this process can regulate the 
cell cycle and the apoptotic process, and therefore affecting cell proliferation, 
differentiation and inflammation. Other down-regulated genes that are 
involved in the regulation of the genetic expression are AKT2 and PPM1A. 
Their proteins are central to the MAPK pathway, especially AKT2 which can 
also regulate the Wnt signaling pathway. The last gene that was down-
regulate is NR4A1 which is a transcription factor that regulates proliferation 
and differentiation. 
The AMPK signaling pathway was also affected, with five 
downregulated genes: PFKB2, AKT2, PFKP, STK11 and SLC2A4 (Figure 
5.100). The most upstream affected gene is the STK11, this protein takes part 
in the direct activation of AMPK upon treatment with antidiabetic drugs or 
antioxidants like quercetin. AMPK in turn can produce the migration of 
SLC2A4 to the cell membrane and subsequent intake glucose from the blood 
stream. This protein which can also be activated by transcription factors, is 
deeply implicated in cellular growth. PFKP and PFKB2 are also implicated in 
the cellular metabolisms, specifically in the glycolysis regulation. In fact, their 
activation may increase this process and a speed-up metabolism is one of the 
principal cancer hallmarks. The last down-regulated gene of the AMPK 
signaling pathway is AKT2, and as already mentioned the encoded protein is 
also a fundamental regulator of cellular metabolism (mTOR signaling 
pathway). In this case the protein may inhibit cell growth and protein synthesis 
and also it can increase autophagy. 
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Figure 7.100 AMPK signalling pathway: GLUT4) SLC2A4; LKB1) STK11; Akt) AKT2; PFK-
2) PFKB2; PFK-1) PFKP. The down-regulated components of the pathway are marked with 
a red star. 
 
Several pathways in cancer were also found to contain down-regulated 
genes, which are five: AKT2, CASP9, FGFR2, HSP90AB1 and PTGER3 
(Figure 5.101). The most up-stream genes are FGFR2 and PTGER3, the first 
one was already described, while the second one is the prostaglandin E2 
receptor EP3 subtype. This last receptor modulate response to inflammation 
and cell death (267, 300), and indirectly regulated different pathways such as 
PI3K/AKT, Jak/STAT MAPK, Ca and VEGF signaling pathways. These 
cascades ultimately control various cellular processes: sustained 
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angiogenesis, apoptosis evasion and proliferation. The same effects may be 
obtained by the downregulation of FGFR2 as shown in figure 5.101. To these 
genes follow CASP9 and HSP90AB1, these genes are responsible mainly for 
the evasion of apoptosis and cell proliferation.  
 
 
Figure 5.101 Pathways in cancer: GPCR) PTGER3; FGFR) FGFR2; CASP9) CASP9; HSP) 
HSP90AB1; PKB/Akt) AKT2. The down-regulated components of the pathway are marked 
with a red star. 
 
In particular the heat-shock protein is activated by the androgen 
receptor (AR) which is sensible to a variety of antioxidant natural products 
(301). The last affected gene for this pathway is AKT2, which in this case can 
participate in the activation of various cancer-related proteins and pathways, 
like the PKB/AKT signaling pathway. Some proteins that interact directly with 
AKT2 are mTOR (as already mentioned), caspase-9, E3 ubiquitin-protein 
ligase MDM2 and IKK (see up-regulated genes section), Bad, FKHR, p27 and 
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p21. All these molecules are related with angiogenesis, apoptosis evasion and 
proliferation. Other cancer-related pathways were the central carbon 
metabolism in cancer and prostate cancer signaling pathways (view figure 
5.94). The genes down regulated of these signalization cascades were AKT2, 
FGFR2, CASP9, HSP90AB1, NTRK3 and PFKP. The functions and affected 
pathways for all these genes were already mentioned in the previous 
pathways and in cancer they regulate multiple aspects of metabolism 
(glycolysis, protein synthesis, TCA cycle, FA biosynthesis, AA metabolism and 
oxidative phosphorylation). Also, they mediate cell survival, migration, 
invasion, proliferation, apoptosis, cell cycle progression and tumor growth, and 
are particularly involved in the transition from localized to metastatic prostate 
cancer.  
p53 signaling pathway is also affected by the pCA treatment, giving four 
down-regulated genes: MDM4, CASP9, CHEK1 and CCNB2 (Figure 5.102). 
The most upstream down-regulated gene is CHEK1, which directly regulates 
the activation p53 and therefore may activate any response of cell cycle 
(senescence), apoptosis, angiogenesis, DNA repair and protein synthesis. 
The same antitumor factor may be regulated indirectly by MDM4 which 
through the modulation of MDM2 can switch on or off the whole p53 pathway. 
CCNB2 is instead cell cycle specific and may cause its G2 arrest, while CASP9 
takes part in the mitochondrion-mediated apoptosis (302). 
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Figure 5.102 p53 signaling pathway: CHK1) CHEK1; MDM-X) MDM4; CASP9) CASP9; 
Cyclin B) CCNB2. The down-regulated components of the pathway are marked with a red 
star. 
 
5.5 In silico study 
 
The proteins encoded in the selected up- and down-regulated genes 
were submitted to molecular docking. The type of docking used in these 
experiments is the flexible ligand docking, where the ligand is allowed to 
change conformation (poses), while the protein is maintained rigid and doesn’t 
change tis conformation in respond to the ligand binding. The targets were 
selected in base on their importance in the identified pathways and on their 
3D structure availability. The experiments showed the possible binding site 
and ligand conformation which could cause the observed aberrant gene 
expression. This was possible through the calculation of a docking score which 
enlightened the ligand conformation, among the nine generated, with the lower 
energy of interaction with all the possible binding sites of each protein. This 
way was possible to select the best conformation of the ligand and the best 
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site of interaction based on the score (lower energy), the ligand-protein 
interaction (number of AAs interacting with the ligand, type of interactions and 
site of interaction) and the number of ligand poses found within or close to the 
same binding site (Clustering). Also, some proteins were modelled to add 
eventual missing chains and parts to their crystal structure and were submitted 
to molecular dynamic simulations, with the ligand placed in its best site of 
interaction and in its best conformation. This way was possible to approximate 
the strength of the binding interaction in a dynamic environment. These 
molecules were also selected in base of their functions and role in the 
analyzed pathways of signalization. 
 
5.5.1 Molecular docking 
From the overexpressed proteins 15 were submitted to molecular 
docking with the pCA as ligand: FGF21, EFNA5, CCNE2, IKBKG, MAPK8, 
PPP2R3C, MKNK2, MEF2C, STK3, MDM2, ANGPT2, ANGPT4, RASA4, 
MAP3K1, and CACNA1G (209 to 2,377 residues). Among the proteins which 
suited the docking requirements, the majority of them were Ser/Thr-protein 
kinases, such as MAP3K1, MAPK8, MEF2C, MKNK2, PPP2R3C and STK3. 
Even though these proteins do not have the same sequence, they share a 
common 3D structure motif which contains the catalytic main site (Figure 
5.103A).  
Also, some inhibitors bind to this region, like pyrazolanthrone (JNK 
inhibitor II) which is a MAPK8 inhibitor and Xmu-MP-1, a benzodiazepine with 
cytotoxic activity which binds to STK3. In these cases pCA binds the same 
active site as the inhibitors, suggesting a similar activity (Figure 5.103 B and 
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C). These findings could be used in the research for other structurally similar 
disease-related targets (target fishing), having a high probability of match.  
 
 
Figure 5.103 A) Conserved proteins structural motif aligned: MAP3K1 (green), MAPK8 
(red), MKNK2 (blue), and STK3 (yellow); B) JNK inhibitor II (green) and pCA bound to 
MAPK8; C) Xmu-MP-1 (green) and pCA bound to STK3. 
 
From the rest of the proteins CACNA1G was the only transmembrane 
channel, composed by six large subunits. Its most interesting binding sites of 
pCA are localized on a pocket between the fourth/fifth/sixth transmembrane 
subunits (833-856 Helical S4; 1411-1434 Helical S5; 1512-1537 Helical S6) 
and in a separated site on the sixth cytosolic subunit of the protein (1855-2377 
Cytoplasmic S6). The first one is responsible for the activation/inactivation of 
the channel, while the cytosolic terminal part is responsible for its interaction 
with scaffold proteins (303). CCNE2 is instead a small protein (404 residues), 
which interacts with other two protein kinases (CDK2 and CDK3) to form 
Ser/Thr kinase holoenzyme complex. The binding site is on a major groove of 
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the protein and could be interfering with its protein kinase binding (304). 
Ephrin-5 is an activator of EFH receptors and its site of interaction with pCA 
corresponds with the protein-protein interaction with the EFHA2 receptor (29-
162 Ephrin RBD; 28-206 Eph LBD) (305). This could make the interaction 
weaker and therefore produce the up regulation of the EFNA5 gene. E3 
ubiquitin-protein ligase MDM2 interacts with various proteins forming a ternary 
complex with p53/TP53, WWOX and a trimeric complex with MDM2, MDM4 
and USP2, also it specifically binds to RNA. The ligand (pCA) binding site for 
this protein corresponds to the protein-protein interacting groove (150-230 and 
276-491 USP2, PYHIN1, RFFL and FRNF34 binding). These interactions are 
fundamental for the protein’s regulation of the MDM2-p53 signaling pathway 
(306). The interaction of pCA and the Ras activator RASA4 is centered on the 
Zn-finger region of the protein (675-711 Btk-type). This could mean that the 
ligand is prying with this region’s activity which is DNA, RNA or protein binding 
(307). Since the structure of MDM2 and RASA4 were modeled using I-
TASSER, cofactors like the Zn2+ ions of the Zn-fingers part these molecules 
were not added. Therefore, for a more precise modeling the cited ions should 
be considered as part of the molecules. For some of the studied proteins the 
site of interaction with the ligand was on the surface of the molecule, like for 
ANGPT2/4, FGF21 and IKBKG with a poor interaction which made them not 
suitable for subsequent analysis. Also, this lack of a strong ligand-protein 
binding might suggest that pCA is interacting in a different manner. For 
example, the ligand could be blocking the protein-protein interaction of these 
molecules with their receptors, or it could be activating these receptors without 
the need of the signaling protein. Another important molecule that was 
 262 
discarded was GNG11, because this signaling peptide is too small (73 
residues) to be suitable for this type of study and also it is unclear how the 
pCA could interact with this molecule. Therefore, the reason for its up 
regulation must to be investigated with a different approach which was not part 
of this study. From the under-expressed proteins 10 were submitted to the 
explorative docking: SLC2A4, CCNB2, CASP9, STK11, CHEK1, MDM4, 
PFKFB2, PFKP, FGFR2, and NTRK3 (387 to 839 residues). In this case, the 
down-regulated genes corresponded to the receptors of the up-regulated 
proteins, like FGFR2, or to some intimate partners like MDM4/MDMX or to 
tumor suppressors like STK11/LKB1. We found again the same motif for the 
Ser/Thr-protein kinases CHEK1, STK11 and NTRK3 in particular these three 
are tumor suppressors found under-expressed in various cancers and are 
commonly activated during carcinogenesis by epigenetic mechanisms (308). 
CHEK1 activates by phosphorylation from other protein kinases and pCA 
binds in a site specific for CLSPN mediated activation (1-265 Interaction with 
CLSPN). STK11 recruits two accesory proteins: STRADA/B and 
CAB39/MO25, which cause the protein to assume its active conformation. 
Meanwhile, NTRK3 is found in equilibrium between monomeric (low affinity 
and dimeric (high affinity) structures and its activation is a ligand-mediated 
auto-phosphorylation. For both STK11 and NTRK3 the ligand (pCA) is bound 
close to the protein kinase active site. In all three proteins pCA had various 
binding sites (allosteric and close to the ATP-binding site) on their surface, and 
it could be enhancing their ability to activate pathways responsible for tumor 
suppression, like p53 and NF-κB (309). Or they could interfere with the 
deactivation of the targets preventing protein-protein binding. PFKP and 
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PFKFB2 are both mediators of cancer cell metabolism, and for PFKP the 
interaction with pCA is at an allosteric activation site and catalytic site (538-
542 and 583-585 Allosteric activator; 1-399 N-terminal catalytic PFK domain). 
This protein forms a homotetramer of considerable weight, and this particular 
binding site is found in a pocket at the interphase of two subunits. This could 
allow the HCA to control the activity of the enzyme. PFKFB2 is instead a 
homodimer and the ligand binds close the fructose-2,6-bisphosphate pocket 
and catalytic site (249-505 Fructos-PP-ase; 2-248 PFK domain). FGFR2 is a 
receptor found in monomeric form before ligand (heparin) binding and 
homodimeric after. Its affinity for fibroblast GFs can be modulated (enhanced) 
by the interaction with other proteins like KLB (283, 310). The binding site of 
the pCA on this receptor is close the protein-protein and the heparin binding 
sites (154-247 Ig-like C2 type 2; 161-178 Heparin-binding), which could mean 
that the HCA could be activating the receptor even in absence of its activators 
and could even be triggering the homodimerization of the receptor. MDM4 is 
a Zn-finger found in a trimeric complex with MDM2 and USP2, and it is found 
to be down regulated by anticancer drugs like cisplatin (311). pCA binds to the 
region necessary for the interaction of the protein with USP2 (393-490 
interaction with USP2) and to its Zn-finger region (437-478 RING-type), which 
could cause the activation of the protein and deregulation of transcription. 
SLC2A4 transmembrane channel is a monomeric protein, which is 
translocated to the cell membrane when needed (312). The binding site of the 
pCA in this molecule is situated into the channel lumen, in correspondence to 
the glucose binding pocket (298-304; 333; 404 Monosaccharide binding). It 
could compete with the substrate and dysregulate the protein function and 
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sugar uptake. CCNB2 interacts with cyclin-dependent kinase 1 (CDK1) to form 
a Ser/Thr kinase holoenzyme known as maturation promoting factor (MPF) 
and the cyclin imparts specificity to the complex (267). The binding site of the 
pCA on this protein is superficial, denoting a probable interference of the acid 
with the protein-protein interaction of the cyclin. Finally, CASP9 is found as a 
heterotetramer, which consists in two antiparallel heterodimers. pCA binds to 
the p53 interacting domain and on the active site of the complex (?-315 CASP 
subunit p35; 287 active site). From the docking results of both up- and down-
regulated proteins it is clear that pCA effectively binds with most of them or 
with their receptors, therefore some of them were selected to perform a 
molecular dynamic simulation experiment in order to determine the ligand-
protein interaction in a dynamic way.  
 
5.5.2 MD simulations 
The selected pCA-protein adducts were allowed to dynamically relax 
and change conformation in physiological-like environment for 10 ns. 
Throughout these experiments it was possible to obtain their interaction with 
each other at any given moment of the simulation, and therefore to 
approximate their binding strength. The approximated binding energy (DEbound) 
was calculated. Finally, some proteins were also studied for their interaction 
with the ligand when complexed with their activator/accessory proteins. This 
allowed to verify how the protein-ligand binding strength changed and to give 
a more accurate hypothesis of the binding mechanism of pCA. Five pCA-
protein complexes of the up-regulated set were submitted to the MD 
simulations: pCA-CCNE2, pCA-MAPK8, pCA-MKNK2, pCA-RASA4, and 
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pCA-MDM2. Meanwhile six complexes from the down-regulated set were 
submitted to the analysis: pCA-CCNB2, pCA-AKT2, pCA-NTRK3, pCA-
SLC2A4, pCA-MDM4 and pCA-STK11. Furthermore, the targets studied in 
complex with their accessory proteins were: pCA-STK11-STRAD-CAB39 and 
pCA-CCNE2-CDK2.  
The calculated ∆Ebound and the variables used for its calculation for each 
of the studied systems are reported in table 5.32. 
 
Table 5.32 Calculated ∆Ebound (Kcal/mol) for each studied system  
Complex (up-reg.) !"#
$"  !"%
$" !"#
&'( !"%
&'( ∆Ebound 
pCA-CCNE2 -37.8221 -69.5421 -3.5492 -6.4070 6.5041 
pCA-MAPK8 -49.7515 -49.1873 -12.0723 -1.7895 -1.9273 
pCA-MKNK2 -40.9289 -51.7441 -5.6498 -5.9280 5.4521 
pCA-RASA4 -53.7024 -34.8041 -16.3229 3.1418 -12.5729 
pCA-MDM2 -55.2929 -43.3222 -15.9776 3.4939 -9.1008 
Complex (down-reg.)      
pCA-CCNB2 -80.4369 -0.2426 -9.1979 -0.22888 -41.5322 
pCA-AKT2* - - - - - 
pCA-NTRK3 -65.4647 -9.2353 -18.7596 -1.4521 -30.8839 
pCA-SLC2A4 -65.0329 -0.2100 -17.6101 -0.3765 -35.1688 
pCA-MDM4 -53.4211 -19.5824 -18.9772 3.1844 -20.4652 
pCA-STK11* - - - - - 
Prot. complex      
pCA-STK11-STRAD-CAB39 -50.1094 -49.1381 -19.9641 4.5729 -4.4116 
pCA-CCNE2-CDK2 -35.4547 -35.4094 -18.1084 0.4557 -2.9929 
*The results of these simulations were corrupted and must be repeated. 
5.5.2.1 Dynamic interaction of pCA with the up-regulated proteins 
From the simulation the dynamic ligand interaction diagram was 
obtained, highlighting a weak interaction between the pCA and the cyclin. The 
diagram shows that only few residues interact with the ligand longer than 10 
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% of the simulation: a glutamate (Glu161), a serine (Ser245), an asparagine 
(Asn248) and a tyrosine (Tyr267). Glu161 is the most consistent bonding 
residue forming H-bond which lasts for 27 % of the MD simulation. Also, few 
molecules of water interact for a maximum of 2 ns (20%) and create a link with 
the Leu263 residue. This result is not unexpected since the binding region is 
on the protein surface, because the latter does not have grooves or pockets 
useful for a strong ligand interaction (Figure 5.104).  
 
 
Figure 5.104 pCA-CCNE2 dynamic ligand-protein interaction diagram: a schematic of 
detailed ligand atom interactions with the protein residues. Interactions that occur more than 
10.0% of the simulation time in the selected trajectory (0.00 through 10.00 ns), are shown. 
 
These labile interactions mean that the pCA interaction with its target 
could be of a different nature of the observed one. It is also important to notice 
that the ∆Ebound found for the ligand-protein complex accounts for 6.5041 
Kcal/mol, which is not a very high value. In fact, it may be that the HCA is 
disrupting an interaction between cyclin E2 and one of its targets, like cyclin-
dependent kinases (CDKs). This interaction could be observed repeating the 
dynamic simulation in presence of one of these proteins. In this case the 
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interactions between the pCA and its target are stronger, and the diagram 
shows five aminoacidic residues involved in the ligand’s binding for more than 
30 % of the simulation: a tryptophan (Trp7), a glutamate (Glu128), a 
methionine (Met130), an aspartate (Asp131) and an asparagine (Asn133). 
Glu128 resulted to form the most stable H-bond kept for 92 % of the simulation, 
followed by Asn133 which forms H-bond that lasts for 7.6 ns (76 %). 
Meanwhile the rest of the residues interact with pCA only through the binding 
of a water molecule and these saline and H-bonds are kept in place between 
43 and 48 % of the simulation time. The dynamic ligand interaction diagram 
and the selected pose of the ligand in its binding site are reported in figure 
5.105. 
 
Figure 5.105 pCA-MAPK8 dynamic ligand-protein interaction diagram: a schematic of 
detailed ligand atom interactions with the protein residues. Interactions that occur more than 
30.0% of the simulation time in the selected trajectory (0.00 through 10.00 ns), are shown. 
The strong interactions between the ligand and this protein are 
indicative of a strong interaction, between them. Also, the part of the water 
molecules found in the binding site is ambiguous since they keep their position 
for half the simulation time. The calculated ∆Ebound (-1.9273 Kcal/mol) is also 
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a negative value which means that the pCA is spontaneously drawn to the 
binding site. The dynamic interaction between pCA and MKNK2 were found to 
be weaker than the previous kinase. Showing only three aminoacidic residues 
interacting poorly (>10 %) with the ligand: a methionine (Met162), a lysine 
(Lys173) and a glutamate (Glu209), plus two molecules of water acting as 
bridges from the phenolic moiety of the HCA and the methionine and 
glutamate of the protein. Instead the lysine directly forms two saline-bridges 
with the carboxylate group. All the interactions are very labile, being observed 
for less than 20 % of the simulation time (Figure 5.106). 
 
 
Figure 5.106 pCA-MKNK2 dynamic ligand-protein interaction diagram: a schematic of 
detailed ligand atom interactions with the protein residues. Interactions that occur more than 
10.0% of the simulation time in the selected trajectory (0.00 through 10.00 ns), are shown. 
Weak binding of pCA shows that a different mode of interaction must 
be the cause of the up regulation of this protein. The small positive ∆Ebound of 
5.4521 Kcal/mol suggests that the conjunction of the ligand and target are not 
spontaneous and could involve a different mechanism. It is also worth noting 
that the simulation time is also very short and therefore gives only a partial and 
approximated view of the system’s evolution. From the AA found in the binding 
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site of RASA4 seven of them were found interacting with pCA functional 
groups: a glutamate (Glu480), three arginine residues (Arg709, Arg711 and 
Arg732), a serine (Ser710), an aspartate (Asp719) and a histidine (His723) 
(Figure 5.107).  
 
 
Figure 5.107 pCA-RASA4 dynamic ligand-protein interaction diagram: a schematic of 
detailed ligand atom interactions with the protein residues. Interactions that occur more than 
20.0% of the simulation time in the selected trajectory (0.00 through 10.00 ns), are shown. 
 
Four of these interactions are mediated by water molecules. The 
strongest interactions are H-bonds, especially the one between Arg711 and 
the carboxylate group of pCA. Other strong but lesser H-bond is found among 
Arg732, Glu489 and the carboxylate group. The latter are mediated by H2O 
molecules, which could be important in ligand binding. Also, Arg709 forms a 
saline bridge with the acidic moiety of pCA which lasts 72 % of the simulation. 
The binding energy (∆Ebound = -12.5729 Kcal/mol) of pCA with RASA4 is a 
highly negative value. This implies that the ligand-protein interaction in the 
physiological-like environment of the simulation is a spontaneous event. Six 
AA side chains of the protein MDM2, bind pCA for more than 20 % of the time: 
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two tyrosine residues (Tyr100, Tyr104), one arginine (Arg155), two serine 
residues (Ser157, Ser159) and one phenylamine 490 (Phe490), as well as 
three water molecules (Figure 5.108).  
 
 
Figure 5.108 pCA-MDM2 dynamic ligand-protein interaction diagram: a schematic of 
detailed ligand atom interactions with the protein residues. Interactions that occur more than 
20.0% of the simulation time in the selected trajectory (0.00 through 10.00 ns), are shown. 
 
The strongest interactions are two saline-bridges formed by the 
arginine residue which last 59 and 80 % of the simulation. The other 
interactions are much weaker and labile (<50 %), especially the water-bridges 
which suggests that the water molecules are probably not essential in the 
ligand-protein binding. Binding energy ∆Ebound (-9.1008 Kcal/mol) of pCA with 
MDM2 is a negative value, which confirms that interaction between the two 
molecules is spontaneously driven, and that this could be its actual binding 
site. For these two last systems (pCA-RASA4 and pCA-MDM2) is important to 
mention that the molecules’ crystallographic files used in the simulations 
lacked Zn2+ ions. Adding the ions to the protein structures and adjust them to 
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their presence would have extended considerably the simulation time (up to 
1µs) and doubled the computational cost and simulation time. Therefore, the 
optimization of these systems exceeded the explorative goal of the present 
study and was not performed. Still, the Zn2+ ions constitute an important part 
of the proteins since they are both Zn-fingers and should be taken into account 
to perform a more accurate study on these systems.  
 
5.5.2.2 Dynamic interaction of pCA with the down-regulated proteins 
Dynamic interaction between pCA and CCNB2 is very strong. Five 
aminoacidic residues are involved in the ligand’s binding for more than 30 % 
of the simulation time: a glycine (Gln149), a serine (Ser150), a tyrosine 
(Tyr188), an arginine (Arg196) and a threonine (Thr294). The saline (ionic) 
bridges and H-bonds formed by these side chains with pCA are very strong 
and all last for more than 90 % of the simulation. The only exception is the 
bond formed by the tyrosine through the water molecule (water-bridge) which 
is 20 % more labile. Still the interaction lasts long enough to hypnotize the 
stable presence of the H2O molecule inside the binding site, or at least the 
necessity of its presence for the formation of that particular saline bridge. One 
saline bridge between the ligand and arginine 196 is reported to last more than 
100 % of simulations, this means that the AA has more than one interaction 
with the same atom of the carboxylic group. The dynamic binding of pCA to 
the cyclin B2 is shown in figure 5.109.  
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Figure 5.109 pCA-CCNB2 dynamic ligand-protein interaction diagram: a schematic of 
detailed ligand atom interactions with the protein residues. Interactions that occur more than 
30.0% of the simulation time in the selected trajectory (0.00 through 10.00 ns), are shown. 
 
Strong interactions of pCA with the selected binding site and the 
extremely negative ∆Ebound of -41.5322 Kcal/mol reported for the dynamic 
simulation, match the experimental results of the treatment. Even if the binding 
site of the cyclin is not characterized, it is acceptable to speculate that it has 
an important role in this protein’s function. Interactions of the ligand with 
NTRK3 were also found to be strong, nine AAs bind pCA for more than 30 % 
of the simulation: two glutamate residues (Glu546, Glu618), an alanine 
(Ala548), a lysine (Lys572), two methionine residues (Met620, Met700), an 
aspartate (Asp697), a phenylalanine (Phe698), and a glycine (Gly699) as well 
as four H2O molecules. Almost all interactions last more than 5 ns, the 
strongest interaction is a H-bond between the phenol group and the glutamate 
618. Only one interaction of π-π stacking is present among the aromatic ring 
of the ligand and the one of the phenylalanine 698 side chain, and this 
interaction lasted for 43 % of the simulation. Three of the interactions mediated 
by the water molecules were present more than 50 % of the time which could 
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mean that these molecules are needed for the pCA-NTRK3 binding interaction 
(Figure 5.110). 
 
 
Figure 5.110 pCA-NTRK3 dynamic ligand-protein interaction diagram: a schematic of 
detailed ligand atom interactions with the protein residues. Interactions that occur more than 
30.0% of the simulation time in the selected trajectory (0.00 through 10.00 ns), are shown. 
 
The dynamic interaction resulted to be strong with ∆Ebound of -30.8839 
Kcal/mol confirming the goodness of the binding. The latter happens in a site 
different from the catalytic one but close to it and therefore pCA could be 
activating the protein without the need of its substrate. The pCA-SLC2A4 
interaction was also very strong consisting only in saline-bridges and H-bonds, 
and therefore involving just the carboxylate moiety of the ligand. The 
interactions lasting above 30 % of the time are given by six AA residues: a 
valine (Val85), a serine (Ser89), an arginine (Arg142), two aspartate residues 
(Asn304, Asn431) and a tyrosine (Tyr308) and, three of which mediated by 
water molecules. Two of the latter lasted for more than 60 % of the simulation, 
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meaning that they could be important for the pCA binding to the channel 
protein. The strongest of all the interactions was a saline bridge between 
arginine 142 and the deprotonated carboxyl group (Figure 5.111). 
 
 
Figure 5.111 pCA-SLC2A4 dynamic ligand-protein interaction diagram: a schematic of 
detailed ligand atom interactions with the protein residues. Interactions that occur more than 
30.0% of the simulation time in the selected trajectory (0.00 through 10.00 ns), are shown. 
 
Strong binding of pCA in the glucose binding site of the channel protein 
could block the passage of the monosaccharide into the cytoplasm and 
consequently cause a cascade of signalizations affecting negatively cell 
metabolism and proliferation. This hypothesis is reinforced by the calculated 
∆Ebound for the dynamic simulation of -35.1688 Kcal/mol. This negative value 
of energy strongly supports the idea of a spontaneous bind of pCA in this site 
of the interaction and hence the inhibition of the protein functions. The pCA-
MDM4 binding was found to be of medium strength, having four AAs 
interacting for more than 2 ns (20 %): a tyrosine (Tyr75), a serine (Ser409), 
histidine (His46) and lysine (Lys469) (Figure 5.112).  
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Figure 5.112 pCA-MDM4 dynamic ligand-protein interaction diagram: a schematic of 
detailed ligand atom interactions with the protein residues. Interactions that occur more than 
20.0% of the simulation time in the selected trajectory (0.00 through 10.00 ns), are shown. 
 
The majority of the interactions were H-bonds and saline interactions, 
two of them mediated by water. Meanwhile only one π-π stacking interaction 
was found, caused by the contact between the ligand aromatic ring and the 
one on the sidechain if the AA Tyr75. The latter was also the AA with the most 
intense interaction creating also a water-bridge with the carboxylate moiety of 
the ligand. Other long-lasting interactions were made by Lys469 which binds 
both the oxygens of the acidic portion of pCA forming an ionic bond for 40 % 
of the simulation. Also, Ser409 forms H-bond with the phenol moiety of the 
ligand for half the duration of the simulation. The various interactions found for 
pCA in the MDM4 binding site are sufficient to speculate over the importance 
of this system. In fact, the calculated ∆Ebound remarks these findings consisting 
of -20.4652 Kcal/mol, this negative value suggest that the binding of the ligand 
to the protein happens spontaneously. As for RASA4 and MDM2, for this 
model were also ignored important Zn2+ ions, which should be considered if a 
more accurate study of this system is attempted. In the pCA-STK11-STRAD-
CAB39 system, the protein STK11 with the ligand in the selected binding 
pocket was aligned with its complex with its accessory/activating proteins and 
the system was submitted to a MD simulation (Figure 5.113).  
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Figure 5.113 pCA-STK11-STRAD-CAB39 dynamic ligand-protein interaction diagram: a 
schematic of detailed ligand atom interactions with the protein residues. Interactions that 
occur more than 30.0% of the simulation time in the selected trajectory (0.00 through 10.00 
ns), are shown. 
 
The dynamic interactions (above 30%) observed were of good strength, 
all were mediated by H2O molecules, and the AAs responsible for them were 
only two: a glycine (Gln137) and a glutamate (Glu138). Gln137 forms a water-
bridge with an ionic interaction with the deprotonated carboxylate group of the 
ligand that lasts for half the simulation. Meanwhile Glu138 has the strongest 
contacts forming two water-bridges with the oxygens of the carboxylate, the 
H-bond lasting 61 % of the time while the saline-bridge was present for 38 % 
of the simulation. The binding of pCA to the protein complex STK11-STRAD-
CAB39 was eficient, since the value reported for its binding energy (∆Ebound) 
is -4.4116 Kcal/mol. This negative value, like for the other down-regulated 
proteins, is an index of its spontaneous interaction with the selected binding 
site and hence its importance in the mechanism of action of pCA. The last 
studied system was the pCA-CCNE2-CDK2, where the interaction between 
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the two proteins was investigated with the pCA placed in its binding site (Figure 
5.114).  
 
 
Figure 7.114 pCA-CCNE2-CDK2 dynamic ligand-protein interaction diagram: a schematic of 
detailed ligand atom interactions with the protein residues. Interactions that occur more than 
30.0% of the simulation time in the selected trajectory (0.00 through 10.00 ns), are shown. 
 
Five AA residues from CCNE2 (Chain B), three AA residues from CDK2 
(Chain C) and three water molecules were found to interact with the HCA 
functional groups: two valine residues (Val113B and Val154C), two 
asparagine lateral chains (Asn116B and Asn248B), a proline (Pro155C), an 
arginine (Arg157C), a glutamate (Glu161B) and lastly a serine (Ser245B). The 
strongest interaction detected is found between Glu161 and the carboxyl 
moiety of pCA. This H-bond account for 131% of the simulation time, which 
means that more than one interaction is present between the AA and the 
functional group at the same time. The latter are also mediated by a H2O 
molecule which could be necessary to keep the binding strong. Other 
interactions that last over 8 ns are the saline bonds between Val113 and the 
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phenol group, Val154, Asn248 and the carboxylate group and among Ser245 
and the carbonyl. In general, almost all the interactions lasted over 50% of 
simulation time which means that they are probably important of pCA binding 
on the protein. The calculated value of the LIE between the HCA and the 
protein complex CCNE2-CDK2 is a negative number (-2.9929 Kcal/mol). 
Confronting this value with the one found for the sole pCA-CCNE2 complex 
(6.5041 Kcal/mol) shows that the interaction requires less energy when the 
CCNE2 is complexed with its protein target CDK2. Therefore, pCA would be 
more easily drown to interact with the complexed proteins than when they are 
in the monomeric state. 
These results need to be confirmed with experimental evidence, but still 
they represent a good approximation of the possible interaction of pCA with its 
targets and give an idea of its possible mechanism or mechanisms of action.  
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CHAPTER 6 
6. CONCLUSIONS 
 
 
This study was the first pharmacological and chemical study conducted 
on H. glomerata.  
The metabolomic study performed on the plant’s leaf extracts give a 
deeper understanding of its chemical composition and highlighted its major 
biosynthetic pathways.  
The results obtained from the antibacterial assays partially confirmed 
this plant as a source of antibacterial phytochemicals and backed up its use in 
the Mexican traditional medicine.  
The cytotoxic assays showed that the plant also produce cytotoxic 
compounds, which is in agreement with is taxonomic relation with plants used 
in the ethnomedical treatment of cancer.  
It was possible to confine the biological activity and therefore the 
bioactive phytochemicals of this plant to its aerial parts, since the root extracts 
had null activity.  
The various non-toxic but bioactive compounds isolated from the 
organic leaf extracts of H. glomerata are partially responsible for the observed 
biological activities.  
Compounds accountable for both antibacterial and cytotoxic activity 
were identified through bio-directed assays of the fractionated active extracts. 
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This contributed to the identification of more metabolites produced by this 
plant.  
In this study were also observed the changes in genetic expression of 
PC3 cancer cells treated with an isolated compound (p-coumaric acid), by 
microarray.  
This is the first report of a microarray assay on p-coumaric acid. The 
latter showed the up- and down-regulation of many genes involved in cancer, 
some of them specific for prostate cancer.  
The microarray results and in silico study, led to the conclusion that p-
coumaric acid’s cytotoxicity is the results of the dysregulation of various 
cellular processes involved in cell survival, growth, migration, and metabolism.  
The tendency of p-coumaric acid to bind with targets possessing a 
similar secondary structure, does this molecule be considered as a good 
candidate for target fishing and the development of new anticancer drugs.  
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6.1 PERSPECTIVES 
 
Synergistic studies on the phenylpropionic acid will be conducted in 
vitro.  
It will be considered the isolation/synthesis of some new interesting 
CAPE-like metabolites, such as 3-(4-hydroxyphenyl) propyl coumarate and 3-
(4-hydroxyphenyl-3-methoxy) propyl coumarate.  
It will be validated the observed genetic expression of some selected 
genes by RT-qPCR.  
Results of in silico experiments will be confirmed performing in vitro 
binding experiments with the available targets of p-coumaric acid. The latter 
will be also derivatized based on its binding sites and its cytotoxic activity 
assessed. 
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